var title_f38_56_39808="Urate crystals diaper";
var content_f38_56_39808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Precipitation of uric acid (urate) crystals in the diaper",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The precipitation of uric acid crystals in the diaper (secondary to increased urinary uric acid excretion in infants) may be misidentified as blood.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gerardo Cabrera-Meza, MD, Associate Professor Pediatrics, Baylor College of Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39808=[""].join("\n");
var outline_f38_56_39808=null;
var title_f38_56_39809="Topical corticosteroids";
var content_f38_56_39809=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of representative topical corticosteroid preparations (classified according to the USA system)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Potency group*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Corticosteroid",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vehicle type/form",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trade names",
"        <br/>",
"        (US)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Available strength(s), percent",
"        <br/>",
"        (except as noted)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generic available in US",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"18\">",
"        <strong>",
"         Super high potency",
"         <br/>",
"         (group one)",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        Betamethasone dipropionate, augmented",
"       </td>",
"       <td>",
"        Ointment, optimized",
"       </td>",
"       <td>",
"        Diprolene&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Diprolene&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Diprolene&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"10\">",
"        Clobetasol propionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Temovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Temovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream, emollient base",
"       </td>",
"       <td>",
"        Temovate E&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Temovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Clobex&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam aerosol",
"       </td>",
"       <td>",
"        Olux-E&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam aerosol (scalp)",
"       </td>",
"       <td>",
"        Olux&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shampoo",
"       </td>",
"       <td>",
"        Clobex&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution (scalp)",
"       </td>",
"       <td>",
"        Temovate&reg;, Cormax&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spray aerosol",
"       </td>",
"       <td>",
"        Clobex&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Halobetasol propionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Ultravate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Ultravate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluocinonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Vanos&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flurandrenolide",
"       </td>",
"       <td>",
"        Tape (roll)",
"       </td>",
"       <td>",
"        Cordran&reg;",
"       </td>",
"       <td>",
"        4 mcg/cm",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diflorasone diacetate",
"       </td>",
"       <td>",
"        Ointment (petrolatum)",
"       </td>",
"       <td>",
"        Psorcon&reg;, ApexiCon&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"15\">",
"        <strong>",
"         High potency",
"         <br/>",
"         (group two)",
"        </strong>",
"       </td>",
"       <td>",
"        Amcinonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cyclocort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , Amcort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Betamethasone dipropionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Diprosone&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream, augmented formulation (AF)",
"       </td>",
"       <td>",
"        Diprolene&reg; AF",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Halcinonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Halog&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Halog&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Fluocinonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Lidex&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Lidex&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream anhydrous",
"       </td>",
"       <td>",
"        Lidex&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Lidex&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Diflorasone diacetate",
"       </td>",
"       <td>",
"        Ointment, emollient",
"       </td>",
"       <td>",
"        ApexiCon&reg;, Florone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream, emollient",
"       </td>",
"       <td>",
"        ApexiCon&reg; E",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Desoximetasone",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Topicort&reg;",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Topicort&reg;",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Topicort&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"14\">",
"        <strong>",
"         High potency",
"         <br/>",
"         (group three)",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        Amcinonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cyclocort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , Amcort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Amcort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Betamethasone dipropionate",
"       </td>",
"       <td>",
"        Cream, hydrophilic emollient",
"       </td>",
"       <td>",
"        Diprosone&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Diprosone&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Betamethasone valerate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Valisone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam",
"       </td>",
"       <td>",
"        Luxiq&reg;",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluticasone propionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cutivate&reg;",
"       </td>",
"       <td>",
"        0.005",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluocinonide",
"       </td>",
"       <td>",
"        Cream aqueous emollient",
"       </td>",
"       <td>",
"        Lidex-E&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mometasone furoate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Elocon&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desoximetasone",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Topicort LP&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diflorasone diacetate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Florone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Kenalog &reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Triderm&reg;, Aristocort HP&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Aristocort A&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"10\">",
"        <strong>",
"         Medium potency",
"         <br/>",
"         (group four)",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aerosol spray",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"       </td>",
"       <td>",
"        0.2 mg per 2 second spray",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flurandrenolide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cordran&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluocinolone acetonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Synalar&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Mometasone furoate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Elocon&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Elocon&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Elocon&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocortisone valerate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Westcort&reg;",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clocortolone pivalate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cloderm&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"20\">",
"        <strong>",
"         Lower-mid potency",
"         <br/>",
"         (group five)",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Betamethasone dipropionate",
"       </td>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Diprosone&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Flurandrenolide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cordran&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Cordran&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Fluticasone propionate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cutivate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Cutivate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Prednicarbate",
"       </td>",
"       <td>",
"        Cream, emollient",
"       </td>",
"       <td>",
"        Dermatop&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Dermatop&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Desonide",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        DesOwen&reg;, Tridesilon&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gel",
"       </td>",
"       <td>",
"        Desonate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Betamethasone valerate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Beta-Val&reg;, Valisone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocortisone valerate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Westcort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Hydrocortisone butyrate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Locoid&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Locoid&reg;, Locoid Lipocream&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion, spray",
"       </td>",
"       <td>",
"        Cortizone10&reg; maximum",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Locoid&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Locoid&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocortisone probutate",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Pandel&reg;",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluocinolone acetonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Synalar&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"13\">",
"        <strong>",
"         Low potency",
"         <br/>",
"         (group six)",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        Alclometasone dipropionate",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Aclovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Aclovate&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Triamcinolone acetonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , Aristocort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.025",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Desonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        DesOwen&reg; , Tridesilon&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        DesOwen&reg;, LoKara&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foam",
"       </td>",
"       <td>",
"        Verdeso&reg;",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Betamethasone valerate",
"       </td>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Beta-Val&reg;, Valisone&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Fluocinolone acetonide",
"       </td>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Synalar&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Synalar&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shampoo",
"       </td>",
"       <td>",
"        Capex&reg;",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oil (scalp)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Derma-Smoothe/FS&reg;",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oil (body)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Derma-Smoothe/FS&reg;",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"15\">",
"        <strong>",
"         Least potent",
"         <br/>",
"         (group seven)",
"        </strong>",
"       </td>",
"       <td rowspan=\"4\">",
"        Hydrocortisone (base)",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Hytone&reg;",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Hytone&reg;, Nutracort&reg;",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Hytone&reg;",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Texacort&reg;",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Hydrocortisone acetate with pramoxine 1 percent combination",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Pramosone&reg;",
"       </td>",
"       <td>",
"        1 or 2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Pramosone&reg;, Analpram HC",
"       </td>",
"       <td>",
"        1 or 2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Pramosone&reg;, Analpram HC",
"       </td>",
"       <td>",
"        1 or 2.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aerosol foam",
"       </td>",
"       <td>",
"        Epifoam&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Hydrocortisone (base)",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cortaid&reg;, Hytone&reg;, Nutracort&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cortaid&reg;, Hytone&reg;, Synacort",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lotion",
"       </td>",
"       <td>",
"        Aquinil HC&reg;, Sarnol HC&reg;, Cortizone-10&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spray",
"       </td>",
"       <td>",
"        Cortaid&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution",
"       </td>",
"       <td>",
"        Cortaid&reg;, Noble&reg;, Scalp relief&reg;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ointment",
"       </td>",
"       <td>",
"        Cortaid&reg;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cream",
"       </td>",
"       <td>",
"        Cortaid&reg;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Listed by potency according to the USA classification system: group one is the most potent, group seven is the least potent. Other countries use a different classification system with only four or five groups.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Vehicle and base ingredient(s) for generic products, in some cases, may not be identical to trade version.",
"      <br>",
"       &Delta; Inactive US trade name for specific product; brand may be available outside US.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved; and Tadicherla S, Ross K, Shenefelt D, Topical corticosteroids in dermatology; Journal of Drugs in Dermatology 2009; 12:1093.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39809=[""].join("\n");
var outline_f38_56_39809=null;
var title_f38_56_39810="Liver cyst 1 with answer";
var content_f38_56_39810=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echinococcus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wet mount of contents of hydatid cyst of liver (x400) shows a scolex of Echinococcus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39810=[""].join("\n");
var outline_f38_56_39810=null;
var title_f38_56_39811="Acyclovir and hydrocortisone: Pediatric drug information";
var content_f38_56_39811=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acyclovir and hydrocortisone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?16/35/16947?source=see_link\">",
"    see \"Acyclovir and hydrocortisone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/1/2068?source=see_link\">",
"    see \"Acyclovir and hydrocortisone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12586583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xerese&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F15582113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F15582120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/35/16947?source=see_link\">",
"      see \"Acyclovir and hydrocortisone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years, Adolescents, and Adults:",
"     <b>",
"      Herpes labialis (cold sores):",
"     </b>",
"     Topical: Apply 5 times daily for 5 days; initiate therapy at first sign of infection (ie, during the prodrome or when lesions appear)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14876700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xerese&reg;: Acyclovir 5% and hydrocortisone 1% (5 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F12586585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15582121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: For external use only. Wash hands before and after use. Apply to clean, dry area; use sufficient amount to cover the affected area(s), including the outer margin of cold sore; do not rub affected area nor cover area with a bandage. Do not bathe or shower for 30 minutes following application. Not for use in the eye, inside the mouth or nose, or on the genitals.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F15582117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at  20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15582114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Early treatment of recurrent herpes labialis (cold sores) to shorten healing time and to reduce likelihood of ulceration (FDA approved in ages &ge;12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F12586599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rare but important or life-threatening: Dermatologic: Burning, contact dermatitis, dryness, erythema, flaking, pigmentation changes, sensitization, signs/symptoms of inflammation, tingling",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15582115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acyclovir, hydrocortisone, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F15582143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in immunocompromised patients; safety and efficacy data are insufficient.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15582116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause local sensitization and irritation. For external use only to area around the mouth and lips; do not apply to mucosal membranes (inside of mouth or nose), eyes, or genital area. If healing fails after 2 weeks of therapy, patient should contact prescriber.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12586601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F12586590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12586591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies and studies in pregnant women have not been conducted with Xerese&trade;.  Systemic exposure of acyclovir and hydrocortisone after topical administration is minimal. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15582118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15582119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F15582122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/1/2068?source=see_link\">",
"      see \"Acyclovir and hydrocortisone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For use on lips or oral lesions around mouth; do not use on mucosal membranes, eyes, or genital area. During application, do not rub or bandage affected area; do not use other skin products on affected area (eg, lip balm, make-up, sunscreen). Avoid showers and bathing for 30 minutes after use. Notify prescriber if no improvement within 2 weeks. This is not a cure for herpes, nor will this medication reduce the risk of transmission to others when lesions are present; avoid sexual intercourse when visible lesions are present.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Strand A, B&ouml;ttiger D, Gever LN, et al, \"Safety and Tolerability of Combination Acyclovir 5% and Hydrocortisone 1% Cream in Adolescents With Recurrent Herpes Simplex Labialis,\"",
"      <i>",
"       Pediatr Dermatol",
"      </i>",
"      , 2012, 29(1):105-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/56/39811/abstract-text/22004219/pubmed\" id=\"22004219\" target=\"_blank\">",
"        22004219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87234 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39811=[""].join("\n");
var outline_f38_56_39811=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586583\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15582113\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15582120\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14876700\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586585\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15582121\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15582117\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15582114\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586599\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15582115\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15582143\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15582116\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298684\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586601\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586590\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586591\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15582118\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15582119\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15582122\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87234\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87234|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/35/16947?source=related_link\">",
"      Acyclovir and hydrocortisone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/1/2068?source=related_link\">",
"      Acyclovir and hydrocortisone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_56_39812="Hydrocodone and chlorpheniramine: Patient drug information";
var content_f38_56_39812=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydrocodone and chlorpheniramine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/1/6167?source=see_link\">",
"     see \"Hydrocodone and chlorpheniramine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      TussiCaps&reg;;",
"     </li>",
"     <li>",
"      Tussionex&reg; Pennkinetic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700969",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give this drug to a child younger than 6 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydrocodone, chlorpheniramine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake suspension well before use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11378 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39812=[""].join("\n");
var outline_f38_56_39812=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179966\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018163\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018162\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018167\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018168\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018170\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018165\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018166\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018171\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018172\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/1/6167?source=related_link\">",
"      Hydrocodone and chlorpheniramine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_56_39813="Nephrology pattern 4 answer";
var content_f38_56_39813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 4 answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diabetic nephropathy. Light micrograph showing diffuse and nodular (N) glomerulosclerosis in diabetic nephropathy. Note the dense appearance of the deposits and the rim of cells around the nodules, which distinguish this disorder on light microscopy from fibrillary glomerulonephritis or amyloidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39813=[""].join("\n");
var outline_f38_56_39813=null;
var title_f38_56_39814="Pneumococcal conjugate vaccine (13-valent): Drug information";
var content_f38_56_39814=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pneumococcal conjugate vaccine (13-valent): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/25/22934?source=see_link\">",
"    see \"Pneumococcal conjugate vaccine (13-valent): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9926715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prevnar 13&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11575096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Prevnar 13&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10010046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Bacterial)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10010070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Immunization:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Efficacy of PCV13 administered &lt;5 years after PPSV23 is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults &ge;50 years (manufacturers labeling): 0.5 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults &ge;19 years with specified underlying medical conditions (CDC, 2012): Eligible adults should be vaccinated at their next pneumococcal vaccination opportunity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Pneumococcal vaccine naive (no previous PCV13 or PPSV23 vaccine):",
"     </i>",
"     Administer PCV13 0.5 mL as a single dose followed by 1 dose of PPSV23 8-weeks later.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Previously vaccinated with PPSV23:",
"     </i>",
"     PCV13 0.5 mL as a single dose &ge;1 year after the last dose of PPSV23.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10010068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/25/22934?source=see_link\">",
"      see \"Pneumococcal conjugate vaccine (13-valent): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Primary immunization:",
"     </b>",
"     I.M.:",
"     <i>",
"      Infants and Children 6 weeks-59 months:",
"     </i>",
"     0.5 mL/dose for a total of 4 doses. The first dose may be given as young as 6 weeks of age, but is typically given at 8 weeks (2 months of age). The 3 remaining doses are usually given at 4, 6, and 12-15 months of age. The recommended dosing interval is 4-8 weeks. The minimum interval between doses in children &lt;1 year of age is 1 month. The minimum interval between the third and fourth dose is 8 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Immunization:",
"     </b>",
"     <i>",
"      Older Infants, Children, and Adolescents:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children 7-11 months (previously unvaccinated):",
"     </i>",
"     0.5 mL for a total of 3 doses; 2 doses at least 4 weeks apart, followed by a third dose after the 1-year birthday (12-15 months), separated from the second dose by at least 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children 12-23 months (previously unvaccinated):",
"     </i>",
"     0.5 mL for a total of 2 doses, separated by at least 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Healthy Children 24-59 months (previously unvaccinated):",
"     </i>",
"     0.5 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children 24-71 months with an underlying medical condition (previously unvaccinated):",
"     </i>",
"     0.5 mL for a total of 2 doses, separated by 8 weeks (CDC 59[RR-11], 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children 6 through17 years:",
"     </i>",
"     0.5 mL as a single dose. If PCV7 was previously administered, give PCV13 &ge;8 weeks after that dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Previously vaccinated with PCV7 and/or PCV13, and with a lapse in vaccine administration (CDC 59[RR-11], 2010):",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Children 7-11 months:",
"     </i>",
"     Previously received 1 or 2 doses: 0.5 mL dose at 7-11 months of age, followed by a second dose &ge;8 weeks later at 12-15 months of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Children 12-23 months:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Previously received 1 dose &lt;12 months of age: 0.5 mL dose, followed by a second dose &ge;8 weeks later",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Previously received 1 dose at &ge;12 months of age: 0.5 mL dose &ge;8 weeks after the most recent dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Previously received 2 or 3 doses before age 12 months: 0.5 mL dose &ge;8 weeks after the most recent dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Healthy Children 24-59 months with any incomplete schedule:",
"     </i>",
"     0.5 mL dose &ge;8 weeks after the most recent dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Children 24-71 months with an underlying medical condition:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Previously received &lt;3 doses: 0.5 mL dose &ge;8 weeks after the most recent dose, followed by a second dose &ge;8 weeks later",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Previously received 3 doses: 0.5 mL as a single dose &ge;8 weeks after the most recent dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Previously vaccinated with PCV7 and completed vaccination series of 4 doses (CDC 59[RR-11], 2010):",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Children 14-59 months:",
"     </i>",
"     0.5 mL as a single supplemental dose &ge;8 weeks after the most recent dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Children 24-71 months with an underlying medical condition:",
"     </i>",
"     0.5 mL as a single supplemental dose &ge;8 weeks after the most recent dose of PCV7 or PPSV23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      High risk for invasive pneumococcal disease (CDC 59[RR-11], 2010):",
"     </b>",
"     I.M.:",
"     <i>",
"      Children and Adolescents 6-18 years:",
"     </i>",
"     0.5 mL as a single dose &ge;8 weeks after the most recent dose of PCV7 or PPSV23 (if applicable)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10010071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10010079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prevnar 13&reg;: 2 mcg of each capsular saccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and 4 mcg of serotype 6B [bound to diphtheria CRM",
"     <sub>",
"      197",
"     </sub>",
"     protein ~34 mcg] per 0.5 mL (0.5 mL) [contains aluminum, polysorbate 80, and yeast]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10010044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10010076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well prior to use. Do not use if a homogenous white suspension does not form. Administer I.M. (deltoid muscle for toddlers, young children, and adults or lateral midthigh in infants). Do not inject I.V. or SubQ; avoid intradermal route. Concurrent administration of PCV13 and PPV23 has not been studied and is not recommended (CDC, 2010).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For patients at risk of hemorrhage following intramuscular injection, the ACIP recommends &ldquo;it should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection.&rdquo; Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10010055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunization of children 6 weeks through 17 years of age against",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     infection caused by serotypes included in the vaccine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Immunization of children 6 weeks through 5 years of age against otitis media caused by",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Immunization of adults &ge;50 years against pneumococcal pneumonia and invasive disease caused by",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     serotypes included in the vaccine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following (CDC 59[RR-11], 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      All children age 2-59 months",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      Children 60-71 months with underlying medical conditions including:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Immunocompetent children with chronic heart disease (particularly cyanotic congenital heart disease and heart failure), chronic lung disease (including asthma if treated with high dose corticosteroids), diabetes, cerebrospinal fluid leaks, or cochlear implants",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Children with functional or anatomic asplenia, including sickle cell disease or other hemoglobinopathies, congenital or acquired asplenia, or splenic dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Children with immunocompromising conditions including congenital immunodeficiency (includes B or T cell deficiency, compliment deficiencies and phagocytic disorders; excludes chronic granulomatous disease),HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancies, solid organ transplant, or other diseases requiring immunosuppressive drugs (including long term systemic corticosteroids and radiation therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      Children who received &ge;1 dose of PCV7",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      Children 6-18 years of age at increased risk for invasive pneumococcal disease",
"     </b>",
"     due to anatomic or functional asplenia (including sickle cell disease), HIV infection or other immunocompromising conditions, cochlear implant, or cerebrospinal fluid leaks (regardless of prior receipt of PCV7 or PPSV23). Routine use is not recommended for healthy children &ge;5 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Adults &ge;19 years of age:",
"     </b>",
"     The ACIP also recommends routine vaccination for adults &ge;19 years of age with the following underlying medical conditions (CDC, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Immunocompetent persons with cerebrospinal fluid leaks or cochlear implants",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Persons with functional or anatomic asplenia, including sickle cell disease or other hemoglobinopathies, congenital or acquired asplenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Persons with immunocompromising conditions including congenital or acquired immunodeficiency (includes B or T cell deficiency, compliment deficiencies and phagocytic disorders; excludes chronic granulomatous disease), HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancies, solid organ transplant, multiple myeloma, or other diseases requiring immunosuppressive drugs (including long term systemic corticosteroids and radiation therapy)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10010021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pneumococcal 13-Valent Conjugate Vaccine (Prevnar 13&reg;) may be confused with Pneumococcal 7-Valent Conjugate Vaccine (Prevnar&reg;) or with Pneumococcal 23-Valent Polysaccharide Vaccine (Pneumovax&reg; 23)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10010062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Chills, drowsiness, fatigue, fever, headache, insomnia, irritability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Appetite decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Erythema, limitation of arm motion, pain, swelling, tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatological: Hives",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal crying, erythema multiforme,  febrile seizures, hypersensitivity reaction (bronchospasm, dyspnea, facial edema), seizure, urticaria, urticaria-like rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adverse reactions observed with PCV7 which may also be seen with PCV-13: Anaphylactic reaction, angioneurotic edema, apnea, breath holding, edema, hypotonic hyporesponsive episode, injection site reaction (dermatitis, pruritus), lymphadenopathy (localized), shock",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10010058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe allergic reaction (eg, anaphylaxis) to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10010059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Apnea: Apnea has been reported following I.M. vaccine administration in premature infants; consider risk versus benefit in infants born prematurely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asplenia: Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children &ge;24 months of age with asplenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic illness: Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children &ge;24 months of age with chronic illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV: Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children &ge;24 months of age with HIV infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pneumococcal infections: Not to be used to treat pneumococcal infections or to provide immunity against diphtheria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sickle cell disease: Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children &ge;24 months of age with sickle cell disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines:  In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy including high dose corticosteroids); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in children &ge;24 months of age who are immunocompromised.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Antibody responses were lower in older adults &gt;65 years of age compared to adults 50-59 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10073253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Inactivated): Pneumococcal Conjugate Vaccine (13-Valent) may diminish the therapeutic effect of Influenza Virus Vaccine (Inactivated). Influenza Virus Vaccine (Inactivated) may diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent).  Management: Immune response to these vaccines may be diminished when given concomitantly to patients 65 years old or older.  When practical, consider separating doses of these vaccines by 1 month or more for these patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10010056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10010057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not shown adverse fetal effects. Inactivated vaccines have not been shown to cause increased risks to the fetus (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13699107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11566484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     It is not known if this vaccine is excreted into breast milk. The manufacturer recommends that caution be exercised when administering this vaccine to nursing women. Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13908781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Prevenar 13 (AR, AT, AU, BE, CH, CN, CO, CR, CZ, DE, DK, DO, EC, EE, FR, GB, GT, HK, HN, ID, IE, IL, KP, MY, NI, NL, NO, NZ, PA, PH, PL, PT, SE, SG, SV, TH, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10010066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes active immunization against invasive disease caused by",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     capsular serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, all which are individually conjugated to CRM197 protein",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Advisory Committee on Immunization Practices (ACIP), &ldquo;Pneumococcal Vaccination for Cochlear Implant Recipients,&rdquo;",
"      <i>",
"       MMWR",
"      </i>",
"      , 2002, 51(41):931.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/56/39814/abstract-text/12408148/pubmed\" id=\"12408148\" target=\"_blank\">",
"        12408148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children -- Advisory Committee on Immunization Practices (ACIP), 2010,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2010, 59(9):258-61. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5909a2.htm?s_cid=mm5909a2_e\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5909a2.htm?s_cid=mm5909a2_e",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/56/39814/abstract-text/20224542/pubmed\" id=\"20224542\" target=\"_blank\">",
"        20224542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention of Pneumococcal Disease Among Infants and Children - Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-11):1-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/56/39814/abstract-text/21150868/pubmed\" id=\"21150868\" target=\"_blank\">",
"        21150868",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/56/39814/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Syncope After Vaccination -- United States, January 2005-July 2007,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/56/39814/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23),&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2010, 59(34):1102-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/56/39814/abstract-text/20814406/pubmed\" id=\"20814406\" target=\"_blank\">",
"        20814406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61:816-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/56/39814/abstract-text/23051612/pubmed\" id=\"23051612\" target=\"_blank\">",
"        23051612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/56/39814/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reefhuis J, Honein MA, Whitney CG, et al, &ldquo;Risk of Bacterial Meningitis in Children With Cochlear Implants,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349:435-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/56/39814/abstract-text/12890842/pubmed\" id=\"12890842\" target=\"_blank\">",
"        12890842",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/56/39814/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9906 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39814=[""].join("\n");
var outline_f38_56_39814=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9926715\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11575096\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010046\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010070\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010068\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010071\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010079\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010044\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010076\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010055\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010021\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010062\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010058\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010059\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299890\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10073253\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010056\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010057\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13699107\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11566484\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13908781\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390245\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10010066\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9906\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9906|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/25/22934?source=related_link\">",
"      Pneumococcal conjugate vaccine (13-valent): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_56_39815="Mandibular and palatal reconstruction in patients with head and neck cancer";
var content_f38_56_39815=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mandibular and palatal reconstruction in patients with head and neck cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/56/39815/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39815/contributors\">",
"     Barry L Wenig, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39815/contributors\">",
"     Michael R Zenn, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/56/39815/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39815/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39815/contributors\">",
"     Marvin P Fried, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/56/39815/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39815/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/56/39815/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoma of the head and neck can be treated and potentially cured by surgical excision either alone or in combination with chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy (RT). The defects caused by surgical excision can cause significant problems in airway management, mastication, deglutition, speech, and cosmesis. In addition, RT has significant adverse effects upon wound healing that can complicate surgical management.",
"   </p>",
"   <p>",
"    The goal of surgical reconstruction is to restore presurgical function and cosmesis. Optimization of the outcome of surgical reconstruction requires a team approach and should include speech pathology, physical therapy, and psychosocial support as appropriate.",
"   </p>",
"   <p>",
"    The basic elements of mandibular reconstruction and palatal reconstruction will be reviewed here. Voice rehabilitation after total laryngectomy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16231?source=see_link\">",
"     \"Alaryngeal speech rehabilitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TIMING OF RECONSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reconstruction may be primary (performed at the time of resection of the tumor) or secondary (performed as a separate procedure after resection, or to repair a defect left by an ulcerative tumor treated by primary radiation). Primary reconstruction has become the standard of care for most patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary reconstruction can rapidly restore anatomy and function and decrease the number of operations and duration of hospitalization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/1\">",
"       1",
"      </a>",
"      ]. Because the head and neck patient may have a limited life span and significant premorbid conditions, rapid recovery and decreased hospital stay are important considerations. However, the possibility of infection with intraoral contamination of the graft is always of concern.",
"     </li>",
"     <li>",
"      The delay in reconstruction with a secondary procedure may lead to significant muscle atrophy and fibrosis with contracture of soft tissues, functional difficulties, and cosmetic deformities that may be hard to correct at a later stage, although secondary reconstruction may avoid some risk of intraoral contamination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The timing of reconstruction relative to RT is controversial. Radiation causes a decrease in the vascular supply to the affected tissues, which can lead to reduced oxygenation and nutrient supply and impaired wound healing. The tissue response to radiation is bimodal with an acute and a chronic phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/2\">",
"     2",
"    </a>",
"    ]. The acute phase occurs during radiation and lasts a few weeks postradiation; the chronic phase causes long-term damage to the tissue.",
"   </p>",
"   <p>",
"    There is no evidence from randomized trials addressing the timing relative to RT. A study of 140 patients who received a fibular free flap found no difference in the rate of complications among patients receiving preoperative radiotherapy with immediate reconstruction, preoperative radiotherapy with delayed reconstruction, or postoperative radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MANDIBULAR RECONSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of mandibular reconstruction include restoration of deglutition, speech, airway support, oral sphincter competence, and cosmesis. In addition, reconstruction must provide adequate strength to support masticatory force and the possibility of future dental implants in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Reconstruction has positive effects on the quality of life in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mandibular defects may range from minimal bony loss to composite loss of both soft tissue and hard tissue. Defects of the posterolateral aspect of the mandible have significant associated mucosa loss and minimal bone requirements, while anterior defects require good bone stock for implants and less bulky tissues for normal facial contour. Restoration of bony continuity is recommended to optimize mastication and speech and to maintain symmetry of the lower third of the face.",
"   </p>",
"   <p>",
"    The type of reconstruction required depends upon the defect and the quality and quantity of the remaining soft and hard tissue bed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/3\">",
"     3",
"    </a>",
"    ]. The choice of reconstruction is also affected by patient factors, including preoperative morbidity, ability to withstand long operations, mental status, and motivation. Rehabilitation and patient motivation play a large role in the success of reconstruction.",
"   </p>",
"   <p>",
"    There are a variety of options for mandibular reconstruction, and each has inherent advantages and disadvantages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/4,6-8\">",
"     4,6-8",
"    </a>",
"    ]. Free flaps transfer blocks of vascularized tissue from a distant site represent the state of the art in head and neck reconstruction and offering a much greater range of tissue options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. Although free tissue transfer techniques require increased operative time, donor site morbidity, and the need for a surgeon trained in microvascular anastomoses, these drawbacks are outweighed by the improved healing and function that can be achieved. Computerized virtual surgery applications exist for planning purposes and for increasing accuracy of shaping of the graft intraoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other approaches include pedicled, vascularized regional grafts, nonvascularized autogenous bone grafts, and alloplasts of foreign material.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Free tissue transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Free tissue transfer has become the treatment of choice, when feasible, and its use is increasing, with success rates approximating 96 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/1,11-15\">",
"     1,11-15",
"    </a>",
"    ]. Free flaps have the following advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improved vascularity compared with pedicled grafts, and an expanded range of bony options [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Flaps can be transferred with a sensory nerve, which can aid in oral sphincter competence, improved deglutition, and decreased aspiration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Free flaps can accept endosteal dental implants that function as tooth root analogs, thereby permitting improved denture stability and retention. This results in superior function and restoration of mastication compared with patients who have not received reconstruction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advantages of free flaps were illustrated in a study which compared the outcomes with vascularized bone flaps to those with nonvascularized bone grafts in 75 consecutive mandibular reconstructions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients receiving vascularized bone flaps had a significantly higher incidence of bony union and implant success compared with nonvascularized bone grafts (96 versus 69 percent and 99 versus 82 percent, respectively). Based upon these data, nonvascularized bone grafts should be used primarily for short bone defects in nonirradiated tissue",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in patients who are too medically compromised to tolerate the additional operative time required for a free flap procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279875982\">",
"    <span class=\"h2\">",
"     Pedicled vascularized grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pedicled, vascularized regional grafts transfer healthy tissue and bone to the defect; however, these grafts are restricted by limited bone and soft tissue mobility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/4\">",
"     4",
"    </a>",
"    ]. Examples include pectoralis major and deltopectoral flaps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279876003\">",
"    <span class=\"h2\">",
"     Nonvascularized autogenous bone grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonvascularized autogenous bone grafts use the patient's own cancellous bone to reform the mandible and stimulate new bone formation. Although theoretically ideal, autogenous bone grafts do have potential complications, including resorption, inadequate soft tissue coverage, infection, and loss of stabilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279875823\">",
"    <span class=\"h2\">",
"     Alloplasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alloplasts are implants made of foreign material and include pins, trays, bars, and plates. The ideal material is made of an inert biocompatible material that can withstand force. Options include vitallium, stainless steel, and titanium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/19\">",
"     19",
"    </a>",
"    ]. The alloplasts are readily available, allow for immediate reconstruction, do not affect later radiation or delayed reconstruction, and obviate the problem of donor site morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/4\">",
"     4",
"    </a>",
"    ]. Complications include extrusion, fracture of the material, and plate exposure. Alloplasts play an important role for patients unable to tolerate long procedures or for those with lateral mandibular defects, but are not recommended for otherwise healthy patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/4,20\">",
"     4,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Donor sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major donor sites for mandibular reconstruction include the fibula, iliac crest, scapula, and radius [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/1,11,21,22\">",
"     1,11,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The fibula osteocutaneous flap is the most versatile bone flaps. This approach allows two teams to operate at the same time, thereby limiting time in the operating room. It also allows longer lengths of bone to be used in patients undergoing wide surgical resections. The bone flap can be harvested with a skin paddle for intraoral or skin defects. The segmental blood supply allows excellent shaping with multiple osteotomies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/23\">",
"       23",
"      </a>",
"      ]. After osseous free flap mandible reconstruction, bone mass, particularly with fibular free flaps, appears to be well preserved over time, and loss of height is not a major problem [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The iliac crest offers good bone stock and allows superior mandibular height. This procedure requires release of the abdominal musculature to access the properitoneal space [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/25\">",
"       25",
"      </a>",
"      ]. As a result of the flap harvest, patients may complain of acute pain, ventral (abdominal wall) hernia formation, and long term sensory disturbances [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/4,25\">",
"       4,25",
"      </a>",
"      ]. The native shape of the iliac crest is similar to a mandible and osteotomies are not required. The iliac crest also offers the best bone stock for osseointegration of dental implants.",
"     </li>",
"     <li>",
"      The scapular flap system is useful because a variety of free flaps can be incorporated with a high degree of mobility relative to the bone. The major drawback to this donor site is the limited length and width of bone, which may be unsuitable for dental implants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The radial forearm flap is the most useful flap for thin soft tissue replacement required for mucosal loss. The flap can be innervated for excellent sensory function. Bone stock, however, is limited and radial fracture is a known complication, especially in elderly women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several techniques have been used to secure the grafts to the remaining mandibular segment. Rigid fixation with reconstruction plates allows more rapid resumption of oral function. As an example, one study compared stainless steel, titanium, and titanium hollow screw reconstruction plates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/28\">",
"     28",
"    </a>",
"    ]. The titanium reconstruction plates were preferred because of their potential for osseointegration and because fewer screws are necessary to attain adequate fixation. Stainless steel had the highest rate of complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Reconstruction plates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reconstruction plates have been used to bridge mandibular defects alone or with vascularized soft tissue coverage at the time of primary surgery. Lateral oromandibular reconstruction with soft tissue free flaps combined with plates maintains dental occlusion and facial contour while avoiding the morbidity associated with harvesting a bone-containing free flap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Bridging plates have also been used successfully with irradiation. In one study, the plate failure rate was about 20 percent and was similar in patients receiving preoperative and postoperative irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early complications are minor. However, some series of patients followed for a minimum of one year report a significant overall rate of delayed reconstructive failure in 25 to 40 percent of patients, which is often due to external plate exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PALATAL RECONSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postsurgical defects may interfere with the physiologic function of the palate and result in problems with deglutition and speech; these include nasal regurgitation and rhinolalia (hypernasal speech).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Function of the palate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hard palate functions as a barrier between the oral and nasal cavities, aids in articulation, and assists in food processing. The function of the soft palate can be divided by anatomic region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anterior soft palate is relatively fixed and slung from the posterior edge of the hard palate.",
"     </li>",
"     <li>",
"      The middle soft palate containing the muscular bulk of the palate is where the levator action is most marked and is involved mostly in speech.",
"     </li>",
"     <li>",
"      The posterior soft palate is involved in deglutition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The soft palate and base of tongue come together while chewing to hold food in the oral cavity. Depression of the soft palate prevents food from prematurely entering the oropharynx and may even increase the size of the nasal airway to help in breathing during oral intake of food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/35\">",
"     35",
"    </a>",
"    ]. If the patient loses the ability to apply the palate to the base of the tongue, inefficient transport of food may occur. This may result in problems with coordination and timing of relaxation of the upper esophageal sphincter and failure of laryngeal closure, leading to pooling of food contents and aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Closure of the velopharynx, as the soft palate reaches the posterior pharyngeal wall, prevents nasal regurgitation by ensuring that food or liquid does not enter the nasal cavity. Velopharyngeal closure is accomplished by elevation of the soft palate, anterior motion of the posterior pharyngeal wall, and medial movement of the lateral pharyngeal wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/37\">",
"     37",
"    </a>",
"    ]. The action of the posterior pharyngeal wall, in an effort to maintain palatopharyngeal closure, is exaggerated in patients with palatal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Speech may also be adversely affected by a palatal defect. Without a partition between the oropharynx and nasopharynx, vocalization may be transmitted through the nasal cavity as opposed to the oral cavity which leads to rhinolalia. Articulation of the sounds \"k\" and \"g\" and the sibilant sounds \"s\" and \"z\" require a functional soft and hard palate, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment of palatal defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of palatal defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palatal insufficiency, which occurs when there is an inadequate length of soft palate to obtain palatopharyngeal closure. Movement of the remaining tissues is normal.",
"     </li>",
"     <li>",
"      Palatal incompetence refers to an inability to obtain palatopharyngeal closure due to the absence of palatal movement. The palatal structure is normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical or prosthetic methods or a combination of both can be used to remedy palatal defects. The type of reconstruction or rehabilitation depends upon the size and placement of the defect, the baseline medical condition of the patient, and the goals of the patient. The prosthodontist and the surgeon must work together as a team.",
"   </p>",
"   <p>",
"    The patient should undergo complete preoperative counseling and discussion of options, as well as formation of dental impressions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/40\">",
"     40",
"    </a>",
"    ]. Not only may the patient be more likely to adjust to the emotional changes caused by the postsurgical defect, but immediately after surgery,",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    may be fitted for a prosthesis that would aid in speech and swallowing and offer structural support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/40\">",
"     40",
"    </a>",
"    ]. This is especially important in the patient undergoing delayed reconstruction or choosing prosthetic rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Obturators",
"    </span>",
"    &nbsp;&mdash;&nbsp;An obturator can be used to close a palatal defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/38\">",
"     38",
"    </a>",
"    ]. A soft palate obturator is a removable dental appliance attached to the remaining teeth and soft tissue structures. The goal is to provide a barrier from the nasal cavity and posterior pharynx when appropriate. The obturator must leave space posteriorly for nasal breathing at rest and must be abutted by the posterior pharynx and lateral pharyngeal walls to close the defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dentate status of the patient and the decision to use a prosthesis may affect the surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If more than one-half of the soft palate needs to be resected for tumor-free margins in a dentate patient, the entire soft palate should be removed, since the small amount of retained soft palate may interfere with obturator function.",
"     </li>",
"     <li>",
"      If the patient is edentulous, the goal is to save as much soft palate as possible because it may aid in stabilization of the obturator. Edentulous mouths are more difficult to treat with a prosthesis due to limited tissue for prosthetic stability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Obturators are more successfully used in defects of the hard palate. Because the defect is bound by the soft palate and remaining hard palate, there is little movement of the boundaries and the obturator is more easily stabilized. As much hard palate tissue must be preserved as is oncologically safe in an effort to save the premaxilla and key teeth, including the canine. These structures give the obturator improved support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Reconstructive flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical reconstruction of palatal defects is accomplished with flaps that may be local, regional, or distant.",
"   </p>",
"   <p>",
"    Local flaps move adjacent tissue to fill in the defect. These include the advancement rotation palatoplasty and lateral pharyngeal wall flap, the superiorly based pharyngeal flap, the lateral based tongue flap, and the uvulopalatal flap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/34-36,42\">",
"     34-36,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The uvulopalatal flap is most appropriate for small to moderate defects of the lateral soft palate. In one study of five patients undergoing partial ipsilateral excision of the soft palate, postoperative rhinolalia and regurgitation were unremarkable and an obturator was seldom needed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The superior-constrictor advancement-rotation flap (SCARF) achieves circumferential closure of the velopharynx and reestablishes its valvular sphincteric function. In one study of 10 patients who underwent a SCARF reconstruction of the velopharynx after 35 to 65 percent resection, normal velopharyngeal function was reestablished in all without significant phonatory or deglutitive disability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other local or regional flaps include the superior based pharyngeal flap, the facial artery musculomucosal (FAMM) flap, the pectoralis flap, and the temporalis flap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/35,42,44\">",
"     35,42,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The superior based pharyngeal flap offers good reliability and allows the donor site to heal by secondary intention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/42\">",
"       42",
"      </a>",
"      ]. Complications may include airway obstruction, which can be prevented by a prophylactic tracheostomy, and hyponasality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The FAMM flap has excellent vascularity based on the facial artery and supplies mucosal replacement for palatal defects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The pectoralis flap is the workhorse for most reconstructive surgeons for many defects of the head and neck. This flap can be used for oropharyngeal defects, including the palate. Bulk, hair-bearing tissue, and breast asymmetry are potential problems that may be decreased by raising only the muscle of the flap, not the overlying skin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/36,46\">",
"       36,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The temporalis flap permits local availability; however, loss of the temporal branch of the facial nerve occurs 20 percent of the time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Distant flaps or free tissue transfers have been performed with the radial forearm flap, anterior lateral thigh (ALT) flap, the fibula flap, and the scapular flap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/27,36\">",
"     27,36",
"    </a>",
"    ]. These flaps differ in tissue bulk, tissue viability, ease of manipulation, strength, sensation, and donor site morbidity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The radial forearm free flap is a popular tissue for reconstruction for the reasons mentioned above. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Donor sites'",
"      </a>",
"      above.) The thinness of the tissues of the flap is perhaps the best replacement for missing palate. Bone may be carried for maxillary support or reconstruction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ALT flap is the most versatile of reconstructive flaps. It is used for its ample supply of thin skin and muscle, and the possibility of chimeric flaps, where secondary flaps such as the rectus femoris or gracilis can be carried on the same vascular pedicle. Like the radial forearm free flap, the ALT flap facilitates a two-team approach, as it is far removed from the head and neck area [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The fibula flap has the advantages mentioned above and is especially valuable when a small skin paddle is needed with a bone segment for maxillary support [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Donor sites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The scapular flap provides the largest available amount of skin with the possibility of bone for maxillary support. Its use has been largely supplanted by the ALT flap for ease of two team approach, but its place in the reconstructive armamentarium remains, especially when other choices are not available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Computerized virtual surgery applications exist for planning purposes and for increasing accuracy of shaping of the graft intraoperatively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39815/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279876188\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of surgical reconstruction is to restore presurgical function and cosmesis. Optimization of the outcome of surgical reconstruction requires a team approach and should include speech pathology, physical therapy, and psychosocial support as appropriate. Primary reconstruction, rather than a secondary procedure, has become the standard of care for most patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Timing of reconstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal mandibular reconstruction is important to restore for deglutition, speech, airway support, oral sphincter competence, and cosmesis. Free flap transfer blocks of vascularized tissue from a distant site represent the state of the art in head and neck reconstruction and offering a much greater range of tissue options. Although free tissue transfer techniques require increased operative time, donor site morbidity, and the need for a surgeon trained in microvascular anastomoses, these drawbacks are outweighed by the improved healing and function that can be achieved. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mandibular reconstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postsurgical defects may interfere with the physiologic function of the palate and result in problems with deglutition and speech. The associated physiologic defects vary depending upon the particular region of the hard or soft palate involved, and the treatment must be directed accordingly. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Palatal reconstruction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/1\">",
"      Urken ML, Buchbinder D, Costantino PD, et al. Oromandibular reconstruction using microvascular composite flaps: report of 210 cases. Arch Otolaryngol Head Neck Surg 1998; 124:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/2\">",
"      Deutsch M, Kroll SS, Ainsle N, Wang B. Influence of radiation on late complications in patients with free fibular flaps for mandibular reconstruction. Ann Plast Surg 1999; 42:662.",
"     </a>",
"    </li>",
"    <li>",
"     Kuriloff D, Sullivan M. Mandibular reconstruction. In: Head and Neck Surgery: Otolaryngology, Bailey B (Ed), JB Lippincott, Philadelphia 1993. p.1980.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/4\">",
"      Burkey BB, Coleman JR Jr. Current concepts in oromandibular reconstruction. Otolaryngol Clin North Am 1997; 30:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/5\">",
"      Becker ST, Menzebach M, K&uuml;chler T, et al. Quality of life in oral cancer patients--effects of mandible resection and socio-cultural aspects. J Craniomaxillofac Surg 2012; 40:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/6\">",
"      Haller JR, Sullivan MJ. Contemporary techniques of mandibular reconstruction. Am J Otolaryngol 1995; 16:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/7\">",
"      Garvey PB, Selber JC, Madewell JE, et al. A prospective study of preoperative computed tomographic angiography for head and neck reconstruction with anterolateral thigh flaps. Plast Reconstr Surg 2011; 127:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/8\">",
"      Hanasono MM, Jacob RF, Bidaut L, et al. Midfacial reconstruction using virtual planning, rapid prototype modeling, and stereotactic navigation. Plast Reconstr Surg 2010; 126:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/9\">",
"      Head C, Alam D, Sercarz JA, et al. Microvascular flap reconstruction of the mandible: a comparison of bone grafts and bridging plates for restoration of mandibular continuity. Otolaryngol Head Neck Surg 2003; 129:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/10\">",
"      Modabber A, Gerressen M, Stiller MB, et al. Computer-assisted mandibular reconstruction with vascularized iliac crest bone graft. Aesthetic Plast Surg 2012; 36:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/11\">",
"      Urken ML. Composite free flaps in oromandibular reconstruction. Review of the literature. Arch Otolaryngol Head Neck Surg 1991; 117:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/12\">",
"      Urken ML, Weinberg H, Buchbinder D, et al. Microvascular free flaps in head and neck reconstruction. Report of 200 cases and review of complications. Arch Otolaryngol Head Neck Surg 1994; 120:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/13\">",
"      L&oacute;pez-Arcas JM, Arias J, Del Castillo JL, et al. The fibula osteomyocutaneous flap for mandible reconstruction: a 15-year experience. J Oral Maxillofac Surg 2010; 68:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/14\">",
"      Chang YM, Tsai CY, Wei FC. One-stage, double-barrel fibula osteoseptocutaneous flap and immediate dental implants for functional and aesthetic reconstruction of segmental mandibular defects. Plast Reconstr Surg 2008; 122:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/15\">",
"      Momoh AO, Yu P, Skoracki RJ, et al. A prospective cohort study of fibula free flap donor-site morbidity in 157 consecutive patients. Plast Reconstr Surg 2011; 128:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/16\">",
"      Urken ML, Buchbinder D, Weinberg H, et al. Functional evaluation following microvascular oromandibular reconstruction of the oral cancer patient: a comparative study of reconstructed and nonreconstructed patients. Laryngoscope 1991; 101:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/17\">",
"      Foster RD, Anthony JP, Sharma A, Pogrel MA. Vascularized bone flaps versus nonvascularized bone grafts for mandibular reconstruction: an outcome analysis of primary bony union and endosseous implant success. Head Neck 1999; 21:66.",
"     </a>",
"    </li>",
"    <li>",
"     Donald PJ, Ness JA. Trays with bone grafts. In: Mandibular Reconstruction, Komisar A (Ed), Thieme, New York 1997. p.15.",
"    </li>",
"    <li>",
"     Komisar A. Mandibular reconstruction: History and review of the literature. In: Mandibular Reconstruction, Komisar A (Ed), Thieme, New York 1997. p.1.",
"    </li>",
"    <li>",
"     Irish JC, Gullane PJ. Reconstruction plates without grafts. In: Mandibular reconstruction, Komisar A (Ed), Thieme, New York 1997. p.33.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/21\">",
"      Moscoso JF, Keller J, Genden E, et al. Vascularized bone flaps in oromandibular reconstruction. A comparative anatomic study of bone stock from various donor sites to assess suitability for enosseous dental implants. Arch Otolaryngol Head Neck Surg 1994; 120:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/22\">",
"      Zenn MR, Hidalgo DA, Cordeiro PG, et al. Current role of the radial forearm free flap in mandibular reconstruction. Plast Reconstr Surg 1997; 99:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/23\">",
"      Hidalgo DA, Pusic AL. Free-flap mandibular reconstruction: a 10-year follow-up study. Plast Reconstr Surg 2002; 110:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/24\">",
"      Disa JJ, Hidalgo DA, Cordeiro PG, et al. Evaluation of bone height in osseous free flap mandible reconstruction: an indirect measure of bone mass. Plast Reconstr Surg 1999; 103:1371.",
"     </a>",
"    </li>",
"    <li>",
"     Moscoso JF, Urken ML. The iliac crest flap. In: Mandibular Reconstruction, Komisar A (Ed), Thieme, New York 1997. p.77.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/26\">",
"      Vinzenz K, Holle J, W&uuml;ringer E. Reconstruction of the maxilla with prefabricated scapular flaps in noma patients. Plast Reconstr Surg 2008; 121:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/27\">",
"      Brown JS, Zuydam AC, Jones DC, et al. Functional outcome in soft palate reconstruction using a radial forearm free flap in conjunction with a superiorly based pharyngeal flap. Head Neck 1997; 19:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/28\">",
"      Futran ND, Urken ML, Buchbinder D, et al. Rigid fixation of vascularized bone grafts in mandibular reconstruction. Arch Otolaryngol Head Neck Surg 1995; 121:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/29\">",
"      Lavertu P, Wanamaker JR, Bold EL, Yetman RJ. The AO system for primary mandibular reconstruction. Am J Surg 1994; 168:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/30\">",
"      Saunders JR Jr, Hirata RM, Jaques DA. Definitive mandibular replacement using reconstruction plates. Am J Surg 1990; 160:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/31\">",
"      Gullane PJ. Primary mandibular reconstruction: analysis of 64 cases and evaluation of interface radiation dosimetry on bridging plates. Laryngoscope 1991; 101:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/32\">",
"      Blackwell KE, Buchbinder D, Urken ML. Lateral mandibular reconstruction using soft-tissue free flaps and plates. Arch Otolaryngol Head Neck Surg 1996; 122:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/33\">",
"      Ueyama Y, Naitoh R, Yamagata A, Matsumura T. Analysis of reconstruction of mandibular defects using single stainless steel A-O reconstruction plates. J Oral Maxillofac Surg 1996; 54:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/34\">",
"      Zohar Y, Buler N, Shvilli Y, Sabo R. Reconstruction of the soft palate by uvulopalatal flap. Laryngoscope 1998; 108:47.",
"     </a>",
"    </li>",
"    <li>",
"     Logemann JA. Upper digestive tract anatomy and physiology. In: Head and Neck Surgery: Otolaryngology, Bailey B (Ed), JB Lippencott, Philadelphia 1993. p.485.",
"    </li>",
"    <li>",
"     Panje WR, Morris MR. The oropharynx. In: Excision and reconstruction in Head and Neck Surgery, Soutar DS, Tiwari R (Eds), Churchill Livingstone, New York 1994. p.141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/37\">",
"      Maldonado AR, Baker BM, Judson WF. Palatal insufficiency: a surgical technique for reconstruction. South Med J 1985; 78:954.",
"     </a>",
"    </li>",
"    <li>",
"     Curtis TA, Beumer J III. Speech, palatopharyngeal function and restoration of soft palate defects. In: Maxillofacial Rehabilitation; Prosthodontic and Surgical Considerations, Beumer J, Curtis T, Firtell DN (Eds), Mosby, St. Louis 1979. p.244.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/39\">",
"      Michiwaki Y, Schmelzeisen R, Hacki T, Michi K. Functional effects of a free jejunum flap used for reconstruction in the oropharyngeal region. J Craniomaxillofac Surg 1993; 21:153.",
"     </a>",
"    </li>",
"    <li>",
"     Finlay PM. Prosthodontics. In: Excision and Reconstruction in Head and Neck Surgery, Soutar DS, Tiwari R (Eds), Churchill Livingstone, New York 1994. p.103.",
"    </li>",
"    <li>",
"     Curtis TA, Beumer J III. Restoration of acquired hard palate defects: Etiology, disability and rehabilitation. In: Maxillofacial Rehabilitation: Prosthodontic and Surgical Considerations, Mosby, St. Louis 1979. p.188.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/42\">",
"      Shapiro BM, Komisar A, Silver C, Strauch B. Primary reconstruction of palatal defects. Otolaryngol Head Neck Surg 1986; 95:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/43\">",
"      Zeitels SM, Kim J. Soft-palate reconstruction with a \"SCARF\" superior-constrictor advancement-rotation flap. Laryngoscope 1998; 108:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/44\">",
"      Thomson CJ, Allison RS. The temporalis muscle flap in intraoral reconstruction. Aust N Z J Surg 1997; 67:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/45\">",
"      Pribaz J, Stephens W, Crespo L, Gifford G. A new intraoral flap: facial artery musculomucosal (FAMM) flap. Plast Reconstr Surg 1992; 90:421.",
"     </a>",
"    </li>",
"    <li>",
"     Truelson JM, Close LG. Regional flaps in head and neck surgery. In: Head and Neck Surgery: Otolaryngology, Bailey B (Ed), JB Lippencott, Philadelphia 1993. p.1937.",
"    </li>",
"    <li>",
"     Panje WR, Morris MR. Oral cavity and oropharyngeal reconstruction. In: Otolaryngology-Head and Neck Surgery, 2nd, Cummings C (Ed), Mosby, St. Louis 1993. p.1479.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/48\">",
"      Wei FC, Jain V, Celik N, et al. Have we found an ideal soft-tissue flap? An experience with 672 anterolateral thigh flaps. Plast Reconstr Surg 2002; 109:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/49\">",
"      Chang YM, Coskunfirat OK, Wei FC, et al. Maxillary reconstruction with a fibula osteoseptocutaneous free flap and simultaneous insertion of osseointegrated dental implants. Plast Reconstr Surg 2004; 113:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/50\">",
"      Swartz WM, Banis JC, Newton ED, et al. The osteocutaneous scapular flap for mandibular and maxillary reconstruction. Plast Reconstr Surg 1986; 77:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39815/abstract/51\">",
"      Shen Y, Sun J, Li J, et al. Special considerations in virtual surgical planning for secondary accurate maxillary reconstruction with vascularised fibula osteomyocutaneous flap. J Plast Reconstr Aesthet Surg 2012; 65:893.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3396 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39815=[""].join("\n");
var outline_f38_56_39815=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H279876188\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TIMING OF RECONSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MANDIBULAR RECONSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Free tissue transfer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279875982\">",
"      Pedicled vascularized grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279876003\">",
"      Nonvascularized autogenous bone grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279875823\">",
"      Alloplasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Donor sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Reconstruction plates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PALATAL RECONSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Function of the palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment of palatal defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Obturators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Reconstructive flaps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H279876188\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16231?source=related_link\">",
"      Alaryngeal speech rehabilitation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_56_39816="Gastroesophageal reflux and asthma";
var content_f38_56_39816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gastroesophageal reflux and asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/56/39816/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39816/contributors\">",
"     Susan M Harding, MD, FCCP, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/56/39816/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39816/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/56/39816/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39816/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/56/39816/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal (GE) reflux is common in patients with asthma and has been identified as a potential trigger for asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. GE reflux is thought to affect asthma through the activation of vagal reflexes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    microaspiration.",
"   </p>",
"   <p>",
"    Gastroesophageal reflux disease (GERD) refers to symptoms or signs suggestive of reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/4\">",
"     4",
"    </a>",
"    ]. The typical symptoms of GERD are heartburn and regurgitation. Other symptoms suggestive of GERD include dysphagia, chest pain, hypersalivation, globus sensation, odynophagia, and nausea. Esophageal inflammation is not necessarily present.",
"   </p>",
"   <p>",
"    The relationship between GE reflux and asthma will be reviewed here. Other issues related to GE reflux disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory symptoms, including those associated with asthma (eg, cough, dyspnea, wheeze, and chest tightness), are increased among patients with GE reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/5\">",
"     5",
"    </a>",
"    ]. Reciprocally, GE reflux is common among patients with asthma. Estimates of the prevalence of GE reflux among patients with asthma have varied from 30 to 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/1,6-19\">",
"     1,6-19",
"    </a>",
"    ]. Part of the variability may be due to differences in the definition of GE reflux, and the extent to which objective measures of reflux were used.",
"   </p>",
"   <p>",
"    The following examples illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of 28 studies of patients with asthma found GE reflux symptoms in 59 percent, abnormal 24-hour esophageal pH tests in 51 percent, hiatal hernia in 51 percent, and esophagitis in 37 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One series included 199 patients with asthma who were referred for 24-hour esophageal pH testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/13\">",
"       13",
"      </a>",
"      ]. Reflux symptoms were present in 164 patients (82 percent), of whom 118 (72 percent) had increased esophageal acid contact times. Among the patients with asthma and GE reflux, 80 percent reported respiratory symptoms that were associated with esophageal acid events. Of the 35 patients with asthma who did not have reflux symptoms, 10 (29 percent) had increased esophageal acid contact times consistent with the diagnosis of GE reflux.",
"     </li>",
"     <li>",
"      In another study, 104 consecutive patients with asthma and 44 control patients underwent esophageal manometry and 24-hour esophageal pH tests [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/9\">",
"       9",
"      </a>",
"      ]. When compared to controls, the patients with asthma had decreased lower esophageal sphincter (LES) pressures, more frequent reflux episodes, and higher esophageal acid contact times (",
"      <a class=\"graphic graphic_figure graphicRef68486 \" href=\"mobipreview.htm?2/42/2734\">",
"       figure 1",
"      </a>",
"      ). Acid reflux, as assessed by acid contact time, was noted in 82 percent of the asthma patients.",
"     </li>",
"     <li>",
"      In a population based survey in the United States, 6 percent of respondents reported that they had significant (ie, occurring at least twice weekly) heartburn or regurgitation within the last month while 3 percent reported regurgitation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies are conflicting as to whether GE reflux can be a contributor to asthma in patients without esophageal symptoms. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Empiric therapy in asymptomatic patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three potential mechanisms whereby esophageal acid may produce bronchoconstriction and therefore exacerbate airflow obstruction in asthmatics: increased vagal tone, heightened bronchial reactivity, and microaspiration of gastric contents into the upper airway. Furthermore, GE reflux can illicit neuroinflammation and increase exhaled oxidative stress biomarkers (8-isoprostane) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Increased vagal tone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal models have demonstrated that exposure of the esophagus to acid is associated with increased respiratory resistance, an effect that is ablated by bilateral vagotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/21\">",
"     21",
"    </a>",
"    ]. Neural mechanisms underlying this pathway appear to involve the release of substance P, which leads to plasma extravasation in the airways and the release of other tachykinins from peripheral nerve terminals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of observations in humans are also compatible with a vagal mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Bernstein test is performed by alternately infusing saline or acid into the mid-esophagus via a nasogastric tube or manometric assembly. A positive test is defined as reproduction of the patient's symptoms with acid perfusion but not with saline. Among patients with asthma who have a positive Bernstein test, a 10 percent increase in total respiratory resistance is observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\", section on 'Additional evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A reduction in peak expiratory flow rate (PEF) was detected during acid infusion into the esophagus in normal controls, patients with asthma plus GE reflux, patients with asthma without GE reflux, and patients with GE reflux alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/25\">",
"       25",
"      </a>",
"      ]. Measures taken to improve esophageal acid clearance resulted in improved PEF in all groups except for the patients with asthma and GE reflux. These effects occurred with acid infusion into the mid-esophagus and were independent of proximal esophageal acid exposure (which is a prerequisite for microaspiration) (",
"      <a class=\"graphic graphic_figure graphicRef78222 \" href=\"mobipreview.htm?10/1/10270\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with asthma who received an infusion of acid into the esophagus had a reduction in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      dose required to decrease the forced expiratory volume at one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) by 20 percent (PD20), compared to patients with asthma who received an infusion of saline (",
"      <a class=\"graphic graphic_figure graphicRef59750 \" href=\"mobipreview.htm?8/16/8461\">",
"       figure 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/27\">",
"       27",
"      </a>",
"      ]. The effect was abolished with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      . Thus, heightened bronchial reactivity may result from reflux, presumably mediated by vagal mechanisms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review summarized the findings of 18 studies that evaluated pulmonary function during esophageal acid perfusion in adults with asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/28\">",
"     28",
"    </a>",
"    ]. Forced expiratory volume at one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ), mid-expiratory flow rate, and peak expiratory flow rate did not change significantly in 97, 94, and 65 percent of patients, respectively. Changes in airway resistance were noted in 42 percent of patients. It is difficult to reach definitive conclusions based on this review because the studies included different subsets of patients, used different techniques in acid-perfusion, and monitored different airway responses.",
"   </p>",
"   <p>",
"    The occurrence of respiratory symptoms following esophageal acid exposure may be due to factors other than bronchoconstriction. As an example, esophageal acid perfusion is associated with increases in respiratory rate and minute ventilation, particularly in patients with a positive Bernstein test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/29\">",
"     29",
"    </a>",
"    ]. This suggests that an increased minute ventilation may be responsible for worsening respiratory symptoms without a decrease in pulmonary function. However, the study was performed in subjects without asthma; whether these data can be applied to patients without asthma remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Heightened bronchial reactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal reflux may also cause neural enhancement of bronchial reactivity. In a study of 105 consecutive patients with asthma, the degree of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    reactivity correlated with the number of episodes of reflux during 24-hour esophageal pH monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Microaspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microaspiration refers to the inhalation into the lungs of tiny amounts of refluxate from the stomach. This fluid can have a low pH from acidic gastric secretions or a weakly acidic or alkaline pH when the refluxate comes from achlorhydric conditions (eg, atrophic gastritis, use of acid suppressive medication) or from the small bowel.",
"   </p>",
"   <p>",
"    Esophageal acid causes bronchoconstriction by a vagally mediated reflex. This response is further augmented if microaspiration is present (",
"    <a class=\"graphic graphic_figure graphicRef80770 \" href=\"mobipreview.htm?38/15/39167\">",
"     figure 4",
"    </a>",
"    ). Much of the evidence supporting a role for microaspiration of acid in reflux-induced bronchoconstriction comes from animal studies that found an increase in airway resistance after inhalational or intratracheal exposure to acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/23,30,31\">",
"     23,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also evidence from human studies. In four patients with coexisting asthma and GE reflux, pH probes were placed into the trachea and esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/32\">",
"     32",
"    </a>",
"    ]. Thirty-seven episodes of esophageal reflux lasting more than five minutes caused a mean decrease in PEF of 8",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"    During five of these episodes, there was also a fall in tracheal pH, associated with a decrease in PEF of 84",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"   </p>",
"   <p>",
"    Gastric contents that are active in a nonacidic environment can also damage the upper airway epithelium. As an example, pepsin present in gastric juice, is active even in nonacidic pH and is endocytosed by epithelial cells in the upper airways, causing tissue damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVIDENCE THAT GERD TREATMENT IMPROVES ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of controlled and uncontrolled trials have found an association between GE reflux therapy and improved asthma symptoms; however, the impact of GE reflux therapy on objective outcome measures of asthma control has been variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/34-49\">",
"     34-49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with both asthma and symptoms of GE reflux, the best evidence that PPI therapy improves some asthma outcomes derives from three large, randomized controlled trials that evaluated high-dose PPI therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial randomly assigned 207 patients with moderate to severe asthma plus reflux symptoms to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"       lansoprazole",
"      </a>",
"      (30 mg) or placebo twice daily for 24 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/50\">",
"       50",
"      </a>",
"      ]. The primary outcome, asthma symptoms, and the secondary outcomes, peak expiratory flow (PEF) and forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ), did not improve. However, lansoprazole therapy improved asthma quality of life questionnaire scores and decreased asthma exacerbations.",
"     </li>",
"     <li>",
"      A randomized trial that compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      40 mg once or twice daily to placebo followed 961 patients with moderate to severe asthma and symptoms suggestive of GERD for 26 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/51\">",
"       51",
"      </a>",
"      ]. In the esomeprazole-treated patients, small, but significant improvements were noted in morning peak expiratory flow rates, the Asthma Quality of Life Questionnaire total score, and the forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ).",
"     </li>",
"     <li>",
"      Another trial randomly assigned 770 patients with persistent moderate to severe asthma who were being treated with asthma antiinflammatory medication to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      (40 mg) or placebo twice daily for 16 weeks in addition to current asthma therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/36\">",
"       36",
"      </a>",
"      ]. Among patients with both nocturnal respiratory symptoms and GE reflux, esomeprazole improved PEF in the morning (8.7",
"      <span class=\"nowrap\">",
"       L/min)",
"      </span>",
"      and evening (10.2",
"      <span class=\"nowrap\">",
"       L/min).",
"      </span>",
"      No significant improvement in PEF was detected among patients without both GERD and nocturnal asthma symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically silent GE reflux has been identified in 24 to 62 percent of patients with asthma and early studies suggested that treatment of GE-reflux improved asthma control in patients with severe or difficult to control asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/34,37,52\">",
"     34,37,52",
"    </a>",
"    ]. However, three controlled trials found that proton pump inhibitor therapy did not improve asthma outcomes in the absence of GE reflux symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/36,53\">",
"     36,53",
"    </a>",
"    ]. These trials reported the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study that randomly assigned 412 patients with poorly controlled asthma and minimal to no symptoms of reflux, no difference was found in the number of episodes of poor asthma control between the group taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      40 mg twice daily and that taking placebo for 24 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/53\">",
"       53",
"      </a>",
"      ]. The outcomes were not affected by the presence or absence of GE reflux determined by pH probe monitoring.",
"     </li>",
"     <li>",
"      In the Study of Acid Reflux in Children With Asthma, 306 children with poorly controlled asthma, but without GE reflux symptoms, were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"       lansoprazole",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      if weighing less than 30 kg or 30",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      if weighing 30 kg or more) or placebo for 24 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/54\">",
"       54",
"      </a>",
"      ]. No differences in the asthma control questionnaire (ACQ) scores or lung function were noted. Among 115 children with pH probe monitoring results, 49 (43 percent) had evidence of reflux; no difference in asthma outcomes was noted in this subgroup, although the number of patients was small.",
"     </li>",
"     <li>",
"      In a separate study, among 201 patients with moderate to severe asthma but no symptoms of reflux, no improvement was seen in peak expiratory flow rate measurements during 16 weeks of treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      40 mg twice daily compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section summarizes a clinical approach to the diagnosis and management of GERD in patients with asthma. The first step is to determine if the patient has symptoms suggestive of GERD. Next, symptomatic patients are given a trial of acid suppression therapy to identify those patients in whom chronic GE reflux therapy leads to improved asthma control. Decisions about possible further therapy are made after approximately three months of empiric therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristics that may predict asthma improvement with GE reflux therapy include symptoms of regurgitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/35\">",
"     35",
"    </a>",
"    ], nocturnal asthma symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/36\">",
"     36",
"    </a>",
"    ], and concurrent symptoms of GE reflux and asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/34,36,50,53\">",
"     34,36,50,53",
"    </a>",
"    ]. As a result, patients with asthma should be questioned about esophageal and extraesophageal manifestations of GE reflux (",
"    <a class=\"graphic graphic_table graphicRef55234 \" href=\"mobipreview.htm?28/25/29083\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Careful questioning is needed since patients with asthma may not identify their symptoms as being related to GERD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/34,55,56\">",
"     34,55,56",
"    </a>",
"    ]. Alternatively, some symptoms that are attributed to asthma may actually be due to GERD. For example, chest tightness may be misinterpreted as asthma, when it is actually due to GERD and cough may be caused by GERD in the absence of asthma.",
"   </p>",
"   <p>",
"    Pertinent historical findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthma symptoms (cough, dyspnea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wheezing) may be associated with a GE reflux episode, or the patient may use an inhaler while experiencing GE reflux symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Asthma symptoms are noticed after eating a high fat meal or foods that lower the lower esophageal sphincter (LES) pressure, such as chocolate, peppermint, caffeine, or alcohol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The patient is taking asthma medication that may promote GE reflux by decreasing LES pressure (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      and systemic or inhaled beta agonists) or possibly by increasing esophageal acid contact time (eg, oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/1,57,58\">",
"       1,57,58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Empiric therapy in patients with symptomatic GERD",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with moderate to severe asthma and symptoms of GE reflux, particularly those with regurgitation symptoms or nocturnal asthma, we suggest empiric therapy with a proton pump inhibitor (PPI) taken twice daily, 30 minutes before breakfast and dinner. PPIs are preferred because they inhibit gastric acid secretion more effectively than H2 blockers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/59\">",
"     59",
"    </a>",
"    ]. Twice daily therapy is preferred because that was the regimen used in the clinical trials cited above. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Symptomatic patients'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients should be instructed about lifestyle modifications for GE reflux. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=see_link&amp;anchor=H2#H2\">",
"     \"Medical management of gastroesophageal reflux disease in adults\", section on 'Lifestyle modifications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Successful trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma improvement during a three month empiric trial of twice daily PPI therapy is considered diagnostic of GE reflux-triggered asthma. A successful trial may be defined as a 20 percent improvement in peak expiratory flow rates, an improvement in asthma symptoms, or a 20 percent decrease in oral glucocorticoid dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the empiric trial is successful, we usually continue PPI therapy long-term, although the PPI dose is often decreased to once daily. Twice daily therapy is resumed if the symptoms recur on the lower dose. Careful monitoring of asthma control should accompany decreases in the PPI dose or discontinuation. It is not known whether substituting an H2 blocker for the PPI will provide comparable control of GE reflux-triggered asthma.",
"   </p>",
"   <p>",
"    GE reflux is a chronic remitting disorder, and most patients require protracted therapy. Surgical fundoplication can be useful in selected patients; however, up to 62 percent of patients still require medical therapy after fundoplication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/18/17706?source=see_link&amp;anchor=H31#H31\">",
"     \"Approach to refractory gastroesophageal reflux disease in adults\", section on 'Surgical treatments'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients whose GERD symptoms improve, but their symptoms and objective measures of asthma are unchanged, we manage their GERD according to current guidelines for GERD therapy. These guidelines are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Unsuccessful trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the empiric therapeutic trial is unsuccessful (ie, no significant improvement in symptoms, peak expiratory flow rate, or systemic glucocorticoid requirement), either asthma is not triggered by GE reflux and GE reflux therapy can be discontinued, or GE reflux was not adequately controlled. A 24-hour esophageal pH test, while the patient continues to take antireflux medications, can be performed to distinguish between these possibilities. Esophageal pH testing should also be considered if the diagnosis of reflux-triggered asthma is suggested but not definite following a three month trial of empiric GE reflux therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Esophageal pH testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If esophageal symptoms improve with therapy, but asthma does not, it is possible that the patient has GE reflux, but it does not trigger asthma. In this situation, GE reflux would be managed according to usual guidelines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Empiric therapy in asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend NOT prescribing empiric proton pump inhibitor therapy in patients with asthma and no symptoms suggestive of GE reflux. This recommendation is based upon the two negative randomized trials described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/7,26\">",
"     7,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Asymptomatic patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL PH TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically obtain esophageal pH testing in patients who have symptoms suggestive of GERD that are refractory to PPI therapy. When interpreting pH probe data, the percentage time with the intraesophageal pH below 4 is the most useful outcome measure in discriminating between physiologic and pathologic esophageal reflux. Esophageal pH testing is accepted as the standard to diagnose GE reflux with a sensitivity of 93 percent and specificity of 95 percent. Esophageal pH testing also allows correlation of asthma symptoms with esophageal acid events. Limitations of this testing include false negatives and inability to determine the degree to which GE reflux affects a patient's asthma over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/4,60,61\">",
"     4,60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\", section on 'Ambulatory esophageal pH monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophageal multichannel intraluminal impedance testing is helpful, when combined with pH probe testing, for detection of gastroesophageal reflux independent of pH (ie, both acid and non-acid reflux); however, this testing is not available at many centers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26247?source=see_link\">",
"     \"Esophageal multichannel intraluminal impedance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Gastroenterological Association (AGA) guideline for esophageal pH recording [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/60\">",
"     60",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     GI REFERRAL AND ENDOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to a gastroenterologist is indicated if GE reflux is not controlled on twice daily proton pump inhibitor therapy or if the patient has alarming symptoms (eg, dysphagia, odynophagia, acute involuntary weight loss, or anemia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a general rule, upper endoscopy is not indicated for the routine evaluation of patients with asthma and symptoms suggestive of GE reflux in the absence of alarming (eg, dysphagia, odynophagia, acute involuntary weight loss, or anemia) or refractory symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\", section on 'Upper gastrointestinal endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, many gastroenterologists recommend that an upper endoscopy be performed in patients requiring long-term maintenance therapy with a proton pump inhibitor to exclude the presence of Barrett's esophagus, especially in patients over 50 years of age who have had GE reflux symptoms for more than 10 years.",
"   </p>",
"   <p>",
"    The indications for upper endoscopy to evaluate for Barrett's esophagus in patients who require long-term PPI therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1161?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus\", section on 'Screening patients for Barrett's esophagus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OTHER TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other diagnostic modalities, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow, capsule endoscopy, Helicobacter pylori testing, technetium-99 sulfur colloid scintigraphic monitoring, and inspection of sputum for lipid-laden macrophages, are not recommended for evaluation of GERD in patients with asthma because of unacceptably low sensitivities and specificities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/16,63,64\">",
"     16,63,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     GE REFLUX SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus has not been achieved on the role of surgery (eg, fundoplication) in patients with asthma-associated GE reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42905?source=see_link\">",
"     \"Surgical management of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies suggest that surgical therapy is associated with improved asthma symptom control; however, there is little compelling evidence that fundoplication is effective in improving pulmonary function in patients with airway obstruction, particularly in patients without symptoms of GERD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/2,38,65,66\">",
"     2,38,65,66",
"    </a>",
"    ]. A meta-analysis of 24 studies (only two of which were controlled) estimated that antireflux surgery improved asthma symptoms by 79 percent, but had little effect on pulmonary function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39816/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endoscopic therapies for GE reflux are considered experimental and their role in the treatment of asthma-associated GERD remains to be defined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25688?source=see_link\">",
"     \"Endoscopic therapy for gastroesophageal reflux disease: Sewing and full-thickness plication techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GE reflux is common among patients with asthma. Reciprocally, respiratory symptoms, including those associated with asthma, are increased among patients with GE reflux. Estimates of the prevalence of GE reflux among patients with asthma have varied from 30 to 90 percent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three potential mechanisms have been proposed whereby esophageal acid may produce bronchoconstriction and therefore exacerbate airflow obstruction in asthmatics: increased vagal tone, heightened bronchial reactivity, and microaspiration of gastric contents into the upper airway. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with asthma should be questioned about esophageal and extraesophageal manifestations of GE reflux (",
"      <a class=\"graphic graphic_table graphicRef55234 \" href=\"mobipreview.htm?28/25/29083\">",
"       table 1",
"      </a>",
"      ). Pertinent historical findings include asthma symptoms during an episode of GE reflux, use of an inhaler while experiencing GE reflux symptoms, or asthma symptoms after eating certain foods (eg, high fat food, chocolate, peppermint, caffeine, alcohol). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Characteristics that may predict asthma improvement with GE reflux therapy include symptoms of regurgitation and nocturnal asthma symptoms. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a trial of GE reflux therapy in patients who have coexisting moderate to severe asthma and GE reflux symptoms, rather than further diagnostic testing (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A trial of GE reflux therapy consists of a proton pump inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"       lansoprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/18/44327?source=see_link\">",
"       rabeprazole",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32009?source=see_link\">",
"       pantoprazole",
"      </a>",
"      ) administered twice per day for three months (taken 30 minutes before breakfast and dinner). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Empiric therapy in patients with symptomatic GERD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that chronic GE reflux therapy be included in ongoing treatment for the patient's asthma if the empiric therapeutic trial is successful (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). A successful trial is defined as a 20 percent improvement in peak expiratory flow rates, an improvement in asthma symptoms, or a 20 percent decrease in oral glucocorticoid dose. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Successful trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternatively, if the empiric therapeutic trial is unsuccessful, either asthma is not triggered by GE reflux and GE reflux therapy can be discontinued, or GE reflux was not adequately controlled. A 24-hour esophageal pH test, performed with the patient on antireflux therapy, can distinguish between these possibilities. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Unsuccessful trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend NOT prescribing empiric proton pump inhibitor therapy for patients with asthma and no symptoms suggestive of GE reflux (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Empiric therapy in asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Referral to a gastroenterologist is indicated if GE reflux is not controlled on twice daily proton pump inhibitor therapy or if patients report alarming symptoms including dysphagia, odynophagia, hematemesis, melena, persistent vomiting (ie, 7 to 10 days), acute involuntary weight loss, or anemia. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'GI referral and endoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consensus has not been achieved on the role of surgery in patients with asthma exacerbated by GE reflux; endoscopic therapies for GE reflux are considered experimental in this population. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'GE reflux surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Sontag SJ, Harding SM. Gastroesophageal reflux and asthma. In: Goyal and Shaker's GI Motility Online, Goyal RK, Shaker R (Eds), Nature Publishing Group, New York 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/2\">",
"      Simpson WG. Gastroesophageal reflux disease and asthma. Diagnosis and management. Arch Intern Med 1995; 155:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/3\">",
"      Harding SM. Recent clinical investigations examining the association of asthma and gastroesophageal reflux. Am J Med 2003; 115 Suppl 3A:39S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/4\">",
"      DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/5\">",
"      Nordenstedt H, Nilsson M, Johansson S, et al. The relation between gastroesophageal reflux and respiratory symptoms in a population-based study: the Nord-Tr&oslash;ndelag health survey. Chest 2006; 129:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/6\">",
"      Harding SM. Gastroesophageal reflux: a potential asthma trigger. Immunol Allergy Clin North Am 2005; 25:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/7\">",
"      Kiljander TO, Laitinen JO. The prevalence of gastroesophageal reflux disease in adult asthmatics. Chest 2004; 126:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/8\">",
"      Sontag SJ, Schnell TG, Miller TQ, et al. Prevalence of oesophagitis in asthmatics. Gut 1992; 33:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/9\">",
"      Sontag SJ, O'Connell S, Khandelwal S, et al. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 1990; 99:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/10\">",
"      Field SK, Underwood M, Brant R, Cowie RL. Prevalence of gastroesophageal reflux symptoms in asthma. Chest 1996; 109:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/11\">",
"      Campo S, Morini S, Re MA, et al. Esophageal dysmotility and gastroesophageal reflux in intrinsic asthma. Dig Dis Sci 1997; 42:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/12\">",
"      Vincent D, Cohen-Jonathan AM, Leport J, et al. Gastro-oesophageal reflux prevalence and relationship with bronchial reactivity in asthma. Eur Respir J 1997; 10:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/13\">",
"      Harding SM, Guzzo MR, Richter JE. 24-h esophageal pH testing in asthmatics: respiratory symptom correlation with esophageal acid events. Chest 1999; 115:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/14\">",
"      Tan WC, Martin RJ, Pandey R, Ballard RD. Effects of spontaneous and simulated gastroesophageal reflux on sleeping asthmatics. Am Rev Respir Dis 1990; 141:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/15\">",
"      Harding SM. Nocturnal asthma: role of nocturnal gastroesophageal reflux. Chronobiol Int 1999; 16:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/16\">",
"      Harding SM, Sontag SJ. Asthma and gastroesophageal reflux. Am J Gastroenterol 2000; 95:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/17\">",
"      Havemann BD, Henderson CA, El-Serag HB. The association between gastro-oesophageal reflux disease and asthma: a systematic review. Gut 2007; 56:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/18\">",
"      Cheung TK, Lam B, Lam KF, et al. Gastroesophageal reflux disease is associated with poor asthma control, quality of life, and psychological status in Chinese asthma patients. Chest 2009; 135:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/19\">",
"      DiMango E, Holbrook JT, Simpson E, et al. Effects of asymptomatic proximal and distal gastroesophageal reflux on asthma severity. Am J Respir Crit Care Med 2009; 180:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/20\">",
"      Shimizu Y, Dobashi K, Zhao JJ, et al. Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease. Respiration 2007; 74:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/21\">",
"      Mansfield LE, Stein MR. Gastroesophageal reflux and asthma: a possible reflex mechanism. Ann Allergy 1978; 41:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/22\">",
"      Hamamoto J, Kohrogi H, Kawano O, et al. Esophageal stimulation by hydrochloric acid causes neurogenic inflammation in the airways in guinea pigs. J Appl Physiol 1997; 82:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/23\">",
"      Ricciardolo FL, Rado V, Fabbri LM, et al. Bronchoconstriction induced by citric acid inhalation in guinea pigs: role of tachykinins, bradykinin, and nitric oxide. Am J Respir Crit Care Med 1999; 159:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/24\">",
"      Mansfield LE, Hameister HH, Spaulding HS, et al. The role of the vague nerve in airway narrowing caused by intraesophageal hydrochloric acid provocation and esophageal distention. Ann Allergy 1981; 47:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/25\">",
"      Schan CA, Harding SM, Haile JM, et al. Gastroesophageal reflux-induced bronchoconstriction. An intraesophageal acid infusion study using state-of-the-art technology. Chest 1994; 106:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/26\">",
"      Wright RA, Miller SA, Corsello BF. Acid-induced esophagobronchial-cardiac reflexes in humans. Gastroenterology 1990; 99:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/27\">",
"      Herve P, Denjean A, Jian R, et al. Intraesophageal perfusion of acid increases the bronchomotor response to methacholine and to isocapnic hyperventilation in asthmatic subjects. Am Rev Respir Dis 1986; 134:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/28\">",
"      Field SK. A critical review of the studies of the effects of simulated or real gastroesophageal reflux on pulmonary function in asthmatic adults. Chest 1999; 115:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/29\">",
"      Field SK, Evans JA, Price LM. The effects of acid perfusion of the esophagus on ventilation and respiratory sensation. Am J Respir Crit Care Med 1998; 157:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/30\">",
"      Tuchman DN, Boyle JT, Pack AI, et al. Comparison of airway responses following tracheal or esophageal acidification in the cat. Gastroenterology 1984; 87:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/31\">",
"      Sant'Ambrogio FB, Sant'Ambrogio G, Chung K. Effects of HCl-pepsin laryngeal instillations on upper airway patency-maintaining mechanisms. J Appl Physiol 1998; 84:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/32\">",
"      Jack CI, Calverley PM, Donnelly RJ, et al. Simultaneous tracheal and oesophageal pH measurements in asthmatic patients with gastro-oesophageal reflux. Thorax 1995; 50:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/33\">",
"      Pearson JP, Parikh S, Orlando RC, et al. Review article: reflux and its consequences--the laryngeal, pulmonary and oesophageal manifestations. Conference held in conjunction with the 9th International Symposium on Human Pepsin (ISHP) Kingston-upon-Hull, UK, 21-23 April 2010. Aliment Pharmacol Ther 2011; 33 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/34\">",
"      Irwin RS, Curley FJ, French CL. Difficult-to-control asthma. Contributing factors and outcome of a systematic management protocol. Chest 1993; 103:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/35\">",
"      Harding SM, Richter JE, Guzzo MR, et al. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med 1996; 100:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/36\">",
"      Kiljander TO, Harding SM, Field SK, et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2006; 173:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/37\">",
"      Kiljander TO, Salomaa ER, Hietanen EK, Terho EO. Gastroesophageal reflux in asthmatics: A double-blind, placebo-controlled crossover study with omeprazole. Chest 1999; 116:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/38\">",
"      Field SK, Gelfand GA, McFadden SD. The effects of antireflux surgery on asthmatics with gastroesophageal reflux. Chest 1999; 116:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/39\">",
"      Kiljander TO. The role of proton pump inhibitors in the management of gastroesophageal reflux disease-related asthma and chronic cough. Am J Med 2003; 115 Suppl 3A:65S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/40\">",
"      Meier JH, McNally PR, Punja M, et al. Does omeprazole (Prilosec) improve respiratory function in asthmatics with gastroesophageal reflux? A double-blind, placebo-controlled crossover study. Dig Dis Sci 1994; 39:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/41\">",
"      Teichtahl H, Kronborg IJ, Yeomans ND, Robinson P. Adult asthma and gastro-oesophageal reflux: the effects of omeprazole therapy on asthma. Aust N Z J Med 1996; 26:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/42\">",
"      Boeree MJ, Peters FT, Postma DS, Kleibeuker JH. No effects of high-dose omeprazole in patients with severe airway hyperresponsiveness and (a)symptomatic gastro-oesophageal reflux. Eur Respir J 1998; 11:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/43\">",
"      Levin TR, Sperling RM, McQuaid KR. Omeprazole improves peak expiratory flow rate and quality of life in asthmatics with gastroesophageal reflux. Am J Gastroenterol 1998; 93:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/44\">",
"      Larrain, A, Carrasco, E, Galleguillos, F, et al. Medical and surgical treatment of non-allergic asthma associated with gastroesophageal reflux. Chest 1991; 99:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/45\">",
"      Field SK, Sutherland LR. Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux?: a critical review of the literature. Chest 1998; 114:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/46\">",
"      So JB, Zeitels SM, Rattner DW. Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery 1998; 124:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/47\">",
"      Coughlan JL, Gibson PG, Henry RL. Medical treatment for reflux oesophagitis does not consistently improve asthma control: a systematic review. Thorax 2001; 56:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/48\">",
"      Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev 2003; :CD001496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/49\">",
"      Chan WW, Chiou E, Obstein KL, et al. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis. Arch Intern Med 2011; 171:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/50\">",
"      Littner MR, Leung FW, Ballard ED 2nd, et al. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest 2005; 128:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/51\">",
"      Kiljander TO, Junghard O, Beckman O, Lind T. Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2010; 181:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/52\">",
"      Harding SM, Guzzo MR, Richter JE. The prevalence of gastroesophageal reflux in asthma patients without reflux symptoms. Am J Respir Crit Care Med 2000; 162:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/53\">",
"      American Lung Association Asthma Clinical Research Centers, Mastronarde JG, Anthonisen NR, et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009; 360:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/54\">",
"      Writing Committee for the American Lung Association Asthma Clinical Research Centers, Holbrook JT, Wise RA, et al. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA 2012; 307:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/55\">",
"      Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000; 162:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/56\">",
"      Liou A, Grubb JR, Schechtman KB, Hamilos DL. Causative and contributive factors to asthma severity and patterns of medication use in patients seeking specialized asthma care. Chest 2003; 124:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/57\">",
"      Crowell MD, Zayat EN, Lacy BE, et al. The effects of an inhaled beta(2)-adrenergic agonist on lower esophageal function: a dose-response study. Chest 2001; 120:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/58\">",
"      Lazenby JP, Guzzo MR, Harding SM, et al. Oral corticosteroids increase esophageal acid contact times in patients with stable asthma. Chest 2002; 121:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/59\">",
"      Maton PN. Omeprazole. N Engl J Med 1991; 324:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/60\">",
"      American Gastroenterological Association medical position statement: guidelines on the use of esophageal pH recording. Gastroenterology 1996; 110:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/61\">",
"      Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996; 110:1982.",
"     </a>",
"    </li>",
"    <li>",
"     Dyspepsia and GERD. Institute for Clinical Systems Improvement (ICSI). Bloomington, MN 2004 www.icsi.org (Accessed on May 07, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/63\">",
"      Reibman J, Marmor M, Filner J, et al. Asthma is inversely associated with Helicobacter pylori status in an urban population. PLoS One 2008; 3:e4060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/64\">",
"      Chen Y, Blaser MJ. Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis 2008; 198:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/65\">",
"      Rakita S, Villadolid D, Thomas A, et al. Laparoscopic Nissen fundoplication offers high patient satisfaction with relief of extraesophageal symptoms of gastroesophageal reflux disease. Am Surg 2006; 72:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39816/abstract/66\">",
"      Sontag SJ, O'Connell S, Khandelwal S, et al. Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies. Am J Gastroenterol 2003; 98:987.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 571 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-A044F949FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39816=[""].join("\n");
var outline_f38_56_39816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Increased vagal tone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Heightened bronchial reactivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Microaspiration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVIDENCE THAT GERD TREATMENT IMPROVES ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Empiric therapy in patients with symptomatic GERD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Successful trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Unsuccessful trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Empiric therapy in asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ESOPHAGEAL PH TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      GI REFERRAL AND ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OTHER TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      GE REFLUX SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/571\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/571|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/42/2734\" title=\"figure 1\">",
"      Esophageal vs reflux parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/1/10270\" title=\"figure 2\">",
"      PEFR in esophageal infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/16/8461\" title=\"figure 3\">",
"      Esophageal acid methacholine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/15/39167\" title=\"figure 4\">",
"      Esophageal acid-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/571|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/25/29083\" title=\"table 1\">",
"      Symptoms of GE reflux",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/18/17706?source=related_link\">",
"      Approach to refractory gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25688?source=related_link\">",
"      Endoscopic therapy for gastroesophageal reflux disease: Sewing and full-thickness plication techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1161?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/40/26247?source=related_link\">",
"      Esophageal multichannel intraluminal impedance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42905?source=related_link\">",
"      Surgical management of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_56_39817="Treatment and prognosis of systemic mastocytosis";
var content_f38_56_39817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of systemic mastocytosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/56/39817/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39817/contributors\">",
"     Mariana C Castells, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39817/contributors\">",
"     Cem Akin, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/56/39817/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39817/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39817/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/56/39817/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39817/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/56/39817/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic mastocytosis (SM) consists of a group of disorders excessive mast cell proliferation and accumulation involving the bone marrow and other extracutaneous tissues.",
"   </p>",
"   <p>",
"    There are four distinct forms of SM (",
"    <a class=\"graphic graphic_table graphicRef82828 \" href=\"mobipreview.htm?12/42/12973\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Indolent systemic mastocytosis (ISM)",
"     </li>",
"     <li>",
"      Systemic mastocytosis with an associated hematologic non-mast cell lineage disorder (SM-AHNMD)",
"     </li>",
"     <li>",
"      Aggressive systemic mastocytosis (ASM)",
"     </li>",
"     <li>",
"      Mast cell leukemia (MCL)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two other forms of mastocytosis have been described, which are not categorized as either systemic or cutaneous disease. Mast cell sarcoma (MCS) and extracutaneous mastocytoma are rare mast cell tumors of malignant and benign nature, respectively. The treatment of these forms of mastocytosis is also discussed in this topic review.",
"   </p>",
"   <p>",
"    There is currently no curative therapy for systemic mastocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/1\">",
"     1",
"    </a>",
"    ]. Treatment is intended to reduce symptoms and improve quality of life. The general management and pharmacologic treatment of systemic mastocytosis will be discussed in this topic review. The clinical manifestations, classification, pathogenesis, evaluation, and diagnosis of systemic mastocytosis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with systemic mastocytosis should avoid triggers for mast cell degranulation. These include physical triggers, alcohol, certain medications, emotional stress, and allergens to which the individual is sensitized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preparation for treating anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epinephrine is the primary treatment for anaphylaxis. Patients should have at least two doses of epinephrine in a self-injectable form available at all times for treatment of possible anaphylaxis, since a single dose may be inadequate to counteract the massive release of mediators that can occur in this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/2\">",
"     2",
"    </a>",
"    ]. The treatment of anaphylaxis in adults and children is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mastocytosis patients should consider wearing a medical identification bracelet, especially if they have a history of anaphylaxis. In addition, patients can be equipped with an Anaphylaxis Emergency Action Plan or wallet card that identifies the condition and describes the proper treatment of anaphylaxis (",
"    <a class=\"graphic graphic_form graphicRef60439 \" href=\"mobipreview.htm?2/42/2722\">",
"     form 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_form graphicRef54466 \" href=\"mobipreview.htm?22/62/23524\">",
"     form 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If patients experience episodes of symptoms that resemble anaphylaxis, serum tryptase should be obtained which can help determine retrospectively if the events are truly caused by mast cell mediator release. In rare instances, patients with systemic mastocytosis can also suffer from panic attacks, and it is important to distinguish the two disorders so that effective treatment can be instituted for the panic disorder and overuse of epinephrine avoided. However, it is important to realize the serum tryptase results will not be available immediately and the emergency evaluations still rely on clinical judgement. Instructions for the proper collection of serum tryptase are provided (",
"    <a class=\"graphic graphic_table graphicRef72041 \" href=\"mobipreview.htm?21/8/21644\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    (anti-IgE), a humanized murine monoclonal antibody that inhibits the binding of IgE to mast cells, reduced the frequency of anaphylaxis in two patients with systemic mastocytosis, in a case report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/3\">",
"     3",
"    </a>",
"    ]. Omalizumab therapy was also reported to improve cutaneous and neurologic symptoms in a patient with UP who did not undergo bone marrow evaluation, and so was not conclusively diagnosed with SM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/4\">",
"     4",
"    </a>",
"    ]. This application of omalizumab is not approved by the Federal Drug Administration (FDA) and requires further study. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17130?source=see_link\">",
"     \"Anti-IgE therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Trigger avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with systemic mastocytosis should be aware that various exposures and situations can trigger symptoms. These triggers include exposure to heat, cold, acute emotional stress, very strenuous exercise, alcohol, spicy food, infections, vaccinations, anesthesia, surgery and endoscopic procedures. Patients with sensitivity to Hymenoptera venom, substantiated by positive skin testing or specific blood IgE, should be offered venom immunotherapy to reduce the risk of anaphylaxis upon subsequent stings. There is considerable variation among patients in tolerance to specific triggers. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Information for patients'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Treatment of coexistent allergic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Problematic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are various medications that may potentially cause mast cell activation in patients with either systemic or cutaneous mastocytosis. As a precaution, these medications should be avoided when possible, unless the patient's tolerance for a specific agent is already known. The medications, as well as medications that are usually tolerated, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41767?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment and prognosis of cutaneous mastocytosis\", section on 'Problematic medications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41767?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment and prognosis of cutaneous mastocytosis\", section on 'Medications that are usually tolerated'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Preparation for medical and surgical procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;If patients have had previous procedures or surgery since developing a mast cell disorder, we attempt to retrieve the medical records of that procedure. If the patient had trouble tolerating the intervention, the medical records can help guide the selection of different perioperative drugs, and if the procedure was tolerated, the same medications could be used again.",
"   </p>",
"   <p>",
"    We usually administer premedications prior to surgery (especially that requiring general anesthesia), minor medical procedures, or the administration of radiocontrast dyes. The optimal regimen for prevention of mast cell degranulation in mastocytosis patients has not been formally studied. We suggest the following combination of medications:",
"   </p>",
"   <p>",
"    One hour before the procedure (one of the authors prefers to give two doses of these medications, 12 hours and 1 hour before):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       Diphenhydramine",
"      </a>",
"      , 25 to 50 mg orally or IV (or equivalent doses of another oral antihistamine)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"       Ranitidine",
"      </a>",
"      , 150 mg orally, or 50 mg IV",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       Montelukast",
"      </a>",
"      (optional), 10 mg orally",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antihistamines and glucocorticoids may be given intravenously if the patient is to have nothing by mouth before surgery.",
"   </p>",
"   <p>",
"    In addition, if the patient has frequent or severe (ie, involving hypotension) episodes of mast cell activation, or has had problems tolerating anesthesia or surgery in the past, we also administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , 25 to 50 mg orally, 12 hours and again 2 hours before the procedure.",
"   </p>",
"   <p>",
"    Finally, the anesthesiology and surgical clinicians involved should be aware of the patient&rsquo;s susceptibility to anaphylaxis and be prepared to treat it promptly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pharmacotherapy for all subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following therapies may be needed for patients with any subtype of systemic mastocytosis, although symptoms arising from mediator release are most prominent in patients with indolent systemic mastocytosis and aggressive systemic mastocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial pharmacologic treatment includes the use of H1- and H2-histamine receptor blockers. H1 antihistamines are administered to prevent flushing and itching. H2 antihistamines are helpful in controlling abdominal pain, heartburn, cramping,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Commonly used H1 antihistamines (adult dosing) include oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      (10 mg daily),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      (180 mg daily),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      (25 mg every six hours), or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/51/32560?source=see_link\">",
"       doxepin",
"      </a>",
"      (10 to 100 mg per day) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/5\">",
"       5",
"      </a>",
"      ]. Each of these agents may be used in children, at",
"      <span class=\"nowrap\">",
"       age/weight-appropriate",
"      </span>",
"      doses. In some patients, a combination of two or more H1 antihistamines or doubling the dose of a nonsedating agent may provide better symptom control than the use of a single agent.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       Diphenhydramine",
"      </a>",
"      (25 to 50 mg QID) may be added on an as-needed basis to manage breakthrough symptoms.",
"     </li>",
"     <li>",
"      H2 antihistamines (adult dosing) include oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      (150 mg every 12 hours),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/45/728?source=see_link\">",
"       famotidine",
"      </a>",
"      (10 mg every 12 hours), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      (400 mg twice daily) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/5\">",
"       5",
"      </a>",
"      ]. Ranitidine and famotidine may be used in children at",
"      <span class=\"nowrap\">",
"       age/weight",
"      </span>",
"      appropriate doses.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33024?source=see_link\">",
"       Ketotifen",
"      </a>",
"      , which has been reported to have both mast cell stabilizing and H1 antihistamine properties, may be administered where available (eg, Canada and Europe), although it can be quite sedating for some patients and they should be cautioned about this side effect. This drug is not available in oral form in the United States. The adult dose is 1 to 4 mg orally every 12 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/6\">",
"       6",
"      </a>",
"      ]. Ketotifen may be used in children at",
"      <span class=\"nowrap\">",
"       age/weight",
"      </span>",
"      appropriate doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Anti-leukotriene drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-leukotriene agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    10 mg daily,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    20 mg daily, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    1200 mg twice daily) may be added in patients with symptoms such as flushing, itching, and abdominal cramping unresponsive to H1 and H2 antihistamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Additional symptom-specific treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional agents are added to treat specific symptoms:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10252946\">",
"    <span class=\"h4\">",
"     Flushing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    (up to 325 mg four times daily) may be administered to control flushing, provided the patient is known to tolerate NSAIDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/5\">",
"     5",
"    </a>",
"    ]. It may be particularly useful in patients who have not responded to antihistamines. The ability of aspirin to reduce the production of prostaglandin D2 (PGD2) is believed to be important in its utility in SM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/8\">",
"     8",
"    </a>",
"    ]. In patients with prominent flushing not responsive to antihistamines, levels of PGD2 or 11-beta PGF2 should be assessed in a 24 hour urine sample. If elevated, a trial of aspirin therapy may be considered.",
"   </p>",
"   <p>",
"    If the patient's tolerance of NSAIDs is not known, the first dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    should be administered in a supervised setting, as NSAIDs may precipitate mast cell mediator release in some patients. We typically give an initial dose of 40 mg, followed by 81 mg, 162 mg, and 325 mg, allowing 90 minutes after each dose to observe for symptoms.",
"   </p>",
"   <p>",
"    In the experience of one of the authors (MC), patients with flushing usually respond to doses between 1.2 and 2 grams per day. However, prolonged",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy may be limited by gastric irritation and many patients with require concomitant treatment with a proton pump inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10252986\">",
"    <span class=\"h4\">",
"     Gastrointestinal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal symptoms may be treated with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    , H2 antihistamines, and proton pump inhibitors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37712?source=see_link\">",
"       Cromolyn sodium",
"      </a>",
"      is an inhibitor of mast cell degranulation in vitro, and oral solutions (100 to 200 mg orally, up to four times daily) may be administered to reduce gastrointestinal symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/9\">",
"       9",
"      </a>",
"      ]. This preparation should be initiated at the lower end of the dose range and gradually increased, as it is minimally absorbed through the intestine and can cause osmotic diarrhea if introduced at high doses.",
"     </li>",
"     <li>",
"      H2 antihistamines are helpful in patients with symptoms of hyperacidity and abdominal pain.",
"     </li>",
"     <li>",
"      Proton pump inhibitors may be used in patients with peptic ulcer disease or those with abdominal complaints unresponsive to H2 antagonists. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25034?source=see_link\">",
"       \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10252967\">",
"    <span class=\"h4\">",
"     Osteoporosis and fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be monitored for osteoporosis and treated appropriately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Treatment with the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    and low-dose interferon alpha has been reported of patients with fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8542397\">",
"    <span class=\"h4\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study found that patients with systemic mastocytosis and depression experienced relief of their psychiatric symptoms following treatment with tyrosine kinase therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/14\">",
"     14",
"    </a>",
"    ]. Other reports have suggested that oral cromolyn sodium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/15\">",
"     15",
"    </a>",
"    ] or antidepressant medications may be helpful. One author has noted improvement in some patients with doxepin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment of coexistent allergic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with systemic mastocytosis develop allergic diseases at a rate similar to that of the general population, and may suffer from allergic rhinitis, asthma, food and drug allergies, and systemic allergic reactions to Hymenoptera venom (bee, wasp, hornet, or fire ant stings) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In most cases, these conditions should be managed as they would be in patients without mastocytosis, although medication requirements may be higher. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Injection immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of subcutaneous immunotherapy (SCIT) for allergic rhinitis or asthma warrants careful consideration in patients with mastocytosis because they are at greater risk for systemic reactions and anaphylaxis as a consequence of the therapy itself. The safety of SCIT with inhalant allergens in patients with SM has not been studied. We generally manage these patients with allergen avoidance and medications, rather than SCIT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Venom immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to immunotherapy for respiratory allergies, the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio for immunotherapy with Hymenoptera venom favors immunotherapy, as patients with mastocytosis can suffer severe anaphylaxis in response to an insect sting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Fatalities have been reported in patients with systemic mastocytosis who were stung by hymenoptera, despite self-treatment with epinephrine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus, patients with anaphylaxis following a known or possible hymenoptera sting should be evaluated with skin tests or in vitro tests for venom-specific IgE, and if found to be sensitized, should be offered venom immunotherapy (VIT). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16936?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/39000?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/30/14824?source=see_link\">",
"     \"Diagnosis of Hymenoptera venom allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The safety and utility of VIT in mastocytosis patients was evaluated in a retrospective series of 21 subjects who underwent VIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/19\">",
"     19",
"    </a>",
"    ]. Twelve patients were re-stung during treatment, and 9 of these developed only local reactions, suggesting protection against repeat anaphylaxis. However, adverse reactions during the build up phase of immunotherapy were experienced by 30 percent, and patients should be counseled about this when giving consent to receive immunotherapy. Most experts agree that the duration of VIT should be life-long [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/20\">",
"     20",
"    </a>",
"    ]. Safety measures during administration of VIT include starting with a less concentrated venom preparation (ie, 0.01 to 0.1",
"    <span class=\"nowrap\">",
"     micrograms/mL)",
"    </span>",
"    and premedicating with an H1 antihistamine on the day of each injection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/39000?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    may reduce the risk of systemic reactions to VIT. A case report described a patient with SM who suffered near fatal anaphylaxis to a Hymenoptera sting and was begun on VIT, but experienced repeated systemic reactions to the injections and was unable to reach maintenance doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/23\">",
"     23",
"    </a>",
"    ]. Omalizumab was administered one week prior to his subsequent venom injection, at a dose of twice what is generally indicated for the treatment of asthma. Using this approach before each monthly injection, he was able to advance immunotherapy to the effective dose. Subsequent attempts to lower the dose of omalizumab, or to extend the time between maintenance injections beyond 30 days, resulted in recurrent systemic reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/24\">",
"     24",
"    </a>",
"    ]. The patient sustained later Hymenoptera stings without reacting. However, another case report described a patient in whom omalizumab was administered to prevent systemic reactions to VIT, but the patient was not able to tolerate VIT once omalizumab was discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/25\">",
"     25",
"    </a>",
"    ]. In the United States, omalizumab is not approved for this use, although the drug can sometimes be obtained on a compassionate use basis in individual cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     GENERAL PROGNOSTIC INDICATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with systemic mastocytosis depends upon the category of disease present, as reviewed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Additional therapy for specific disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, certain clinical features are associated with an increased risk of death due to disease progression, independent of the category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. These features include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older age at onset of systemic symptoms",
"     </li>",
"     <li>",
"      Weight loss",
"     </li>",
"     <li>",
"      Low platelet count",
"     </li>",
"     <li>",
"      Low serum albumin",
"     </li>",
"     <li>",
"      Low hemoglobin levels",
"     </li>",
"     <li>",
"      Elevated LDH",
"     </li>",
"     <li>",
"      High alkaline phosphatase",
"     </li>",
"     <li>",
"      Qualitative changes in red blood cell",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      white blood cells",
"     </li>",
"     <li>",
"      Hepatosplenomegaly",
"     </li>",
"     <li>",
"      Ascites",
"     </li>",
"     <li>",
"      Excess bone marrow blasts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Absence of cutaneous lesions has been noted as a poor prognostic indicator in patients who fulfill WHO criteria for systemic mastocytosis, although this concept may require further study. Specifically, less than 50 percent of patients with systemic mastocytosis presenting with hymenoptera sting anaphylaxis have urticaria pigmentosa or other forms of cutaneous mastocytosis, yet this subset of patients does not appear to have a worse prognosis or to be at increased risk for disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, one study indicated that patients with indolent systemic mastocytosis, who initially presented with UP lesions, may lose the UP lesions over the years and have an excellent prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of high grade mast cell morphologic features, such as bilobed nuclei and significant hypogranulation, is usually associated with advance forms of systemic mastocytosis, such as ASM or MCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some evidence for detectable mast cell precursors in patients with aggressive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. One study found that peripheral blood CD34-CD117+ cells were more prevalent in patients with aggressive forms of systemic mastocytosis, compared to those with indolent forms and cutaneous mastocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/30\">",
"     30",
"    </a>",
"    ]. Upon culture, these cells matured into mast cells, indicating that they are precursor forms. The study also found that this population decreased after successful treatment, and rose again with relapse, correlating to mast cell burden. Thus, although the patient numbers in this study were small, if the findings are confirmed, this cell population may represent a marker of disease severity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    activity and may provide prognostic information for patients with aggressive forms of disease. More information is also needed about the presence of precursors in patients with longstanding but less aggressive forms of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ROLE OF TYROSINE KINASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kit (CD117) is a tyrosine kinase, and activating mutations of KIT in mast cells (most commonly D816V) stimulate mast cell proliferation and transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Therefore, tyrosine kinase inhibitors may be appropriate for some patients with SM-AHNMD, ASM, or MCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Effective suppression of constitutively activated c-kit can result in killing of KIT mutated mast cells in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/33,34,36\">",
"     33,34,36",
"    </a>",
"    ] and in vivo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/37\">",
"     37",
"    </a>",
"    ]. Tyrosine kinase inhibitors vary in their ability to act on wild type or mutated molecules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    (Gleevec) is an agent that preferentially kills mast cells with wild type KIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/36\">",
"     36",
"    </a>",
"    ]. However, most patients with systemic mastocytosis are NOT candidates for imatinib therapy because they have the D816V KIT mutation, which confers resistance to imatinib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/38\">",
"     38",
"    </a>",
"    ]. Some patients without the D816V mutation and with ASM, MCL, or SM-AHNMD may respond to imatinib, although the optimal treatment for these patients has not been determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/32,37-40\">",
"     32,37-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most reported responses of \"mastocytosis\" to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    were observed in patients with the subset of hypereosinophilic syndrome caused by a FIP1L1-PDGFRA fusion mutation and known as chronic eosinophilic leukemia. These patients are almost always male and typically have an associated mast cell hyperplasia and an elevated serum tryptase level. HES rather than mastocytosis is the likely diagnosis if, upon presentation, the ratio of peripheral blood eosinophils to serum tryptase is greater than 100 or the eosinophil count is greater than 10,000. If the ratio of peripheral blood eosinophils to serum tryptase is less than or equal to 100, SMCD is more likely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/41\">",
"     41",
"    </a>",
"    ]. The FIP1L1-PDGFRA fusion protein can be detected by deletion of the CHIC2 locus by FISH analysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25898?source=see_link\">",
"     \"Treatment of the hypereosinophilic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other TK inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with multitargeted tyrosine kinase inhibitor PKC412 (midostaurin) induced temporary decreases in mast cell numbers and inhibition of D816V c-kit receptor in a patient with MCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/42\">",
"     42",
"    </a>",
"    ]. This agent is currently in clinical trials.",
"   </p>",
"   <p>",
"    Masitinib is a tyrosine kinase inhibitor with activity against wild type but not D816V mutant kit. Phase two trials of masitinib in patients with wild type or unknown mutational c-kit status reported a clinical response rate of 56 percent although adverse effects such as edema (44 percent), nausea (44 percent), muscle spasms (28 percent), and rash (28 percent) were quite common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/43\">",
"     43",
"    </a>",
"    ]. Further study of this agent is needed.",
"   </p>",
"   <p>",
"    Clinical trials with the tyrosine kinase inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    have been generally disappointing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ADDITIONAL THERAPY FOR SPECIFIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional therapy is based upon the type of disease present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/46\">",
"     46",
"    </a>",
"    ]. As mentioned previously, there are currently no curative therapies for patients with systemic mastocytosis. Patients with advanced forms of systemic mastocytosis should be referred to centers with expertise in these disorders when possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Indolent systemic mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for ISM is intended to prevent mast cell mediator release and minimize the resulting symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/5\">",
"     5",
"    </a>",
"    ]. Additional therapies to reduce mast cell numbers, which can be associated with significant toxicity, are generally not indicated. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'General measures'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;ISM progresses slowly or not at all and most patients have normal life expectancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/26,47\">",
"     26,47",
"    </a>",
"    ]. However, severe disability and death have been reported from anaphylactic episodes, and in one study, severe anaphylaxis was seen more in patients with ISM compared to those with more aggressive forms of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 1 to 5 percent of patients with an initial diagnosis of ISM will progress to a more severe form of SM, including SM-AHNMD, ASM, or MCL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/47\">",
"     47",
"    </a>",
"    ]. Progression may occur within months to years from the initial diagnosis.",
"   </p>",
"   <p>",
"    A large prospective study of 145 consecutive patients with ISM, followed for a median of 9 years, found that increased serum levels of beta-2-microglobulin, combined with the presence of D816 KIT mutation in all hematopoietic cell lines, identified patients at higher risk for progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/47\">",
"     47",
"    </a>",
"    ]. However, detection of KIT mutations in different hematopoietic cells is done only in research labs at the present time. In the future, it may become a more widely available prognostic tool.",
"   </p>",
"   <p>",
"    Development of unexplained hematologic abnormalities (eg, increased WBC, immature forms, increased or decreased platelets, monocytosis), hepatosplenomegaly, unexplained weight loss, coagulopathy, ascites, or gastrointestinal bleeding should alert the clinician to the possibility of disease progression.",
"   </p>",
"   <p>",
"    About 10 to 15 percent of patients with indolent systemic mastocytosis and UP may experience a regression of UP lesions, which may correspond to either improvement or worsening in the systemic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/28\">",
"     28",
"    </a>",
"    ]. Changes in UP lesions do not necessitate additional evaluation if the patient is feeling well.",
"   </p>",
"   <p>",
"    Women with ISM may have healthy pregnancies and give birth to unaffected infants, as mastocytosis is not genetically transmitted in the great majority of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Yearly monitoring is appropriate for uncomplicated patients with indolent systemic mastocytosis (ISM), although the frequency of evaluation should be increased if symptoms worsen or new symptoms appear. In patients whose physical exam is unremarkable and weight is stable, the following yearly assessment is suggested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tryptase levels, complete blood count with differential, and chemistry panel",
"     </li>",
"     <li>",
"      Yearly bone densitometry for patients with documented osteopenia or osteoporosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Systemic mastocytosis with associated hematologic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further treatment of patients with SM-AHNMD depends upon the associated hematologic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. The approach is to treat AHNMD as if systemic mastocytosis were not present, and to treat the mastocytosis as if the AHNMD were not present, although patients should be monitored closely for mast cell activation symptoms during therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis of patients with SM-AHNMD is that of the hematologic disorder present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32202?source=see_link\">",
"     \"Prognosis and treatment of essential thrombocythemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/39/34425?source=see_link\">",
"     \"Prognosis of the myelodysplastic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients have the D816V KIT mutation, but for the few who DO NOT, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , or possibly another tyrosine kinase inhibitor is an option. It should be noted that false negative results can occur when peripheral blood is analyzed. Therefore, samples of bone marrow or lesional tissue are preferred for mutational analysis. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Role of tyrosine kinase inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Aggressive systemic mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with aggressive systemic mastocytosis (ASM) are candidates for mast cell cytoreductive therapies if C findings are present. C findings are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=see_link&amp;anchor=H35#H35\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\", section on 'C findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Therapeutic options",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly administered therapies are interferon alpha 2b,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    , glucocorticoids, tyrosine kinase inhibitors, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/32,50,53-56\">",
"     32,50,53-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Interferon alpha 2b",
"      </strong>",
"      &mdash; For patients with severe bone disease and multiple fractures, interferon alpha 2b is often used as an initial therapy. It is initially administered at 1 million units three times per week to a maximum of 3 million units per day. Up to 20 percent of patients may experience partial remission of bone pain and lesions, although complete remissions are rare [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/50,55,57-59\">",
"       50,55,57-59",
"      </a>",
"      ]. Adverse effects include flu-like symptoms, thrombocytopenia, cardiac toxicity, and depression.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"       Cladribine",
"      </a>",
"      &mdash; Cladribine may be appropriate for some patients with slowly-progressive ASM, as therapy can reduce the total burden of mast cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/50,60,61\">",
"       50,60,61",
"      </a>",
"      ]. Patients can experience transient responses, although nearly all relapse eventually [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/44,62\">",
"       44,62",
"      </a>",
"      ]. Side effects are mainly related to bone marrow suppression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/60,63\">",
"       60,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Glucocorticoids",
"      </strong>",
"      &mdash; Orally administered glucocorticoids are helpful for patients with ASM and severe malabsorption or ascites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/64\">",
"       64",
"      </a>",
"      ]. A typical dose is 20 to 60 mg daily of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      for two to three weeks or longer, followed by a slow taper. Some patients may require low dose maintenance therapy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       Hydroxyurea",
"      </a>",
"      &mdash; Hydroxyurea has also been administered to patients with ASM and SM-AHNMD, although there is little published data on efficacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/50\">",
"       50",
"      </a>",
"      ]. Hydroxyurea has relatively few side effects compared to other chemotherapeutic agents, although hematological toxicity and gastrointestinal side effects may be problematic at higher doses. Complete blood counts should be monitored regularly. Patients should use contraception because hydroxyurea is a teratogen.",
"     </li>",
"     <li>",
"      <strong>",
"       A",
"      </strong>",
"      <strong>",
"       tyrosine",
"      </strong>",
"      <strong>",
"       kinase inhibitor",
"      </strong>",
"      &mdash; Imatinib is approved by the FDA for aggressive systemic mastocytosis in patients who do not have a D816V KIT mutation or those with unknown mutational status. However, our experience indicates that greater than 90 percent of patients with systemic mastocytosis have the D816V KIT mutation and are therefore NOT candidates for imatinib. D816V KIT mutation should be assessed in bone marrow by a sensitive technique, such as PCR employing mutation specific primers, before concluding that it is negative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/65\">",
"       65",
"      </a>",
"      ]. Patients with ASM who have the D816V KIT mutation may be candidates for clinical trials employing investigational tyrosine kinase inhibitors if they do not respond to cladribine, prednisone or IFN-alpha.",
"     </li>",
"     <li>",
"      <strong>",
"       Splenectomy",
"      </strong>",
"      may be indicated for hypersplenism in association with severe anemia and thrombocytopenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hematopoietic cell transplantation has not been shown to improve survival significantly, although individual cases of remission have been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/67-69\">",
"       67-69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of patients with ASM is variable, with some experiencing a rapidly declining course over 12 to 24 months, while others follow a slower course with several years of survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/53-56\">",
"     53-56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Mast cell leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mast cell leukemia (MCL) are treated with polychemotherapy, similarly to those with acute leukemia. Administered agents have included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    , tyrosine kinase inhibitors, and polychemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/5,32\">",
"     5,32",
"    </a>",
"    ]. Bone marrow transplantation may be considered, although response rates are low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with MCL are particularly prone to gastrointestinal bleeding due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    release from the high number of mast cells present and possibly associated coagulopathies, and should be maintained on a proton pump inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25034?source=see_link\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MCL have a poor prognosis. Progression to multiple organ failure with weight loss, bone pain, and organomegaly develops over weeks to months, with death usually occurring within 12 to 24 months of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Mast cell sarcomas and extracutaneous mastocytomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is surgical for benign mast cell tumors that cause excessive symptoms of mediator release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39817/abstract/70\">",
"     70",
"    </a>",
"    ]. Mast cell sarcomas may progress to mast cell leukemia, although these tumors are so rare that there has not been sufficient experience to determine an effective treatment. Surgery, radiation and polychemotherapy, or therapy with a tyrosine kinase inhibitor may be considered, depending upon the location and mutational status of the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information for patients, including lists of triggers for mast cell degranulation, is available online at",
"    <a class=\"external\" href=\"file://www.tmsforacure.org/\">",
"     www.tmsforacure.org",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.niaid.nih.gov/topics/mastocytosis/pages/overview.aspx\">",
"     www.niaid.nih.gov/topics/mastocytosis/pages/overview.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently no curative therapies for systemic mastocytosis, and treatment is intended to reduce symptoms and improve quality of life. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Interventions for all subtypes of disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients require personalized education about the various stimuli that trigger mediator release from mast cells, so that they can be aware of the medications, situations, medical procedures, and dietary factors that may precipitate symptoms. This information can be attained through both clinicians and reliable Internet websites. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Trigger avoidance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Information for patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum tryptase should be drawn shortly after acute episodes of mast cell mediator",
"      <span class=\"nowrap\">",
"       release/anaphylaxis",
"      </span>",
"      to document that the event was mast cell mediated (",
"      <a class=\"graphic graphic_table graphicRef72041 \" href=\"mobipreview.htm?21/8/21644\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      All patients with systemic mastocytosis should have at least two doses of epinephrine in a self-injectable form available at all times for treatment of possible anaphylaxis (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Preparation for treating anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients require one or more medications to counteract the symptoms caused by baseline overproduction and release of mast cell mediators. These therapies include H1 and H2 antihistamines,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37712?source=see_link\">",
"       cromolyn sodium",
"      </a>",
"      , anti-leukotriene agents, proton pump inhibitors, bisphosphonates, and others. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pharmacotherapy for all subtypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with venom hypersensitivity and positive skin tests or in vitro tests for venom sensitization, we suggest venom immunotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment should be life-long. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Venom immunotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Subtype-specific therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for cytoreductive therapies depends upon the form of systemic mastocytosis (SM) present.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with indolent SM rarely require cytoreductive therapy and have an excellent long-term prognosis. Fewer than 5 percent will experience progression to more aggressive forms of disease. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Indolent systemic mastocytosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with SM with an associated hematologic disorder should be treated for the associated disorder. Prognosis depends upon the characteristics of that disorder. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Systemic mastocytosis with associated hematologic disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with aggressive SM and mast cell leukemia may derive some benefit from cytoreductive therapies, although the disease usually recurs and the long-term prognosis is poor. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Aggressive systemic mastocytosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Mast cell leukemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extracutaneous mastocytomas are treated surgically. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Mast cell sarcomas and extracutaneous mastocytomas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/1\">",
"      Hennessy B, Giles F, Cortes J, et al. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol 2004; 77:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/2\">",
"      Turk J, Oates JA, Roberts LJ 2nd. Intervention with epinephrine in hypotension associated with mastocytosis. J Allergy Clin Immunol 1983; 71:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/3\">",
"      Carter MC, Robyn JA, Bressler PB, et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007; 119:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/4\">",
"      Siebenhaar F, K&uuml;hn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and M&eacute;ni&egrave;re disease with anti-IgE therapy. J Allergy Clin Immunol 2007; 120:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/5\">",
"      Worobec AS. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000; 14:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/6\">",
"      P&oacute;voa P, Ducla-Soares J, Fernandes A, Palma-Carlos AG. A case of systemic mastocytosis; therapeutic efficacy of ketotifen. J Intern Med 1991; 229:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/7\">",
"      Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 2004; 350:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/8\">",
"      Butterfield JH, Weiler CR. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. Int Arch Allergy Immunol 2008; 147:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/9\">",
"      Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990; 85:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/10\">",
"      Rossini M, Zanotti R, Bonadonna P, et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 2011; 49:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/11\">",
"      Barete S, Assous N, de Gennes C, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010; 69:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/12\">",
"      Lim AY, Ostor AJ, Love S, Crisp AJ. Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 2005; 64:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/13\">",
"      Laroche M, Livideanu C, Paul C, Cantagrel A. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 2011; 124:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/14\">",
"      Moura DS, Sultan S, Georgin-Lavialle S, et al. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. PLoS One 2011; 6:e26375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/15\">",
"      Soter NA, Austen KF, Wasserman SI. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med 1979; 301:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/16\">",
"      Brockow K, Akin C, Huber M, Metcalfe DD. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol 2003; 48:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/17\">",
"      M&uuml;ller U, Helbling A, Hunziker T, et al. Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa. Allergy 1990; 45:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/18\">",
"      Greenhawt M, Akin C. Mastocytosis and allergy. Curr Opin Allergy Clin Immunol 2007; 7:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/19\">",
"      Gonz&aacute;lez de Olano D, Alvarez-Twose I, Esteban-L&oacute;pez MI, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008; 121:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/20\">",
"      Niedoszytko M, de Monchy J, van Doormaal JJ, et al. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009; 64:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/21\">",
"      Bonadonna P, Zanotti R, Caruso B, et al. Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J Allergy Clin Immunol 2008; 121:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/22\">",
"      Ru&euml;ff F, Placzek M, Przybilla B. Mastocytosis and Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006; 6:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/23\">",
"      Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008; 63:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/24\">",
"      Kontou-Fili K, Filis CI. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy 2009; 64:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/25\">",
"      Jandus P, Hausmann O, Haeberli G, et al. Unpredicted adverse reaction to omalizumab. J Investig Allergol Clin Immunol 2011; 21:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/26\">",
"      Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009; 113:5727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/27\">",
"      Lawrence JB, Friedman BS, Travis WD, et al. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991; 91:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/28\">",
"      Brockow K, Scott LM, Worobec AS, et al. Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease. Arch Dermatol 2002; 138:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/29\">",
"      Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/30\">",
"      Georgin-Lavialle S, Lhermitte L, Baude C, et al. Blood CD34-c-Kit+ cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor. Blood 2011; 118:5246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/31\">",
"      Castells MC, Friend DS, Bunnell CA, et al. The presence of membrane-bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis. J Allergy Clin Immunol 1996; 98:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/32\">",
"      Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004; 114:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/33\">",
"      Longley BJ, Ma Y, Carter E, McMahon G. New approaches to therapy for mastocytosis. A case for treatment with kit kinase inhibitors. Hematol Oncol Clin North Am 2000; 14:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/34\">",
"      Akin C, Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004; 114:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/35\">",
"      Shah NP, Lee FY, Luo R, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/36\">",
"      Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/37\">",
"      Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103:3222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/38\">",
"      Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009; 33:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/39\">",
"      Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/40\">",
"      Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 2006; 107:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/41\">",
"      Maric I, Robyn J, Metcalfe DD, et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007; 120:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/42\">",
"      Gotlib J, Berub&eacute; C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/43\">",
"      Paul C, Sans B, Suarez F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 2010; 85:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/44\">",
"      Aichberger KJ, Sperr WR, Gleixner KV, et al. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 2008; 38:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/45\">",
"      Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008; 14:3906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/46\">",
"      Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 2010; 3:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/47\">",
"      Escribano L, Alvarez-Twose I, S&aacute;nchez-Mu&ntilde;oz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009; 124:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/48\">",
"      Wimazal F, Geissler P, Shnawa P, et al. Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. Int Arch Allergy Immunol 2012; 157:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/49\">",
"      Worobec AS, Akin C, Scott LM, Metcalfe DD. Mastocytosis complicating pregnancy. Obstet Gynecol 2000; 95:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/50\">",
"      Lim KH, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009; 84:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/51\">",
"      Parker RI. Hematologic aspects of mastocytosis: II: management of hematologic disorders in association with systemic mast cell disease. J Invest Dermatol 1991; 96:52S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/52\">",
"      Sperr WR, Drach J, Hauswirth AW, et al. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res 2005; 11:6787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/53\">",
"      Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma 1996; 22:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/54\">",
"      Lehmann T, Beyeler C, L&auml;mmle B, et al. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol 1996; 35:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/55\">",
"      Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 2002; 119:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/56\">",
"      Escribano L, P&eacute;rez de Oteyza J, N&uacute;&ntilde;ez R, Orfao A. Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis. Report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma. Leuk Res 2002; 26:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/57\">",
"      Kluin-Nelemans HC, Jansen JH, Breukelman H, et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 1992; 326:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/58\">",
"      Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 1998; 138:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/59\">",
"      Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004; 28:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/60\">",
"      Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001; 344:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/61\">",
"      Tefferi A. Treatment of systemic mast cell disease: beyond interferon. Leuk Res 2004; 28:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/62\">",
"      Radojkovi�� M, Risti�� S, Colovi�� N, et al. Response to cladribine in patient with systemic mastocytosis. Vojnosanit Pregl 2011; 68:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/63\">",
"      Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102:4270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/64\">",
"      Friedman BS, Metcalfe DD. Effects of tixocortol pivalate on gastrointestinal disease in systemic mastocytosis: a preliminary study. Clin Exp Allergy 1991; 21:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/65\">",
"      Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006; 8:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/66\">",
"      Friedman B, Darling G, Norton J, et al. Splenectomy in the management of systemic mast cell disease. Surgery 1990; 107:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/67\">",
"      Nakamura R, Chakrabarti S, Akin C, et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006; 37:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/68\">",
"      Spyridonidis A, Thomas AK, Bertz H, et al. Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/69\">",
"      Przepiorka D, Giralt S, Khouri I, et al. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 1998; 57:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39817/abstract/70\">",
"      Castells MC. Extracutaneous mastocytoma. J Allergy Clin Immunol 2006; 117:1513.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4787 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39817=[""].join("\n");
var outline_f38_56_39817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preparation for treating anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Trigger avoidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Problematic medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Preparation for medical and surgical procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pharmacotherapy for all subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Antihistamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Anti-leukotriene drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Additional symptom-specific treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10252946\">",
"      Flushing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10252986\">",
"      Gastrointestinal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10252967\">",
"      Osteoporosis and fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8542397\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment of coexistent allergic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Injection immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Venom immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      GENERAL PROGNOSTIC INDICATORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ROLE OF TYROSINE KINASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Imatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other TK inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ADDITIONAL THERAPY FOR SPECIFIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Indolent systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Systemic mastocytosis with associated hematologic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Aggressive systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Therapeutic options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Mast cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Mast cell sarcomas and extracutaneous mastocytomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Interventions for all subtypes of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Subtype-specific therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/4787\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4787|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?2/42/2722\" title=\"form 1\">",
"      Anaphylaxis action plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?22/62/23524\" title=\"form 2\">",
"      Anaphylaxis wallet card",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4787|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/42/12973\" title=\"table 1\">",
"      Diagnostic criteria SM variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/8/21644\" title=\"table 2\">",
"      Tryptase and histamine collection instructions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/30/14824?source=related_link\">",
"      Diagnosis of Hymenoptera venom allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18650?source=related_link\">",
"      Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16936?source=related_link\">",
"      Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/39000?source=related_link\">",
"      Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32202?source=related_link\">",
"      Prognosis and treatment of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/39/34425?source=related_link\">",
"      Prognosis of the myelodysplastic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41767?source=related_link\">",
"      Treatment and prognosis of cutaneous mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25898?source=related_link\">",
"      Treatment of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_56_39818="Standard immunizations for children and adolescents";
var content_f38_56_39818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Standard immunizations for children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/56/39818/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39818/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/56/39818/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39818/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39818/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/56/39818/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/56/39818/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/56/39818/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The national vaccine immunization program, directed principally at children, is one of the most successful examples of effective preventive care in the United States. One of the most dramatic examples of the benefits of appropriate immunization is the marked decrease in cases of invasive",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    type b (Hib) infection since the introduction of Hib conjugate vaccines (HbCVs) in December 1987. The number of cases in children younger than five years of age declined by &gt;99 percent by 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/1\">",
"     1",
"    </a>",
"    ]. To further emphasize the success of the&nbsp;immunization program, it is important to note the&nbsp;remarkable benefits achieved with recommended administration of the pneumococcal conjugate vaccine (",
"    <a class=\"graphic graphic_figure graphicRef64834 \" href=\"mobipreview.htm?10/26/10658\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42489?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention of Haemophilus influenzae infection\", section on 'Efficacy/effectiveness'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link&amp;anchor=H8#H8\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Efficacy and effectiveness'",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p>",
"    Prevention of disease is essential for both patient health and control of medical costs. With rapid advances in virology, immunology, cell biology, and genetics, newer and more effective vaccines have been licensed and produced. To stay abreast of ongoing breakthroughs, immunization guidelines from the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), the Committee on Infectious Diseases of the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the American College of Obstetricians and Gynecologists (ACOG) are revised and updated continuously (",
"    <a class=\"graphic graphic_figure graphicRef82617 graphicRef58209 \" href=\"mobipreview.htm?4/7/4218\">",
"     figure 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58271 graphicRef72079 \" href=\"mobipreview.htm?22/18/22817\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The preparations, dosing schedule, contraindications, and adverse reactions to vaccines included in the recommended childhood immunization schedule are reviewed here. Diphtheria, tetanus, pertussis, poliovirus, pneumococcal, Hib, influenza, rotavirus, meningococcal, and human papillomavirus immunization, addressed briefly here, are discussed in detail separately. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Other vaccines, which are not currently part of the recommended childhood immunization schedule, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40057?source=see_link\">",
"     \"Vaccinia virus as the smallpox vaccine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link\">",
"     \"Immunizations for travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization against hepatitis A and B, diphtheria, tetanus, pertussis,",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b, polio, rotavirus, measles, mumps, rubella, varicella-zoster virus (VZV), pneumococcus, influenza, meningococcus, and human papillomavirus is considered the standard for the United States (",
"    <a class=\"graphic graphic_figure graphicRef82617 graphicRef58209 \" href=\"mobipreview.htm?4/7/4218\">",
"     figure 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of combination vaccines (eg, hepatitis",
"    <span class=\"nowrap\">",
"     B/Hib",
"    </span>",
"    [Comvax], hepatitis A and B [Twinrix], diphtheria, tetanus, acellular pertussis",
"    <span class=\"nowrap\">",
"     (DTaP)/hepatitis",
"    </span>",
"    <span class=\"nowrap\">",
"     B/inactivated",
"    </span>",
"    poliovirus (IPV) [Pediarix],",
"    <span class=\"nowrap\">",
"     DTaP/Hib/IPV",
"    </span>",
"    [Pentacel], and",
"    <span class=\"nowrap\">",
"     DTaP/IPV",
"    </span>",
"    [Kinrix]) can help to reduce the number of inoculations at each visit and improve vaccination coverage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaccine requirements for school entry vary from state to state. The recommended schedule for children whose immunizations have been delayed is provided in the Table (",
"    <a class=\"graphic graphic_table graphicRef58271 graphicRef72079 \" href=\"mobipreview.htm?22/18/22817\">",
"     table 1A-B",
"    </a>",
"    ). Health care providers can generate a personal, customized immunization schedule for their patients through the Center for Disease Control and Prevention&rsquo;s (CDC&rsquo;s)",
"    <a class=\"external\" href=\"file://www2a.cdc.gov/nip/kidstuff/newscheduler_le/\">",
"     Instant Childhood Immunization Schedule",
"    </a>",
"    . The schedule can be given to the patient's parents at the time of discharge from the nursery or at the first office visit and may serve to help parents remember when their child is due for vaccines.",
"   </p>",
"   <p>",
"    The CDC has also developed a",
"    <a class=\"external\" href=\"https://www.vacscheduler.org/\">",
"     Catch-up Immunization Schedule",
"    </a>",
"    to help determine which immunizations a child younger than six years has missed and when the vaccines should be scheduled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vaccination coverage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination coverage in 2011 among children ages 19 to 35 months in the United States was as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diphtheria-tetanus-pertussis (&ge;3 doses) &ndash; 96 percent",
"     </li>",
"     <li>",
"      Poliovirus (&ge;3 doses) &ndash; 94 percent",
"     </li>",
"     <li>",
"      Hib (&ge;3 doses) &ndash; 94 percent",
"     </li>",
"     <li>",
"      Measles-mumps-rubella (MMR, &ge;1 dose) &ndash; 92 percent",
"     </li>",
"     <li>",
"      Hepatitis B (&ge;3 doses) &ndash; 91 percent",
"     </li>",
"     <li>",
"      Varicella (&ge;1 dose) &ndash; 91 percent",
"     </li>",
"     <li>",
"      Pneumococcal conjugate vaccine (&ge;3 doses) &ndash; 94 percent",
"     </li>",
"     <li>",
"      Hepatitis A (&ge;2 doses) &ndash; 52 percent",
"     </li>",
"     <li>",
"      Rotavirus (&ge;3 doses for RV5; &ge;2 doses for RV1) &ndash; 67 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the 2010-2011 influenza season, the estimated seasonal influenza vaccination coverage (at least one dose) among children (&ge;6 months to 18 years) was approximately 49 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/7\">",
"     7",
"    </a>",
"    ]. At eight sentinel immunization sites (2009-2010), the average percentage of children who were fully vaccinated was only 22.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link&amp;anchor=H3#H3\">",
"     \"Seasonal influenza vaccination in children\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaccination coverage is also high among children entering school, in part related to state laws that require proof of vaccination before school entry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. Among states that received funding from the CDC to monitor compliance with immunization requirements and reported vaccination coverage for children entering kindergarten during the 2011-2012 school year, the median coverage rate for hepatitis B, diphtheria, tetanus, pertussis, and polio vaccines according to state requirements was &ge;95 percent; median coverage with two doses of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/59/12215?source=see_link\">",
"     measles-mumps-rubella vaccine",
"    </a>",
"    was almost 95 percent; and median coverage with two doses of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    was 93 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The high coverage rates at two years of age and school entry do not reflect the delays that may occur before children become fully vaccinated. Review of data from the 2003 National Immunization Survey indicates that 37 percent of children were undervaccinated for more than six months during the first 24 months of life and 21 percent were severely delayed (undervaccinated for more than six months and for four or more vaccines) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Failure by physicians, healthcare providers, parents, and guardians to comply with immunization guidelines or the timing of administering the doses leaves individuals susceptible to these preventable diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/15\">",
"     15",
"    </a>",
"    ], particularly when cases of the illness can be imported from countries where vaccination may be less available. Rubella and measles are examples of infections for which imported cases have led to secondary disease among unimmunized or partially immunized individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/16-21\">",
"     16-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective analysis of reported cases of measles and pertussis among Colorado children aged 3 to 18 years between 1987 and 1998 demonstrated that children who were not vaccinated for religious or philosophic reasons were more likely to develop measles and pertussis than were those who were vaccinated (relative risk [RR] 22; 95% CI, 15-31 and RR 6; 95% CI, 4-8 for measles and pertussis, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, the incidence of pertussis infection in vaccinated children (3 to 18 years) was increased according to the number of exemptors in their county or school. The incidence of measles infection in vaccinated children (3 to 10 years) was increased according to the number of exemptors in their county but not their school.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Impact of thimerosal controversy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1999, concern about the preservative thimerosal present in several childhood vaccines led the American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP), and Advisory Committee on Immunization Practices (ACIP) to propose that all of the standard childhood vaccines be produced without this preservative, which is a derivative of mercury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/22\">",
"     22",
"    </a>",
"    ]. Pending availability of thimerosal-free hepatitis B vaccines, a recommendation was also made to delay administration of the first dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/17/15639?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    for infants born to mothers seronegative for hepatitis B surface antigen (HBsAg) until the infants reached 2 to 6 months of age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21066?source=see_link\">",
"     \"Autism and chronic disease: Little evidence for thimerosal as a contributing factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All children in the United States had access to thimerosal-free hepatitis B vaccines, Hib vaccines, and DTaP vaccines by July 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/23\">",
"     23",
"    </a>",
"    ]. MMR, varicella, inactivated polio, and pneumococcal conjugate vaccines never contained thimerosal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the availability of thimerosal-free vaccine and a recommendation to resume hepatitis B vaccination to infants born to mothers seronegative for HBsAg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/24\">",
"     24",
"    </a>",
"    ], there has been a decline in the routine administration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/17/15639?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    to newborns of HBsAg-negative mothers before discharge from the newborn nursery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/25-27\">",
"     25-27",
"    </a>",
"    ], and even to some infants born to HBsAg-positive mothers or mothers whose HBsAg status was unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/25,28-30\">",
"     25,28-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Administration of injectable vaccines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88268678\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injectable vaccines should be administered using aseptic technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. It is not necessary to change needles between drawing a vaccine into a syringe and injecting it. A different needle and syringe should be used for each injection.",
"   </p>",
"   <p>",
"    The injection site should be as free as possible from risk of local neural, vascular, or tissue injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The anterolateral aspect of the thigh is the preferred site for injection in infants younger than 12 months. Either the anterolateral aspect of the thigh or deltoid area of the upper arm may be used for children older than 12 months; the anterolateral thigh is preferred for children younger than three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/31\">",
"     31",
"    </a>",
"    ]. The deltoid area of the upper arm is the preferred site for adolescents and young adults.",
"   </p>",
"   <p>",
"    When multiple vaccines are required at a single visit, separate sites should be used if possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/32\">",
"     32",
"    </a>",
"    ]. However, if necessary, two or more vaccines can be given in the same limb (usually the anterolateral thigh). The injections should be separated by at least one inch (if possible) to avoid overlap of local reactions.",
"   </p>",
"   <p>",
"    The needles used for intramuscular injections should be long enough to reach the muscle mass, thereby decreasing the risk of local reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/31-36\">",
"     31-36",
"    </a>",
"    ]. However, they should not be so long as to involve underlying nerves, blood vessels, or bone. Penetration into the bone can cause pain, damage to the periosteum, and detachment of the needle from the syringe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/37\">",
"     37",
"    </a>",
"    ]. The suggested needle length for intramuscular injection is listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60863 \" href=\"mobipreview.htm?27/20/27980\">",
"     table 2",
"    </a>",
"    ). For subcutaneous injections a 23- or 25-gauge needle",
"    <span class=\"nowrap\">",
"     5/8",
"    </span>",
"    (16 mm) long is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study, the thickness between the skin and bone of the anterior thigh and shoulder were measured on computed tomographic and magnetic resonance images in 250 healthy children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/37\">",
"     37",
"    </a>",
"    ]. The thickness was less than the recommended needle length for IM injections (",
"    <a class=\"graphic graphic_table graphicRef60863 \" href=\"mobipreview.htm?27/20/27980\">",
"     table 2",
"    </a>",
"    ) in 11 to 61 percent of children (depending upon age, site, and needle length). However, these measurements did not take into account the practice of pinching the skin at the injection site and assumed insertion of the needle to its hub. Given the variability in fat and muscle thickness among children of the same age, clinical judgment should be used in determining the best needle length for a particular patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews and randomized trials indicate that a number of nonpharmacologic and pharmacologic options alone or in combination are effective in reducing injection pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/38-48\">",
"     38-48",
"    </a>",
"    ]. For infants, nonpharmacologic options include oral sucrose, breastfeeding during immunization, or various physical interventions (eg, swaddling, pacifiers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. A small randomized trial suggests that the order of administration may affect injection pain in infants; administration of the DTaP-Hib combination vaccine before PCV was associated with less pain than administration in the reverse order [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/41\">",
"     41",
"    </a>",
"    ]. For older children, nonpharmacologic options include breathing exercises; distraction techniques; or stroking, rocking, or \"blowing the pain away\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/38,39,48\">",
"     38,39,48",
"    </a>",
"    ]. Pharmacologic management, if indicated, may include topical anesthetics applied 30 to 60 minutes before injection or oral analgesics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ) before or after immunization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Prophylactic acetaminophen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pain and fever that may occur after vaccination can be attenuated by administering",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    at the time of immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. However, this practice may be associated with decreased vaccine response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of prophylactic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    on fever and immunogenicity were evaluated in a multicenter, open-label trial in which 459 infants (aged 9 to 16 weeks at study entry) were randomly assigned to receive acetaminophen at the time of vaccination and for the next 24 hours or no prophylaxis before primary and booster immunizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/52\">",
"     52",
"    </a>",
"    ]. Primary immunizations consisted of 10-valent pneumococcal conjugate vaccine, nontypeable",
"    <em>",
"     H. influenzae",
"    </em>",
"    protein D conjugate vaccine (PHiD-CV), and hexavalent diphtheria-tetanus-acellular-pertussis-hepatitis B-inactivated polio-",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b vaccine",
"    <span class=\"nowrap\">",
"     (DTaP-HBV-IPV/Hib)",
"    </span>",
"    at three, four, and five months, and oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/29/33237?source=see_link\">",
"     rotavirus vaccine",
"    </a>",
"    at three and four months. Booster immunizations consisted of PHiD-CV and",
"    <span class=\"nowrap\">",
"     DTaP-HBV-IPV/Hib",
"    </span>",
"    at 12 to 15 months of age. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fewer children who received",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      had fever &gt;38&ordm;C (42 versus 66 percent and 36 percent versus 58 percent after primary and booster immunization, respectively). However, there was no difference between groups in occurrence of fever &ge;39.5&ordm;C (&lt;1 to 2 percent) or fever requiring medical attention.",
"     </li>",
"     <li>",
"      The vaccines were highly immunogenic in both groups, with at least 96 percent of children achieving protective levels of antibody for all antigens. However, prophylactic",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      was associated with lower geometric mean antibody titers (GMT) to pneumococcus,",
"      <em>",
"       H. influenzae",
"      </em>",
"      , pertussis, diphtheria, and tetanus after the primary series, and lower GMT to",
"      <em>",
"       pneumococcus",
"      </em>",
"      ,",
"      <em>",
"       Haemophilus",
"      </em>",
"      , and tetanus after the booster doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether these findings apply to other antipyretics, older age groups, or to",
"    <strong>",
"     therapeutic",
"    </strong>",
"    administration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    requires further study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. In the meantime, the relative lack of effect on clinically significant fever and potential decreased immune response (with unknown clinical significance) should be factored into the risk-benefit ratio when considering whether to administer prophylactic acetaminophen. Some editorialists suggest that routine use of prophylactic acetaminophen should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/55\">",
"     55",
"    </a>",
"    ], whereas others suggest that additional information is necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/54,56\">",
"     54,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adverse event reporting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse events associated with vaccines should be reported to the United States Department of Health and Human Services using the Vaccine Adverse Events Reporting System (VAERS,",
"    <a class=\"external\" href=\"file://vaers.hhs.gov/index\">",
"     vaers.hhs.gov/index",
"    </a>",
"    , telephone number 1-800-822-7967). Reportable events include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anaphylaxis or anaphylactic shock within seven days of any vaccine",
"     </li>",
"     <li>",
"      Any sequelae of reportable events",
"     </li>",
"     <li>",
"      Any other serious or unusual event",
"     </li>",
"     <li>",
"      Vaccine side effects that are listed as contraindications to future vaccination in the package insert",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vaccine-specific reportable events include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tetanus &ndash; Brachial neuritis within 28 days",
"     </li>",
"     <li>",
"      Pertussis &ndash; Encephalopathy or encephalitis within seven days",
"     </li>",
"     <li>",
"      Measles, mumps,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rubella &ndash; Encephalopathy or encephalitis within 15 days",
"     </li>",
"     <li>",
"      Rubella &ndash; Chronic arthritis within six weeks",
"     </li>",
"     <li>",
"      Measles &ndash; Thrombocytopenic purpura within 7 to 30 days; vaccine-strain measles infection in an immunodeficient recipient within six months of measles vaccination",
"     </li>",
"     <li>",
"      Oral polio &ndash; Paralytic polio or vaccine-strain polio within 30 days to 6 months (this vaccine is no longer used for routine childhood immunization)",
"     </li>",
"     <li>",
"      Rotavirus &ndash; Intussusception within 30 days of rotavirus immunization (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40937?source=see_link&amp;anchor=H10#H10\">",
"       \"Rotavirus vaccines\", section on 'Intussusception after RV5'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate-type allergic reactions to vaccines are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=see_link\">",
"     \"Allergic reactions to vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HEPATITIS B VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly 250,000 people in the United States contract acute hepatitis B virus (HBV) infection each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/57\">",
"     57",
"    </a>",
"    ]. More than one million individuals in this country have chronic liver disease and hepatocellular carcinoma. Although acute HBV infection can occur at any age, the number of cases increases during adolescence. Acquisition of HBV at a younger age is associated with an increased probability of developing chronic HBV infection, cirrhosis, or hepatocellular carcinoma. HBV is transmitted from exposure to contaminated blood, sexual intercourse, and vertically from mother to infant at the time of delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31386?source=see_link\">",
"     \"Overview of hepatitis B virus infection in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two recombinant hepatitis B vaccines, Engerix-B and Recombivax HB, are available for use in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/58\">",
"     58",
"    </a>",
"    ]. Although these vaccine preparations are supplied in different concentrations and vial sizes, they can be used interchangeably. Doses vary depending upon the age of the patient and whether the individual is receiving dialysis or is immunocompromised; doses of the two preparations also differ (",
"    <a class=\"graphic graphic_table graphicRef60075 \" href=\"mobipreview.htm?1/60/1998\">",
"     table 3",
"    </a>",
"    ). In addition,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/17/15639?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    is a component in several combination vaccines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comvax: hepatitis B (Recombivax HB) and HbCV (PedvaxHIB); this vaccine should not be administered at birth, before 6 weeks of age, or after 71 months of age.",
"     </li>",
"     <li>",
"      Pediarix: hepatitis",
"      <span class=\"nowrap\">",
"       B/diphtheria-tetanus-acellular",
"      </span>",
"      pertussis",
"      <span class=\"nowrap\">",
"       (DTaP)/poliovirus;",
"      </span>",
"      this vaccine should not be administered at birth, before 6 weeks of age, or at &ge;7 years of age.",
"     </li>",
"     <li>",
"      Twinrix: hepatitis B (Engerix-B) and hepatitis A (Havrix); this vaccine is approved for individuals 18 years and older.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dosing schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine screening of all pregnant women for hepatitis B surface antigen (HBsAg) is now mandatory because the timing of HepB vaccine administration and the need for",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/39/24181?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    (HBIG) for infants depend upon whether or not the mother is HBsAg-positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\", section on 'Perinatal transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     HBsAg-negative mother",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HepB vaccine should be administered in three doses: ideally, to infants during the birth hospitalization; at 1 to 2 months of age; and at 6 to 18 months of age (",
"    <a class=\"graphic graphic_table graphicRef76345 \" href=\"mobipreview.htm?23/39/24189\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Alternatively, infants born to HBsAg-negative mothers and who weigh more than 2000 g can receive the HepB vaccine during routine health maintenance examinations at 1 to 2 months, 4 months, and 6 to 18 months of age. The Advisory Committee on Immunization Practices (ACIP) recommends that this strategy be used only in rare circumstances, on a case-by-case basis, and only if a physician's order to withhold the birth dose and a copy of the mother's original HBsAg-negative laboratory report are documented in the infant's medical record [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/59\">",
"     59",
"    </a>",
"    ]. Receipt of the birth dose has been associated with higher rates of on-time completion of the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/17/15639?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/27,60\">",
"     27,60",
"    </a>",
"    ]. In addition, one study of inner city children showed that children immunized against HBV within the first month of life were more likely to receive other vaccines on time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only monovalent HepB vaccine can be used for the birth dose. Monovalent or combination vaccines containing HepB vaccine can be used for subsequent doses if the infant is at least six weeks of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Four doses of vaccine may be administered to infants who receive a dose at birth (monovalent) and combination vaccines to complete the series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/62\">",
"     62",
"    </a>",
"    ]. In either case, the minimum age for the final dose of HepB vaccine is 24 weeks of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/2,59\">",
"     2,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaccine-induced protection should result in antibody levels of 10",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    or higher. Adults and immunocompetent children do not need booster doses or routine serologic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     HBsAg-positive mother",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants of HBsAg-positive mothers should receive",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/39/24181?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    (HBIG) shortly after birth and should be immunized with monovalent HepB vaccine, preferably within 12 hours of age (",
"    <a class=\"graphic graphic_table graphicRef60075 \" href=\"mobipreview.htm?1/60/1998\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76345 \" href=\"mobipreview.htm?23/39/24189\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/63\">",
"     63",
"    </a>",
"    ]. These infants should be given their second and third doses of HepB vaccine at one and six months of age, respectively. Testing for HBsAg and anti-HBs antibody should be performed at 9 to 18 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/58\">",
"     58",
"    </a>",
"    ]. If the HBsAg test is negative and the anti-HBs antibody level &lt;10",
"    <span class=\"nowrap\">",
"     mIU/mL,",
"    </span>",
"    a fourth dose should be administered. If on subsequent testing, the level remains low, up to two more doses of HepB vaccine may be given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Mother's HBsAg status unknown",
"    </span>",
"    &nbsp;&mdash;&nbsp;An infant born to a mother with unknown HBsAg status should receive the first dose of monovalent HepB vaccine soon after birth (",
"    <a class=\"graphic graphic_table graphicRef60075 \" href=\"mobipreview.htm?1/60/1998\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76345 \" href=\"mobipreview.htm?23/39/24189\">",
"     table 4",
"    </a>",
"    ). The schedule for the remaining doses of HepB vaccine depends upon subsequent HBsAg testing of the mother. If she is found to be HBsAg-positive, the infant must be given HBIG no later than one week after birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Premature infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV immunization in premature infants is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37881?source=see_link&amp;anchor=H12#H12\">",
"     \"Hepatitis viruses and the newborn: Clinical manifestations and treatment\", section on 'Hepatitis B vaccine and premature infants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Older children",
"    </span>",
"    &nbsp;&mdash;&nbsp;All unvaccinated children and adolescents &lt;19 years should receive the HepB vaccine series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/59\">",
"     59",
"    </a>",
"    ]. After the first injection, subsequent doses of HepB vaccine should be given at one and six months after the first dose (",
"    <a class=\"graphic graphic_table graphicRef58271 graphicRef72079 \" href=\"mobipreview.htm?22/18/22817\">",
"     table 1A-B",
"    </a>",
"    ). An acceptable alternative schedule for adolescents 11 to 15 years of age consists of two doses of the adult formulation of the Recombivax HB vaccine (10",
"    <span class=\"nowrap\">",
"     mcg/1.0",
"    </span>",
"    mL per dose) administered four to six months apart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/64\">",
"     64",
"    </a>",
"    ]. Children and adolescents, who previously have received the first dose or two of the pediatric 5",
"    <span class=\"nowrap\">",
"     mcg/0.5",
"    </span>",
"    mL preparation, should complete the three-dose series with that vaccine. In addition, if it is unclear as to which strength HepB vaccine was administered to an adolescent as the initial dose in a series, then the 5",
"    <span class=\"nowrap\">",
"     mcg/0.5",
"    </span>",
"    mL preparation should be used to complete a three-dose series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals at particular risk of HBV infection include heterosexuals with more than one sexual partner in the previous six months and those with a recent sexually transmitted disease, homosexual and bisexual males, hemophiliacs, injection drug users, and healthcare workers and others with occupational risk.",
"   </p>",
"   <p>",
"    Screening for hepatitis B immunity (from past infection) before administration of the HepB vaccine series is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link&amp;anchor=H10#H10\">",
"     \"Hepatitis B virus vaccination\", section on 'Prevaccination screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV vaccination is contraindicated in individuals with a history of hypersensitivity to yeast or any of the vaccine components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/59\">",
"     59",
"    </a>",
"    ]. Vaccination is",
"    <strong>",
"     not",
"    </strong>",
"    contraindicated in persons with a history of multiple sclerosis, Guillain-Barr&eacute; syndrome, autoimmune disease, or other chronic disorder; nor is it contraindicated in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIPHTHERIA, TETANUS, AND/OR PERTUSSIS VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diphtheria, tetanus, and pertussis immunization in children and adolescents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5722?source=see_link\">",
"     \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34233?source=see_link\">",
"     \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     HIB CONJUGATE VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until universal vaccination of infants and children was recommended,",
"    <em>",
"     H. influenzae",
"    </em>",
"    serotype b (Hib) infections were a common cause of meningitis and other invasive infections in early childhood. The prevention of Hib infections, including active immunization with Hib conjugate vaccines, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42489?source=see_link&amp;anchor=H2#H2\">",
"     \"Prevention of Haemophilus influenzae infection\", section on 'Immunization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     POLIOVIRUS VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with wild-type poliovirus, which was at one time a commonly encountered and devastating viral infection, is now nonexistent in the United States. Poliovirus vaccination, including the rationale for the exclusive use of inactivated polio vaccine (IPV) in the United States, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17223?source=see_link\">",
"     \"Poliovirus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MMR VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measles virus causes an acute infection characterized by fever, cough, coryza, conjunctivitis, rash, and enanthem that may be followed by severe complications, including encephalitis. The mumps virus causes an acute self-limited viral syndrome, which occurred principally in school-children before the widespread use of mumps vaccine. Rubella virus causes German measles, a generally mild infection with a characteristic rash that can affect both children and adults. However, rubella infection can cause significant birth defects if it occurs early in fetal life. Rubella and congenital rubella syndrome are no longer endemic in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/65\">",
"     65",
"    </a>",
"    ]. However, sporadic cases continue to be reported, particularly among immigrant populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The clinical manifestations and diagnosis of measles, mumps, and rubella are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43192?source=see_link\">",
"     \"Clinical presentation and diagnosis of measles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/36/42567?source=see_link\">",
"     \"Mumps virus vaccine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26855?source=see_link\">",
"     \"Rubella\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     MMR preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination measles-mumps-rubella (MMR) vaccine, which is administered subcutaneously, includes the measles, mumps, and rubella live-virus vaccines. Single-antigen preparations of these vaccines are no longer available in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a combination measles, mumps, rubella, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    (MMRV,",
"    <span class=\"nowrap\">",
"     Oka/Merck,",
"    </span>",
"    ProQuad) is approved by the United States Food and Drug Administration (FDA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/67\">",
"     67",
"    </a>",
"    ]. It is indicated for simultaneous immunization against measles, mumps, rubella, and varicella among children 12 months to 12 years of age. The immunogenicity of the MMRV vaccine is discussed below. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'MMRV vaccine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Decisions regarding the use of MMRV or separate MMR and varicella vaccines should be made on a case-by-case basis after a discussion of the risks and benefits of each strategy with the child's parents. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'MMR adverse reactions'",
"    </a>",
"    below.) The",
"    <a class=\"external\" href=\"file://www.cdc.gov/vaccines/vpd-vac/combo-vaccines/mmrv/vacopt.htm\">",
"     Centers for Disease Control and Prevention",
"    </a>",
"    (CDC) provides information and a fact sheet to help parents understand their options. The Advisory Committee on Immunization Practices (ACIP) and American Academy of Pediatrics (AAP) recommend separate MMR and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    for the first doses of MMR and varicella vaccines in children aged 12 through 47 months if the parents do not have a preference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. However, for the second doses of MMR and varicella vaccines at any age (15 months through 12 years), MMRV generally is preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Dosing schedule",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196182557\">",
"    <span class=\"h3\">",
"     Routine schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first dose of MMR is administered at 12 to 15 months of age. A second dose is recommended at school entry (between four and six years of age) and by 11 to 12 years of age if not previously administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/70\">",
"     70",
"    </a>",
"    ]. However, the second dose may be administered as early as four weeks after the first dose, provided that both doses are administered after at least 12 months of age (",
"    <a class=\"graphic graphic_table graphicRef58271 graphicRef72079 \" href=\"mobipreview.htm?22/18/22817\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/2,71\">",
"     2,71",
"    </a>",
"    ]. Such a dosing schedule may be considered during an outbreak or before international travel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/72\">",
"     72",
"    </a>",
"    ]. At least one month should elapse between administration of MMRV and a dose of measles-containing vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/36/42567?source=see_link&amp;anchor=H23#H23\">",
"     \"Mumps virus vaccine\", section on 'Use of vaccine in outbreak situations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/61/8154?source=see_link&amp;anchor=H34#H34\">",
"     \"Epidemiology, clinical manifestations, diagnosis and management of mumps\", section on 'Evidence of immunity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When administered at age 11 to 12 years, the second dose of MMR vaccine may be administered concurrently with the booster dose of Tdap, HepB, and the meningococcal conjugate vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/73\">",
"     73",
"    </a>",
"    ]. However, data regarding the safety and immunogenicity of concomitant administration of Tdap and other vaccines are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196182513\">",
"    <span class=\"h3\">",
"     International travel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children traveling outside the United States should receive MMR vaccine earlier than it is routinely recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link&amp;anchor=H3181096#H3181096\">",
"     \"Immunizations for travel\", section on 'Measles, mumps and rubella'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before departure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/72\">",
"     72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children &ge;12 months of age should receive two doses of MMR vaccine separated by at least four weeks, with the first dose administered on or after the first birthday.",
"     </li>",
"     <li>",
"      Children aged 6 to 11 months should receive one dose of MMR vaccine. Children who receive the first dose of MMR vaccine before age 12 months should receive two additional doses, separated by at least four weeks, beginning at age 12 to 15 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Immune globulin recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The receipt of parenterally administered immune globulin or blood products can blunt or block the host response to certain live-virus vaccines. The suggested interval between receipt of these products and administration of MMR or monovalent measles vaccine varies between three and 11 months depending upon the product (",
"    <a class=\"graphic graphic_table graphicRef72640 \" href=\"mobipreview.htm?1/48/1805\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. In addition, if immune globulin or blood products must be given within 14 days after administration of MMR or monovalent measles vaccine, another dose of the vaccine should be administered after the interval suggested in the table (",
"    <a class=\"graphic graphic_table graphicRef72640 \" href=\"mobipreview.htm?1/48/1805\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMR should be administered to all asymptomatic HIV-infected persons and to HIV-infected persons who are not severely immunocompromised and who have no evidence of measles immunity. Routine immunization of the severely immunocompromised HIV-infected individual remains controversial. Should a person in this latter group be at risk for measles exposure during an outbreak, the choice between measles vaccination and immune globulin prophylaxis should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22793?source=see_link&amp;anchor=H2455889#H2455889\">",
"     \"Prevention and treatment of measles\", section on 'Immunocompromised patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;True contraindications to administration of MMR vaccine include pregnancy, known altered immunodeficiency states such as congenital immunodeficiencies, long-term immunosuppressive therapy, and hematologic or solid tumors. Immunization should be withheld temporarily from patients with moderate or severe febrile illnesses until the acute phase has subsided. Patients experiencing thrombocytopenia within six weeks of having had MMR vaccine probably should not receive a subsequent dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'MMR adverse reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are vaccinated with MMR should be advised to avoid pregnancy for at least 28 days after vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/78\">",
"     78",
"    </a>",
"    ]. The Advisory Committee on Immunization Practices (ACIP) shortened the recommended interval from three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/75\">",
"     75",
"    </a>",
"    ] to 28 days after review of data from the United States, United Kingdom, Sweden, and Germany confirmed no cases of congenital rubella syndrome in infants born to mothers who were vaccinated between two weeks before and six weeks after conception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=see_link&amp;anchor=H9#H9\">",
"     \"Immunizations during pregnancy\", section on 'Measles, mumps, rubella'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6087?source=see_link\">",
"     \"Rubella in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because MMR and its component vaccines contain hydrolyzed gelatin, as a stabilizer, and trace amounts of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/42/29348?source=see_link\">",
"     neomycin",
"    </a>",
"    , extreme caution should be used before the vaccine is given to individuals with a history of anaphylaxis to these additives. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=see_link\">",
"     \"Allergic reactions to vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A personal or family (sibling or parent) history of seizure is a precaution for the use of MMRV vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     MMR adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse reactions to the MMR vaccine include fever, rash, joint complaints, hypersensitivity reactions, the development of immune thrombocytopenia (ITP), and seizures. These reactions occur more frequently with the first than with the second dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever (&gt;39.4&ordm;C) develops in 5 to 15 percent of MMR recipients, usually within 6 to 12 days after immunization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transient rashes also occur in approximately 5 percent of MMR recipients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Joint complaints (secondary to the rubella component of the vaccine) may occur 7 to 21 days after MMR immunization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/80\">",
"       80",
"      </a>",
"      ]. Joint pain, usually of small peripheral joints, has been reported in 0.5 percent of young children and arthralgia and transient arthritis in 25 and 10 percent of postpubertal females, respectively.",
"     </li>",
"     <li>",
"      Hypersensitivity reactions to the MMR vaccine are usually minor (wheal and flare, or urticaria) and have been attributed to trace amounts of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/42/29348?source=see_link\">",
"       neomycin",
"      </a>",
"      or gelatin, but not to egg antigens, since the MMR vaccine does not contain significant amounts of egg-white cross-reacting proteins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/72,81,82\">",
"       72,81,82",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=see_link\">",
"       \"Allergic reactions to vaccines\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is an increased risk of development of immune thrombocytopenia (ITP) in the six weeks following MMR vaccination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/83,84\">",
"       83,84",
"      </a>",
"      ]. However, MMR-associated ITP is rare. In a systematic review of 12 studies, the median incidence of ITP after MMR was 2.6 cases per 100,000 doses (range 0.87 to 4 cases per 100,000 doses) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/85\">",
"       85",
"      </a>",
"      ]. This incidence is lower than ITP after natural measles or rubella infection, and similar to the incidence of ITP in the general population (between 3 and 8 cases per 100,000 children per year). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23833?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\", section on 'Epidemiology'",
"      </a>",
"      .) Severe bleeding manifestations were rare, and thrombocytopenia resolved within six months in 93 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/85\">",
"       85",
"      </a>",
"      ]. MMR vaccination was not associated with recurrence of thrombocytopenia in children with ITP (either MMR-associated or nonvaccine-associated). The ACIP suggests that the benefits of MMR immunization outweigh the risks in unimmunized children with a history of ITP but that it may be prudent to withhold the booster dose of MMR in patients who developed thrombocytopenia within six weeks of the initial dose of MMR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of febrile and nonfebrile seizures following MMR vaccine was calculated in a cohort study of almost 680,000 in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/86\">",
"       86",
"      </a>",
"      ]. Receipt of the MMR vaccine was associated with an increased risk (relative risk [RR] 2.8) of febrile seizures 8 to 14 days after immunization. There was no increased risk of nonfebrile seizures, and the children with febrile seizures after vaccination had no higher risk of subsequent seizure or neurodevelopmental disability than other children with febrile seizures in the absence of vaccine administration. Similar results were reported in a cohort study of Danish children (RR 2.8 for febrile seizure within two weeks of MMR vaccination) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/87\">",
"       87",
"      </a>",
"      ]. Compared with children who had not received MMR at the time of their first febrile seizure, children with post-MMR febrile seizure had a slightly increased risk of recurrent febrile seizures (RR 1.2), but no increased risk of epilepsy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3226?source=see_link\">",
"       \"Febrile seizures\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/35/39473?source=see_link\">",
"       \"Patient information: Febrile seizures (Beyond the Basics)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Large postlicensure studies suggest that the risk of febrile seizures one to two weeks after immunization is increased by approximately twofold in children aged 12 to 23 months who receive MMRV compared with children who receive separate injections of MMR and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef65930 \" href=\"mobipreview.htm?21/46/22252\">",
"       table 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/88,89\">",
"       88,89",
"      </a>",
"      ]. Nonetheless, the absolute risk of febrile seizures remains low (approximately 1 per 2300 to 2600 vaccinees) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/68\">",
"       68",
"      </a>",
"      ]. Neither MMRV nor separate injections of MMR and varicella vaccine appear to be associated with an increased risk of febrile seizures at age 4 to 6 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of encephalopathy after MMR vaccine was evaluated in a retrospective case-control study including 452 children with encephalopathy and related conditions and up to three controls for each case [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/91\">",
"       91",
"      </a>",
"      ]. Cases were no more likely than controls to have received MMR vaccine during the 90 days before onset of encephalopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Lack of association with autism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern has been raised periodically about a possible link between receipt of MMR vaccine and autism and other chronic diseases (eg, multiple sclerosis and diabetes mellitus). This association is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26857?source=see_link\">",
"     \"Autism and chronic disease: Little evidence for vaccines as a contributing factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     VARICELLA VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-zoster virus (VZV) is the virus responsible for varicella (chickenpox) and herpes zoster (\"shingles\"). The clinical manifestations and treatment of VZV infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=see_link\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VZV vaccine (Varivax) was added to the list of standard childhood vaccines in 1995. Before its recommended use, an estimated 3.7 million cases of chickenpox occurred in the United States annually, resulting in nearly 9000 hospitalizations and approximately 100 deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. A cost-effectiveness study of vaccination in 1994 estimated savings of nearly $400 million in the costs of medical care and time lost from work for parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/92\">",
"     92",
"    </a>",
"    ]. Data from the United States Nationwide Inpatient Sample indicate that varicella-related hospitalizations decreased from 0.5 per 10,000 population during 1993-1995 to 0.13 per 10,000 population in 2001 (before and after VZV vaccine was routinely recommended), resulting in a savings of $95 million in hospital charges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    is a live virus vaccine. Similar to the measles-mumps-rubella (MMR) vaccine, it contains trace amounts of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/42/29348?source=see_link\">",
"     neomycin",
"    </a>",
"    and gelatin.",
"   </p>",
"   <p>",
"    A combination measles, mumps, rubella, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    (MMRV,",
"    <span class=\"nowrap\">",
"     Oka/Merck,",
"    </span>",
"    ProQuad) is also available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/67\">",
"     67",
"    </a>",
"    ]. It is indicated for simultaneous immunization against measles, mumps, rubella, and varicella among children 12 months to 12 years of age.",
"   </p>",
"   <p>",
"    Decisions regarding the use of MMRV or separate MMR and varicella vaccines should be made on a case-by-case basis after a discussion of the risks and benefits of each strategy with the child's parents. (See",
"    <a class=\"local\" href=\"#H45\">",
"     'Adverse reactions'",
"    </a>",
"    below.) The",
"    <a class=\"external\" href=\"file://www.cdc.gov/vaccines/vpd-vac/combo-vaccines/mmrv/vacopt.htm\">",
"     Centers for Disease Control and Prevention",
"    </a>",
"    (CDC) provides information and a fact sheet to help parents understand their options. The Advisory Committee on Immunization Practices (ACIP) and American Academy of Pediatrics (AAP) recommend separate MMR and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    for the first doses of MMR and varicella vaccines in children aged 12 through 47 months if the parents do not have a preference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. However, for the second doses of MMR and varicella vaccines at any age (15 months through 12 years), MMRV generally is preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Dosing schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP and AAP recommend two doses (0.5 mL) of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    for routine immunization of immunocompetent individuals without evidence of immunity; and catch-up immunization with a second dose of VZV vaccine for persons who received one dose previously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Evidence of immunity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Two doses of VZV vaccine provide increased protection against varicella disease compared with one dose as had been previously recommended. Fifteen to 20 percent of children who have received one dose of VZV vaccine may develop chickenpox after contact with VZV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/96\">",
"     96",
"    </a>",
"    ]. In addition, protection provided by one dose of VZV vaccine may not last into adulthood when the disease can be more severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first dose is usually administered at 12 to 15 months of age. The second dose is usually administered at four to six years of age, but can be administered earlier (eg, during a varicella outbreak). For children between 2 and 12 years, at least three months should elapse between administration of any two doses of varicella vaccines (whether single antigen",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    or MMRV vaccine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/67\">",
"     67",
"    </a>",
"    ]. For adolescents 13 years or older, at least four weeks should elapse between administration of any two doses of varicella vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. The subcutaneous route is recommended; however intramuscular administration results in similar rates of seroconversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Children with ALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with acute lymphocytic leukemia (ALL) in remission for at least one year and with platelet counts",
"    <span class=\"nowrap\">",
"     &gt;100,000/microL",
"    </span>",
"    and T-lymphocyte counts higher than",
"    <span class=\"nowrap\">",
"     700/microL",
"    </span>",
"    24 hours before immunization should be considered potential recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\", section on 'Primary care considerations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Immune globulin recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The receipt of parenterally administered immune globulin or blood products can blunt or block the host response to certain live-virus vaccines. The effect of these products on the antibody response to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/77\">",
"     77",
"    </a>",
"    ]. However, because of potential inhibition of the immune response, the administration of varicella vaccine should be delayed in children who have received immune globulin or blood products. The suggested interval is the same as is recommended for measles vaccine&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef72640 \" href=\"mobipreview.htm?1/48/1805\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/77\">",
"     77",
"    </a>",
"    ]. In addition, if immune globulin or blood products must be given within 14 days after administration of MMR or monovalent measles vaccine, another dose of the vaccine should be administered after the interval suggested in the table (",
"    <a class=\"graphic graphic_table graphicRef72640 \" href=\"mobipreview.htm?1/48/1805\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended interval between discontinuation of high-dose systemic glucocorticoids (&ge;2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent; or &ge;20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    if child weighs more than 10 kg) and varicella vaccination depends upon the duration of glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/98\">",
"     98",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If glucocorticoids have been administered for &lt;14 days, varicella vaccination can be administered immediately after discontinuation of treatment, although some experts would delay immunization until two weeks after discontinuation",
"     </li>",
"     <li>",
"      If glucocorticoids have been administered for &ge;14 days, the recommended interval between discontinuation of treatment and varicella vaccination is one month",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Evidence of immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of immunity to varicella includes any of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/96\">",
"     96",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Documentation of age-appropriate vaccination with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Laboratory evidence of immunity or laboratory confirmation of the disease.",
"     </li>",
"     <li>",
"      Birth in the United States before 1980.",
"     </li>",
"     <li>",
"      Diagnosis or verification of a history of varicella disease by a healthcare provider. For persons reporting a history of atypical or mild disease (often having occurred in infants younger than one year of age), assessment by a clinician or their designee is recommended and one of the following should be sought:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An epidemiologic link to a typical varicella case or to a laboratory-confirmed case, or",
"     </li>",
"     <li>",
"      Evidence of laboratory confirmation if it was performed at the time of acute disease",
"      <br/>",
"      <br/>",
"      When such documentation is lacking, persons should not be considered as having a valid history of disease because other diseases might mimic mild atypical varicella.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis or verification of a history of herpes zoster by a healthcare provider.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Immunogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV vaccine appears to confer a high rate of protection against severe disease. Seroconversion rates for children one to 12 years of age are 98 percent after one dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/99\">",
"     99",
"    </a>",
"    ]. Seroconversion rates for those older than 12 years are 99 percent after two doses at least four weeks apart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     In children with asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunogenicity of VZV vaccine among children with asthma was evaluated in a prospective open-label study of 274 children aged one to eight years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/101\">",
"     101",
"    </a>",
"    ]. The children were assigned to treatment with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    or nonsteroidal conventional asthma therapy at the investigators' discretion. Children were vaccinated after they had received four weeks of treatment and continued treatment for &ge;8 weeks after vaccination; the use of oral, topical, or inhaled glucocorticoids (other than the inhaled budesonide in the budesonide group) was not permitted during the study. A similar proportion of children in the budesonide and conventional therapy groups achieved protective levels of antibody six weeks after vaccination (85 and 90 percent, respectively).",
"   </p>",
"   <p>",
"    These results are consistent with those of a retrospective cohort review that found no association between vaccine failure and asthma or the use of inhaled glucocorticoids, but did find an association between vaccine failure and the use of oral glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     MMRV vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who receive MMRV vaccine develop antibody levels to measles, mumps, rubella, and varicella that are similar to those of children who receive MMR vaccine and varicella vaccines at separate injection sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/67\">",
"     67",
"    </a>",
"    ]. This is true whether MMRV is administered for the first time at 12 to 23 months of age, or as a booster at four to six years of age to children who received separate doses of MMR and varicella vaccines at age 12 months or older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MMRV is also an effective booster of varicella immunity when it is used in a two dose series. In a group of 1035 children who received a second dose of MMRV three months after the first dose, the geometric mean titers (GMTs) for varicella increased approximately 41-fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case-control study of effectiveness of the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in the United States showed that patients with chickenpox confirmed by polymerase chain reaction (PCR) were significantly less likely than were matched controls to have been vaccinated (23 versus 61 percent, vaccine effectiveness of 85 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/103\">",
"     103",
"    </a>",
"    ]. Fifty-six vaccinated children developed chickenpox (all with wild-type virus); these children were far more likely than were matched controls to have mild disease (86 versus 48 percent). Thus, the vaccine was 97 percent effective against moderately severe or severe infection.",
"   </p>",
"   <p>",
"    Retrospective population-based data indicate that hospitalizations related to varicella infection declined by 88 percent among individuals &le;49 years between 1994 and 2002 (before and after the introduction of the vaccine to the routine childhood immunization schedule) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/104\">",
"     104",
"    </a>",
"    ]. Ambulatory visits related to varicella infection declined by 59 percent during the same time period.",
"   </p>",
"   <p>",
"    Reports of outbreaks of varicella in daycare centers and elementary schools suggest that vaccine-induced immunity wanes over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/105-112\">",
"     105-112",
"    </a>",
"    ]. Postlicensure studies indicate that levels of protective efficacy fall from 97 to 84 percent at eight years after immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/107,110\">",
"     107,110",
"    </a>",
"    ], and that the rate of breakthrough varicella increases with time since vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/113\">",
"     113",
"    </a>",
"    ]. In addition, vaccination before 15 to 18 months of age appears to be associated with breakthrough varicella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/107,111\">",
"     107,111",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link&amp;anchor=H18#H18\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\", section on 'Waning of immunity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to administration of VZV vaccine include primary or acquired immunocompromised states, pregnancy, moderate or severe illnesses, and a previous anaphylactoid reaction to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/42/29348?source=see_link\">",
"     neomycin",
"    </a>",
"    or gelatin.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     Varicella vaccine",
"    </a>",
"    should not be administered to children receiving high doses of systemic glucocorticoids (&ge;2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent; or &ge;20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    if the child weighs more than 10 kg) daily or on alternate days for &ge;14 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/98\">",
"     98",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Glucocorticoids'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not known whether Reye syndrome results from administration of salicylates after varicella immunization. However, because of the association between salicylates, natural varicella, and Reye syndrome, the vaccine manufacturer recommends that salicylates should be avoided for at least six weeks after VZV vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A personal or family (sibling or parent) history of seizure is a precaution for the use of MMRV vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse reactions among recipients of the VZV vaccine include rash and fever.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 3 to 5 percent of all patients who receive the VZV vaccine develop a localized rash consisting of two to five lesions at the injection site, and another 3 to 5 percent develop or a generalized varicella-like rash within one month of immunization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/114\">",
"       114",
"      </a>",
"      ]. Most of the varicella-form rashes that occur within the first two weeks after varicella immunization are caused by wild-type VZV.",
"     </li>",
"     <li>",
"      Approximately one-fifth of children, and up to one-third of adolescents and adults, complain of pain, tenderness, or redness at the injection site. Temperature higher than 102&ordm;F, occurring up to 1.5 months after varicella immunization, has been noted in 15 percent of patients, but because of similar febrile response in placebo recipients, the reaction is not considered significant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/115\">",
"       115",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Large postlicensure studies suggest that the risk of febrile seizures one to two weeks after immunization is increased by approximately twofold in children aged 12 to 23 months who receive MMRV compared with children who receive separate injections of MMR and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef65930 \" href=\"mobipreview.htm?21/46/22252\">",
"       table 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/88,89\">",
"       88,89",
"      </a>",
"      ]. Nonetheless, the absolute risk of febrile seizures remains low (approximately 1 per 2300 to 2600 vaccinees) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/68\">",
"       68",
"      </a>",
"      ]. Neither MMRV nor separate injections of MMR and varicella vaccine appear to be associated with an increased risk of febrile seizures at age 4 to 6 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (FDA), in association with the CDC, have published the results of more than three years of reports to the United States Vaccine Adverse Event Reporting System (VAERS) postlicensure of the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    ; 6574 reports were received for a rate of 67.5 per 100,000 doses sold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/116\">",
"     116",
"    </a>",
"    ]. Four percent of these reports were of serious adverse events, none of which could be confirmed to have resulted from varicella vaccination, although some were caused by wild-type VZV and several remain under investigation. The authors conclude that most reactions to varicella vaccination are mild.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Transmission of VZV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although VZV has been recovered from skin lesions of healthy vaccine recipients, transmission of vaccine-associated VZV rarely occurs, but has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. The risk of transmission is present only if the vaccine recipient develops skin lesions [Merck &amp; Co, unpublished data].",
"   </p>",
"   <p>",
"    Subclinical or extremely mild cases of vaccine-associated varicella have been reported in the healthy siblings of children with leukemia who had received",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Risk of herpes zoster",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although herpes zoster has been noted in both immunocompetent and immunosuppressed recipients of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    , data from postlicensure surveillance indicate that the age-specific risk for this condition is less in immunocompetent hosts who received the vaccine than in those who acquired the natural disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/114\">",
"     114",
"    </a>",
"    ]. However, care must be taken in interpreting these data since duration and intensity of surveillance of the groups varied (patients with natural infection group were more actively monitored and for longer periods of time than those in the vaccine group).",
"   </p>",
"   <p>",
"    Wild-type VZV also has been identified in persons with herpes zoster after immunization, indicating that herpes zoster in immunized persons also may result from antecedent natural varicella infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     PNEUMOCOCCAL VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    is the leading cause of bacterial pneumonia worldwide and a principal cause of sepsis and meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/120\">",
"     120",
"    </a>",
"    ], particularly in infants and children younger than two years of age. The pneumococcal conjugate vaccine was added to the recommended childhood immunization schedule in 2001 and is discussed in detail separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/121\">",
"     121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h1\">",
"     MENINGOCOCCAL VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningococcal vaccines protect against one or more serogroups of",
"    <em>",
"     Neisseria meningitidis",
"    </em>",
"    . The indications and schedule for meningococcal vaccination in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link&amp;anchor=H20#H20\">",
"     \"Meningococcal vaccines\", section on 'In children and adolescents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h1\">",
"     HEPATITIS A VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly 60 percent of viral hepatitis cases in the United States are caused by hepatitis A virus (HAV). A significant number of pediatric cases occur in daycare settings, where fecal-oral transmission is common. Manifestations of disease in children younger than five years old tend to be relatively mild [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/122\">",
"     122",
"    </a>",
"    ]. However, acute liver failure and death can occur, especially in patients with chronic liver disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16295?source=see_link\">",
"     \"Overview of hepatitis A virus infection in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adults with HAV infection generally manifest more significant signs and symptoms of illness than do children. An advantage to immunizing children with the HepA vaccine is the reduction of transmission to susceptible adult household contacts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Universal HAV immunization of all children 12 to 23 months of age is recommended by the Centers for Disease Control and Prevention (CDC) and American Academy of Pediatrics (AAP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/2,122\">",
"     2,122",
"    </a>",
"    ]. HAV immunization also is recommended for specific high-risk groups, such as international travelers, close contacts of newly arriving international adoptees, persons with clotting factor disorders, patients with chronic liver disease, males with homosexual activity,",
"    <span class=\"nowrap\">",
"     injecting/non-injecting",
"    </span>",
"    drug users, and people living in communities with HAV outbreaks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/122,124,125\">",
"     122,124,125",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two licensed hepatitis A vaccines are available in the United States (HAVRIX and VAQTA), each consisting of viral antigens purified from HAV-infected human diploid fibroblast cell cultures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VAQTA is approved for individuals older than one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/126,127\">",
"       126,127",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HAVRIX is approved for use in individuals 1 to 18 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/128\">",
"       128",
"      </a>",
"      ]. HAVRIX is a component of the Twinrix combination vaccine, which also contains hepatitis B (Engerix-B).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it is preferable to use the same preparation for both doses of the series, it is acceptable to use a different preparation for the second dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/129,130\">",
"     129,130",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Dosing schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HepA vaccine is recommended for all children beginning at one year (ie, 12 to 23 months) of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/2,122\">",
"     2,122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dosing schedule for HepA vaccines depends upon the age of the recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/122\">",
"     122",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      One to 18 years: Two 0.5 mL IM doses at least six months apart",
"     </li>",
"     <li>",
"      &ge;19 years: Two 1.0 mL IM doses administered 6 to 18 months apart",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies in infants and young children &le;18 years suggest that the HepA vaccine does not affect immunogenicity or reactogenicity to diphtheria, tetanus, acellular pertussis (DTaP),",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib), hepatitis B, measles-mumps-rubella (MMR), oral poliovirus, or inactivated poliovirus vaccines when administered at the same visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/122,131-135\">",
"     122,131-135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only true contraindication to vaccine administration is in those individuals with a history of a severe reaction to a prior dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/43/38581?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    or a hypersensitivity reaction to vaccine additives (eg, alum or phenoxyethanol) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brief pain and tenderness have been the main side effects following injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/122\">",
"     122",
"    </a>",
"    ]. In &le;15 percent of cases, fever and headaches have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h1\">",
"     INFLUENZA VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza immunization is recommended for all children &ge;6 months of age. Influenza immunization is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link\">",
"     \"Seasonal influenza vaccination in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h1\">",
"     ROTAVIRUS VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotavirus vaccines are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40937?source=see_link\">",
"     \"Rotavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h1\">",
"     HUMAN PAPILLOMAVIRUS VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papillomavirus (HPV) vaccine is recommended for routine administration in girls beginning at 11 to 12 years of age and for girls and women ages 13 to 26 years who have not received or completed the vaccine series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/136\">",
"     136",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link&amp;anchor=H7#H7\">",
"     \"Recommendations for the use of human papillomavirus vaccines\", section on 'Recommendations for HPV immunization in females'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The quadrivalent human papillomavirus recombinant vaccine also is recommended for boys beginning at 11 to 12 years and boys and men ages 13 to 21 years who have not received or completed the vaccine series; in addition it may be given to men up to 26 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/137\">",
"     137",
"    </a>",
"    ]. HPV vaccine reduces the likelihood of acquiring",
"    <span class=\"nowrap\">",
"     anal/genital",
"    </span>",
"    warts and may reduce the risk of anal cancer in males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/2,138\">",
"     2,138",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link&amp;anchor=H93840009#H93840009\">",
"     \"Recommendations for the use of human papillomavirus vaccines\", section on 'Recommendations for HPV immunization in males'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h1\">",
"     NEW TECHNOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impressive efforts are being made to develop new effective vaccines and mechanisms for optimal delivery. Biodegradable polymer technology is being considered as a mechanism for delivering multiple doses of a vaccine after a single injection (eg, a single injection of diphtheria, tetanus, acellular pertussis (DTaP) vaccine could be given with timed release at two, four, and six months of age).",
"   </p>",
"   <p>",
"    In the near future, newer more effective adjuvants for vaccine delivery may be available. Use of these adjuvants may allow for the needle-free administration of vaccines by direct application of vaccine antigen(s) to skin surfaces. Using DNA technology, genomic sequencing of particular organisms may be feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/139\">",
"     139",
"    </a>",
"    ] and would allow for the elimination of virulent segments of a particular organism while preserving those portions essential for immune protection. The best vaccines to be produced and presumably the easiest to deliver will be those that can be administered orally or via the intranasal route. Once vaccine antigen(s) come in contact with mucosal lymphocytes, they can be transported throughout the body, stimulating appropriate immune response.",
"   </p>",
"   <p>",
"    Growing vaccines in certain fruits",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vegetables (eg, banana plants, peas, potatoes, cucumbers) by using genetic engineering techniques may allow children to be immunized by simply ingesting the particular food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/56/39818/abstract/140\">",
"     140",
"    </a>",
"    ]. Potential vaccines to be administered in this fashion may include those used to protect against certain enteric organisms (eg,",
"    <em>",
"     Vibrio cholerae",
"    </em>",
"    ,",
"    <em>",
"     Shigella",
"    </em>",
"    sp.,",
"    <em>",
"     Escherichia coli",
"    </em>",
"    ). No special refrigeration will be required, and the cost of these vaccines may be minimal compared with the cost of vaccines produced by more expensive technology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=see_link\">",
"       \"Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18547?source=see_link\">",
"       \"Patient information: Vaccines for children age 7 to 18 years (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18084?source=see_link\">",
"       \"Patient information: Why does my child need vaccines? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"       \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/18/37156?source=see_link\">",
"       \"Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2115055251\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Universal immunization of children and adolescents against hepatitis A and B, diphtheria, tetanus, pertussis,",
"      <em>",
"       Haemophilus influenzae",
"      </em>",
"      type b, polio, rotavirus, measles, mumps, rubella, varicella-zoster virus, influenza, meningococcus, and human papillomavirus is recommended in the United States (",
"      <a class=\"graphic graphic_figure graphicRef82617 graphicRef58209 \" href=\"mobipreview.htm?4/7/4218\">",
"       figure 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The recommended schedule for children whose immunizations have been delayed is provided in the tables (",
"      <a class=\"graphic graphic_table graphicRef58271 graphicRef72079 \" href=\"mobipreview.htm?22/18/22817\">",
"       table 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse events associated with vaccines should be reported to the United States Department of Health and Human Services using the Vaccine Adverse Events Reporting System (VAERS,",
"      <a class=\"external\" href=\"file://vaers.hhs.gov/index\">",
"       vaers.hhs.gov/index",
"      </a>",
"      , telephone number 1-800-822-7967). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Adverse event reporting'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998-2000. MMWR Morb Mortal Wkly Rep 2002; 51:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/2\">",
"      ACIP Childhood/Adolescent Immunization Work Group, Akinsanya-Beysolow I, Jenkins R, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/3\">",
"      Zangwill KM, Eriksen E, Lee M, et al. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization. Pediatrics 2008; 122:e1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/4\">",
"      Marshall GS, Happe LE, Lunacsek OE, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J 2007; 26:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/5\">",
"      Guerra FA, Blatter MM, Greenberg DP, et al. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics 2009; 123:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/6\">",
"      Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among children aged 19-35 months--United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Interim results: state-specific influenza vaccination coverage--United States, August 2010-February 2011. MMWR Morb Mortal Wkly Rep 2011; 60:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Seasonal influenza vaccination coverage among children aged 6 months-18 years --- eight immunization information system sentinel sites, United States, 2009-10 influenza season. MMWR Morb Mortal Wkly Rep 2010; 59:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Vaccination coverage among children entering school--United States, 2003-04 school year. MMWR Morb Mortal Wkly Rep 2004; 53:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Vaccination coverage among children entering school--United States, 2005-06 school year. MMWR Morb Mortal Wkly Rep 2006; 55:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Vaccination coverage among children in kindergarten--United States, 2006-07 school year. MMWR Morb Mortal Wkly Rep 2007; 56:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Vaccination coverage among children in kindergarten--United States, 2009-10 school year. MMWR Morb Mortal Wkly Rep 2011; 60:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/13\">",
"      Centers for Disease Control and Prevention (CDC). Vaccination coverage among children in kindergarten--United States, 2011-12 school year. MMWR Morb Mortal Wkly Rep 2012; 61:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/14\">",
"      Luman ET, Barker LE, Shaw KM, et al. Timeliness of childhood vaccinations in the United States: days undervaccinated and number of vaccines delayed. JAMA 2005; 293:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/15\">",
"      Fair E, Murphy TV, Golaz A, Wharton M. Philosophic objection to vaccination as a risk for tetanus among children younger than 15 years. Pediatrics 2002; 109:E2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/16\">",
"      Feikin DR, Lezotte DC, Hamman RF, et al. Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA 2000; 284:3145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/17\">",
"      Danovaro-Holliday MC, LeBaron CW, Allensworth C, et al. A large rubella outbreak with spread from the workplace to the community. JAMA 2000; 284:2733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Measles outbreak among internationally adopted children arriving in the United States, February-March 2001. MMWR Morb Mortal Wkly Rep 2002; 51:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). Import-associated measles outbreak--Indiana, May-June 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/20\">",
"      Centers for Disease Control and Prevention (CDC). Epidemiology of measles--United States, 2001-2003. MMWR Morb Mortal Wkly Rep 2004; 53:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). Multistate measles outbreak associated with an international youth sporting event--Pennsylvania, Michigan, and Texas, August-September 2007. MMWR Morb Mortal Wkly Rep 2008; 57:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/22\">",
"      Joint statement of the American Academy of Pediatrics (AAP) and the United States Public Health Service (USPHS). Pediatrics 1999; 104:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/23\">",
"      Centers for Disease Control and Prevention (CDC). Summary of the joint statement on thimerosal in vaccines. American Academy of Family Physicians, American Academy of Pediatrics, Advisory Committee on Immunization Practices, Public Health Service. MMWR Morb Mortal Wkly Rep 2000; 49:622, 631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/24\">",
"      Centers for Disease Control and Prevention (CDC). Availability of hepatitis B vaccine that does not contain thimerosal as a preservative. MMWR Morb Mortal Wkly Rep 1999; 48:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/25\">",
"      Centers for Disease Control and Prevention (CDC). Impact of the 1999 AAP/USPHS joint statement on thimerosal in vaccines on infant hepatitis B vaccination practices. MMWR Morb Mortal Wkly Rep 2001; 50:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/26\">",
"      Oram RJ, Daum RS, Seal JB, Lauderdale DS. Impact of recommendations to suspend the birth dose of hepatitis B virus vaccine. JAMA 2001; 285:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/27\">",
"      Schier JG, Hoffman RS. Treatment of sarin exposure. JAMA 2004; 291:182; author reply 182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/28\">",
"      Biroscak BJ, Fiore AE, Fasano N, et al. Impact of the thimerosal controversy on hepatitis B vaccine coverage of infants born to women of unknown hepatitis B surface antigen status in Michigan. Pediatrics 2003; 111:e645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/29\">",
"      Hurie MB, Saari TN, Davis JP. Impact of the Joint Statement by the American Academy of Pediatrics/US Public Health Service on thimerosal in vaccines on hospital infant hepatitis B vaccination practices. Pediatrics 2001; 107:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/30\">",
"      Brayden RM, Pearson KA, Jones JS, et al. Effect of thimerosal recommendations on hospitals' neonatal hepatitis B vaccination policies. J Pediatr 2001; 138:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/31\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Vaccine administration. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.20.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/33\">",
"      Diggle L, Deeks JJ, Pollard AJ. Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial. BMJ 2006; 333:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/34\">",
"      Poland GA, Borrud A, Jacobson RM, et al. Determination of deltoid fat pad thickness. Implications for needle length in adult immunization. JAMA 1997; 277:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/35\">",
"      Groswasser J, Kahn A, Bouche B, et al. Needle length and injection technique for efficient intramuscular vaccine delivery in infants and children evaluated through an ultrasonographic determination of subcutaneous and muscle layer thickness. Pediatrics 1997; 100:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/36\">",
"      Jackson LA, Starkovich P, Dunstan M, et al. Prospective assessment of the effect of needle length and injection site on the risk of local reactions to the fifth diphtheria-tetanus-acellular pertussis vaccination. Pediatrics 2008; 121:e646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/37\">",
"      Lippert WC, Wall EJ. Optimal intramuscular needle-penetration depth. Pediatrics 2008; 122:e556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/38\">",
"      Schechter NL, Zempsky WT, Cohen LL, et al. Pain reduction during pediatric immunizations: evidence-based review and recommendations. Pediatrics 2007; 119:e1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/39\">",
"      Chambers CT, Taddio A, Uman LS, et al. Psychological interventions for reducing pain and distress during routine childhood immunizations: a systematic review. Clin Ther 2009; 31 Suppl 2:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/40\">",
"      Harrison D, Stevens B, Bueno M, et al. Efficacy of sweet solutions for analgesia in infants between 1 and 12 months of age: a systematic review. Arch Dis Child 2010; 95:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/41\">",
"      Ipp M, Parkin PC, Lear N, et al. Order of vaccine injection and infant pain response. Arch Pediatr Adolesc Med 2009; 163:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/42\">",
"      Dilli D, K&uuml;&ccedil;&uuml;k IG, Dallar Y. Interventions to reduce pain during vaccination in infancy. J Pediatr 2009; 154:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/43\">",
"      Berberich FR, Landman Z. Reducing immunization discomfort in 4- to 6-year-old children: a randomized clinical trial. Pediatrics 2009; 124:e203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/44\">",
"      Harrington JW, Logan S, Harwell C, et al. Effective analgesia using physical interventions for infant immunizations. Pediatrics 2012; 129:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/45\">",
"      Stevens B, Yamada J, Ohlsson A. Sucrose for analgesia in newborn infants undergoing painful procedures. Cochrane Database Syst Rev 2010; :CD001069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/46\">",
"      Shah PS, Aliwalas L, Shah V. Breastfeeding or breastmilk to alleviate procedural pain in neonates: a systematic review. Breastfeed Med 2007; 2:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/47\">",
"      Taddio A, Ilersich AL, Ipp M, et al. Physical interventions and injection techniques for reducing injection pain during routine childhood immunizations: systematic review of randomized controlled trials and quasi-randomized controlled trials. Clin Ther 2009; 31 Suppl 2:S48.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Managing injection pain. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, American Academy of Pediatrics.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/49\">",
"      Ipp MM, Gold R, Greenberg S, et al. Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr Infect Dis J 1987; 6:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/50\">",
"      Uhari M, Hietala J, Viljanen MK. Effect of prophylactic acetaminophen administration on reaction to DTP vaccination. Acta Paediatr Scand 1988; 77:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/51\">",
"      Long SS, Deforest A, Smith DG, et al. Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy. Pediatrics 1990; 85:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/52\">",
"      Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009; 374:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/53\">",
"      Chen RT, Clark TA, Halperin SA. The yin and yang of paracetamol and paediatric immunisations. Lancet 2009; 374:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/54\">",
"      Brady MD, Swanson JT. More study needed on antiypretics' effect on vaccine responses. AAP News 2010; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/55\">",
"      Prophylactic acetaminophen blunts immunogenicity of childhood vaccines. Journal Watch Pediatrics &amp; Adolescent Medicine 2009; 8:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/56\">",
"      American Academy of Pediatrics. Prophylactic acetaminophen may blunt immune response to vaccines. AAP Grand Rounds 2010; 23:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/57\">",
"      American Academy of Pediatrics Committee on Infectious Diseases: Universal hepatitis B immunization. Pediatrics 1992; 89:795.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Hepatitis B. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.369.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/59\">",
"      Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/60\">",
"      Yusuf HR, Daniels D, Smith P, et al. Association between administration of hepatitis B vaccine at birth and completion of the hepatitis B and 4:3:1:3 vaccine series. JAMA 2000; 284:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/61\">",
"      Lauderdale DS, Oram RJ, Goldstein KP, Daum RS. Hepatitis B vaccination among children in inner-city public housing, 1991-1997. JAMA 1999; 282:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/62\">",
"      Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR Recomm Rep 1999; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/63\">",
"      Lee C, Gong Y, Brok J, et al. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2006; :CD004790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/64\">",
"      Notice to readers: Alternate two-dose hepatitis B vaccination schedule for adolescents aged 11 to 15 years. MMWR Morb Mortal Wkly Rep 2000; 49:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/65\">",
"      Centers for Disease Control and Prevention (CDC). Elimination of rubella and congenital rubella syndrome--United States, 1969-2004. MMWR Morb Mortal Wkly Rep 2005; 54:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/66\">",
"      Kimberlin DW, Bocchini JA. Monovalent vaccines no longer available for measles, mumps, rubella. AAP News 2009; 30:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/67\">",
"      Notice to Readers. Licensure of a combined live attenuated measles, mumps, rubella, and varicella vaccine. MMWR Morbid Mortal Wkly Rep 2005; 54:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/68\">",
"      Marin M, Broder KR, Temte JL, et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/69\">",
"      Committee on Infectious Diseases. Policy statement&mdash;Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Pediatrics 2011; 128:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/70\">",
"      Davis RL, Marcuse E, Black S, et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics 1997; 100:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/71\">",
"      Centers for Disease Control and Prevention (CDC). Notice to readers: updated recommendations of the Advisory Committee on Immunization Practices (ACIP) for the control and elimination of mumps. MMWR Morb Mortal Wkly Rep 2006; 55:629.",
"     </a>",
"    </li>",
"    <li>",
"     Measles. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, Illinois 2012. p.444.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/73\">",
"      Cassidy WM, Jones G, Williams K, et al. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds. J Adolesc Health 2005; 36:187.",
"     </a>",
"    </li>",
"    <li>",
"     BOOSTRIX (tetanus toxoid, reduced diptheria toxoid and acellular pertussis vaccine, adsorbed) prescribing information, 2011. file://us.gsk.com/products/assets/us_boostrix.pdf (Accessed on August 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/75\">",
"      Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/76\">",
"      Recommended timing of routine measles immunization for children who have recently received immune globulin preparations. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 1994; 93:682.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Active immunization of people who recently received immune globulin and other blood products. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.37.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/78\">",
"      Centers for Disease Control and Prevention (CDC). Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR Morb Mortal Wkly Rep 2001; 50:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/79\">",
"      LeBaron CW, Bi D, Sullivan BJ, et al. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine. Pediatrics 2006; 118:1422.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Rubella. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.629.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/81\">",
"      James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995; 332:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/82\">",
"      Beck SA, Williams LW, Shirrell MA, Burks AW. Egg hypersensitivity and measles-mumps-rubella vaccine administration. Pediatrics 1991; 88:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/83\">",
"      France EK, Glanz J, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008; 121:e687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/84\">",
"      O'Leary ST, Glanz JM, McClure DL, et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics 2012; 129:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/85\">",
"      Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr 2010; 156:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/86\">",
"      Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001; 345:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/87\">",
"      Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 2004; 292:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/88\">",
"      Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 2009; 27:4656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/89\">",
"      Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010; 126:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/90\">",
"      Klein NP, Lewis E, Baxter R, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics 2012; 129:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/91\">",
"      Ray P, Hayward J, Michelson D, et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatr Infect Dis J 2006; 25:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/92\">",
"      Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994; 271:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/93\">",
"      Centers for Disease Control and Prevention (CDC). Varicella-related deaths among adults--United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/94\">",
"      Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 2004; 114:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/95\">",
"      American Academy of Pediatrics Committee on Infectious Diseases. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule. Pediatrics 2007; 120:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/96\">",
"      Marin M, G&uuml;ris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/97\">",
"      Dennehy PH, Reisinger KS, Blatter MM, Veloudis BA. Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children. Pediatrics 1991; 88:604.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Immunocompromised children. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.74.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/99\">",
"      Ngai AL, Staehle BO, Kuter BJ, et al. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J 1996; 15:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/100\">",
"      Kuter BJ, Ngai A, Patterson CM, et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. Vaccine 1995; 13:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/101\">",
"      Murphy K, Ververeli K, Harvey BM, et al. Antibody response after varicella vaccination in children treated with budesonide inhalation suspension or non-steroidal conventional asthma therapy. Int J Clin Pract 2006; 60:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/102\">",
"      Verstraeten T, Jumaan AO, Mullooly JP, et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics 2003; 112:e98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/103\">",
"      V&aacute;zquez M, LaRussa PS, Gershon AA, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001; 344:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/104\">",
"      Zhou F, Harpaz R, Jumaan AO, et al. Impact of varicella vaccination on health care utilization. JAMA 2005; 294:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/105\">",
"      Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med 2002; 347:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/106\">",
"      Tugwell BD, Lee LE, Gillette H, et al. Chickenpox outbreak in a highly vaccinated school population. Pediatrics 2004; 113:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/107\">",
"      V&aacute;zquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA 2004; 291:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/108\">",
"      Gershon AA. Varicella vaccine--are two doses better than one? N Engl J Med 2002; 347:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/109\">",
"      Lee BR, Feaver SL, Miller CA, et al. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. J Infect Dis 2004; 190:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/110\">",
"      V&aacute;zquez M, Shapiro ED. Varicella vaccine and infection with varicella-zoster virus. N Engl J Med 2005; 352:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/111\">",
"      Haddad MB, Hill MB, Pavia AT, et al. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003. Pediatrics 2005; 115:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/112\">",
"      Centers for Disease Control and Prevention (CDC). Varicella outbreak among vaccinated children--Nebraska, 2004. MMWR Morb Mortal Wkly Rep 2006; 55:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/113\">",
"      Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007; 356:1121.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Varicella zoster infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.774.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/115\">",
"      American Academy of Pediatrics. Committee on Infectious Diseases. Varicella vaccine update. Pediatrics 2000; 105:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/116\">",
"      Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000; 284:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/117\">",
"      Salzman MB, Sharrar RG, Steinberg S, LaRussa P. Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother. J Pediatr 1997; 131:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/118\">",
"      Grossberg R, Harpaz R, Rubtcova E, et al. Secondary transmission of varicella vaccine virus in a chronic care facility for children. J Pediatr 2006; 148:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/119\">",
"      Tsolia M, Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Pediatr 1990; 116:184.",
"     </a>",
"    </li>",
"    <li>",
"     Lederberg J, Shope RE, Oaks SC Jr. Emerging infections: Microbial threats to Health in the United States, National Academy Press, Washington, DC 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/121\">",
"      American Academy of Pediatrics. Committee on Infectious Diseases. Recommended childhood immunization schedule-United States, January-December 2001. Committee on Infectious Diseases. Pediatrics 2001; 107:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/122\">",
"      Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/123\">",
"      Staes CJ, Schlenker TL, Risk I, et al. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics 2000; 106:E54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/124\">",
"      Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for use of hepatitis A vaccine in close contacts of newly arriving international adoptees. MMWR Morb Mortal Wkly Rep 2009; 58:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/125\">",
"      American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for administering hepatitis A vaccine to contacts of international adoptees. Pediatrics 2011; 128:803.",
"     </a>",
"    </li>",
"    <li>",
"     VAQTA&reg; (Hepatitis A vaccine, inactivated) product information, Merck and Co, Inc, Whitehouse Station, NJ, August, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/127\">",
"      Notice to readers: FDA approval of VAQTA&reg; (hepatitis A vaccine, inactivated) for children aged &ge;1 year. MMWR Morb Mortal Wkly Rep 2005; 54:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/128\">",
"      Notice to Readers. FDA Approval of Havrix&reg; (Hepatia A Vaccine, Inactivated) for persons aged 1-18 years. MMWR Morb Mortal Wkly Rep 2005; 54:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/129\">",
"      Centers for Disease Control and Prevention (CDC). Notice to readers: Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2007; 56:1265.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Hepatitis A. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.361.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/131\">",
"      Nolan T, Bernstein H, Blatter MM, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age. Pediatrics 2006; 118:e602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/132\">",
"      Guerra FA, Gress J, Werzberger A, et al. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatr Infect Dis J 2006; 25:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/133\">",
"      Dagan R, Amir J, Livni G, et al. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Pediatr Infect Dis J 2007; 26:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/134\">",
"      Trofa AF, Klein NP, Paul IM, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age. Pediatr Infect Dis J 2011; 30:e164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/135\">",
"      Rinderknecht S, Michaels MG, Blatter M, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age. Pediatr Infect Dis J 2011; 30:e179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/136\">",
"      Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/137\">",
"      Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/138\">",
"      Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/139\">",
"      Seder RA, Gurunathan S. DNA vaccines--designer vaccines for the 21st century. N Engl J Med 1999; 341:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/56/39818/abstract/140\">",
"      Streatfield SJ, Jilka JM, Hood EE, et al. Plant-based vaccines: unique advantages. Vaccine 2001; 19:2742.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2876 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-1C6C0C3C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39818=[""].join("\n");
var outline_f38_56_39818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2115055251\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vaccination coverage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Impact of thimerosal controversy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Administration of injectable vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88268678\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Pain control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Prophylactic acetaminophen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adverse event reporting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HEPATITIS B VACCINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dosing schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - HBsAg-negative mother",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - HBsAg-positive mother",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Mother's HBsAg status unknown",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Premature infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Older children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIPHTHERIA, TETANUS, AND/OR PERTUSSIS VACCINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      HIB CONJUGATE VACCINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      POLIOVIRUS VACCINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MMR VACCINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MMR preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Dosing schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H196182557\">",
"      - Routine schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H196182513\">",
"      - International travel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Immune globulin recipients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      MMR adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Lack of association with autism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      VARICELLA VACCINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Dosing schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Children with ALL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Immune globulin recipients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Evidence of immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - In children with asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - MMRV vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Transmission of VZV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Risk of herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      PNEUMOCOCCAL VACCINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      MENINGOCOCCAL VACCINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      HEPATITIS A VACCINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Dosing schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      INFLUENZA VACCINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      ROTAVIRUS VACCINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      HUMAN PAPILLOMAVIRUS VACCINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      NEW TECHNOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2115055251\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2876\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2876|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/26/10658\" title=\"figure 1\">",
"      Rates of IPD after PCV7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/55/25463\" title=\"figure 2A\">",
"      Childhood immunization schedule 0 to 6 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/56/27523\" title=\"figure 2B\">",
"      Childhood immunization schedule 7 to 18 yrs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2876|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/54/22383\" title=\"table 1A\">",
"      Catch-up immunization schedule age 4 months through 6 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/52/20302\" title=\"table 1B\">",
"      Catch-up immunization schedule for children 7 to 18 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/20/27980\" title=\"table 2\">",
"      Needle length IM shots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/60/1998\" title=\"table 3\">",
"      Recom doses of hepB vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24189\" title=\"table 4\">",
"      HBV immunoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/48/1805\" title=\"table 5\">",
"      MMR and VZV in immune globulin or blood product recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/46/22252\" title=\"table 6\">",
"      MMRV febrile seizure risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21066?source=related_link\">",
"      Autism and chronic disease: Little evidence for thimerosal as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26857?source=related_link\">",
"      Autism and chronic disease: Little evidence for vaccines as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23833?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34233?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5722?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/61/8154?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis and management of mumps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3226?source=related_link\">",
"      Febrile seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37881?source=related_link\">",
"      Hepatitis viruses and the newborn: Clinical manifestations and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/36/42567?source=related_link\">",
"      Mumps virus vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16295?source=related_link\">",
"      Overview of hepatitis A virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31386?source=related_link\">",
"      Overview of hepatitis B virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/35/39473?source=related_link\">",
"      Patient information: Febrile seizures (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18547?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17223?source=related_link\">",
"      Poliovirus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22793?source=related_link\">",
"      Prevention and treatment of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42489?source=related_link\">",
"      Prevention of Haemophilus influenzae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40937?source=related_link\">",
"      Rotavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26855?source=related_link\">",
"      Rubella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6087?source=related_link\">",
"      Rubella in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40057?source=related_link\">",
"      Vaccinia virus as the smallpox vaccine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_56_39819="Etiology of osteonecrosis";
var content_f38_56_39819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologic factors associated with osteonecrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Traumatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Femoral neck fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dislocation or fracture-dislocation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minor trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nontraumatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corticosteroid administration, rarely hypersecretion of cortisol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell hemoglobinopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caisson (dysbarism) disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gaucher's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic renal failure or hemodialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperlipidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organ transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravascular coagulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombophlebitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cigarette smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperuricemia/gout",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human immunodeficiency virus infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39819=[""].join("\n");
var outline_f38_56_39819=null;
var title_f38_56_39820="CRS case definition";
var content_f38_56_39820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Case definition and classification criteria for congenital rubella syndrome (CRS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Clinical case definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        An illness, usually manifesting in infancy, resulting from rubella infection in utero and characterized by signs or symptoms from the following categories:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Category A: Cataracts/congenital glaucoma, congenital heart disease (most commonly patent ductus arteriosus or peripheral pulmonary artery stenosis), hearing impairment, pigmentary retinopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Category B: Purpura, hepatosplenomegaly, jaundice, microcephaly, developmental delay, meningoencephalitis, radiolucent bone disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Laboratory criteria (any one of the following)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Isolation of rubella",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Demonstration of rubella-specific immunoglobulin M (IgM)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Infant rubella antibody level (immunoglobulin G, IgG) that persists at a higher level and for a longer time than expected from passive transfer of maternal antibody (ie, rubella titer that does not drop at the expected rate of a twofold dilution per month)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Polymerase chain reaction (PCR) positive for rubella virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Classification",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suspected",
"       </td>",
"       <td>",
"        A case with some compatible clinical findings but not meeting the criteria for a probable case",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Probable",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         A case that is not laboratory confirmed and that has either:",
"        </p>",
"        <p>",
"         - Any two complications from category A above,",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         - One complication from category A and one from category B above",
"        </p>",
"        <p>",
"         <strong>",
"          AND",
"         </strong>",
"        </p>",
"        <p>",
"         Lacks evidence of any other etiology",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confirmed",
"       </td>",
"       <td>",
"        A clinically consistent case that is laboratory confirmed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection only",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        A case that demonstrates laboratory evidence of infection, but without any clinical symptoms or signs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Infants with symptoms consistent with CRS who test negative soon after birth should be retested at age one month. Approximately 20 percent of infected infants tested for rubella IgM may not have detectable titers before age one month.",
"     <br>",
"      &bull; In probable cases, either or both of the eye-related findings (cataracts and congenital glaucoma) count as a single complication.",
"      <br>",
"       &Delta; If any compatible signs or symptoms (eg, hearing impairment) are identified later, the case is reclassified as confirmed.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. Rubella, congenital syndrome 2007 case definition. Available at: www.cdc.gov/ncphi/disss/nndss/casedef/rubellasccurrent.htm. Accessed on March 3, 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39820=[""].join("\n");
var outline_f38_56_39820=null;
var title_f38_56_39821="Neuropathy and glycemic control I";
var content_f38_56_39821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F70914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F70914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Glycemic control prevents diabetic neuropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 274px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Incidence of the development of clinically evident diabetic neuropathy at five years in patients with type 1 diabetes treated with conventional or intensive insulin therapy. Glycemic control was beneficial in both the primary prevention (no retinopathy) and secondary intervention (background retinopathy) cohorts. Patients with confirmed clinical neuropathy at baseline were excluded from the study. This comprised 3.5 percent of patients in the primary prevention cohort and 9.4 percent in the secondary intervention cohort.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The Diabetes Control and Complications Research Group, N Engl J Med 1993; 329:977.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39821=[""].join("\n");
var outline_f38_56_39821=null;
var title_f38_56_39822="Reclassification of presumed NLPHL";
var content_f38_56_39822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Reclassification of presumed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 310px; background-image: url(data:image/gif;base64,R0lGODlh9gE2AfcAAP///4+Pj/8AAGYzZgAzmf+ZMyBzOQAAAMDAwICAgEBAQPDw8NDQ0ODg4KCgoBAQED0wPSAgIHBwcFBQUGBgYJCQkDAwMLCwsEdHR38AAL8AAGtra4aGhu+PLwAZTO8AAB5rNRA5HH19fc98KRhWKl8vXwAmcgAvj59fH2MjI3R0dGNjY1lZWWlpaZ8AAAAfX1IpUhRHIxxkMd8AADMZMyMjIxkMGT8mDH9MGQAMJgAshYBAQBpdLm8AAD8fP88AAI8AAD4+Pq8AAEtLSwAWQj8MJnBgYAAjaUwmTDQ0NCoqKkVFRQgjIUhISAIaPDYcKQApfD8AAN+FLG9CFgwuHr9yJkYjRmY8GTUyFA4yGAgcDlksWRs0GEImHGJiYgQbLV85E01NTY9WHGFAFq9pIxZPJ3AQEGAQEDkcOV8DCVpaWg8TOVlNWRJAIDk5OTo6OgwrFSwWLFFRUXAgIF8wMDw8PDU1NUEtEB8PL08GEzMcGRktFTUjNUNDQyUoETYfD0JCQkBGU18AAFAQECYTJlBAQAAcVlYzFm9AQFE3E1AwMDwjFhcmEQgfFzMrEHBJIy8ZIwITKWERESMTFmBQUF9AQCkWHAonGxs7JVMjIz8wP01GTQATOUYpExUfDXBQUEM5Q1xWXFFXU2BjaVZTVgQUGkBJXGZjZj8GEwADCXBpY0AQEDM+NloaGjAgMBAgQD8wMFBJQwYDBh8MJiU1KjksOV9MOTExMVBWY08gIF8gIAIXM0U1NS8MJgQXI2JnYykcKU9MTzZFOwIHA1RUVEFHQxAjSQQOBwwGDCAwTz8JHDw2PEAsGYBwcFNJU2gICHh4eAAGE2BAIAgICB8TBjEjDR8AAE88KQYVCgYbHU8vDyAZE0k8SS8AADMjIw8JAwIKDTIpMjAqMBEREVA1HAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD2ATYBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdudCOImmJsgFJu7eIOt2LtXjQS6DuIueEu4sGGHCxA4qMtGEw0aVpAgKTGgsuXLEAJo3sx5g2cMGOqsYJGgAoIGh1OrPougAgU2hGgggXG5tu3amTnr3r1ZxQYMdlZQMD14tfHjUhlUOMUN8pbb0KNXzs27enUVXjD0aVGBAfLv4IUi/0jgjJCP59LTR6duvf11FnbkJEAQvr79mA0chOLjg7L6/+u5J6B7IrCwBAsVoHbfggyCxIAEoKBBG4AUBjjghe2pgMEbEnjX4IcgRvSgJv1VaKKFGKZYXYFhUEBfiDDGKFADCZDo34k42saeijzqxgELfXQo45D2LeDAJmigl+OSuPXo5IoT3FJBcURWeVgDFPCBBJNc6vjkl7ypYAcLL1pp5loXIHljl2wOsCOYcP4oJZVn1gmWkbVY0eaelr0J558b1EGBgnYWmtUCCWjJ56Ju/unobiLY0UKZhlYKFaJ8KMnonn4++icHGDRBqaWkHoWpppty6umqnIEqaqmwEv+VKKqpqsrqrQG4OmqsvN7kQC1b1ppqp7h+ikELhPaqbEwIbKKnsLUSW+yfkUpA57LYorTAKTRAC6200/6pQhIVZGuuSRW4sqa3m4Ib7p9eALLrufRixMAywbIrrLvvxokBBdfWK3BEiNKwrr7t9tuvCEk4MPDDECEQzoQIf6uwwhM0kSzEHBckQbcVs8vvxdSS2/HJAjEACsUhW0wyxk0EjPK5FcRxcMvDvnwxwxfMXO8CpDyLs8g6k4yBtT5niwAwNw+dc9EXqwCIh0nzWrPTFY8MtaMc1OFw1aUCLTTWRG9N8gQUgG2pyiyT7a3WZju6gRsyqz3kBeq6nXXcL4v/oATVdhNZAch6Iww335/a8XXgMqoChg+F7434yxgkoFRicWWueeYbM65tLCMUMEW+kbs8OckspI0UAtPU4PrrsNcwjuWeq7SALaEXUMAhbZee8Okvq0D3UQjU4F7lDi32NY30jUfpeHR56PyMCThM4+IGLWDBA97RSFcChF4APrNlUnAA9lQxcE0HuuveQRdN+97m4cCLO3xRxR9PO0MKHHBAzwg4gOUSIECCENB//htgAQEQQAUw8AAORAgBy/VABB6geRJ4wAVj4r+BLCACD6ibUxhADva1z32TkF+06qczDgwBcEHJX3uQ15D+HSCEAVTg/gBAQMtd4IY8XGAD/x8YwYM8IAIDGSJBHKAADc5rLgiYwAQ8dIEJKABgApnLAhIEAAdYkQLeYQAFFDDFLM5Hit5xQAK/pkYKToUBjzihHEfwBBX+joUk48DfiCJD69CQfweYQCBzGMQd9hAAC+ggARUwF/M5UIkGIaRAAvgAMlKqf/PyXwQscAAkqnECEjiABQTiPyear5IPSAADHmCBBDzgAajRZAQ6CYBQQlACAxElVRAQRznKEQVosOOi6IfHOO1RPMab4Q4V0r8FaDCUOjQgBBPQv7Qd0IKPhKAENzjJCCiAkwegGiYP0kEAzJIBs7wAAjjpHf8NpgE3HExizDcf85Wrg4k8ACn1Sf+Q/k3FAWDwpUBxMDZhcomYxQSTHmHYkz5W548L8ecPE1hIaZYSi4ckokYPQsB50XMg4zRIOTFpQf/Rp5yQBIANEWi5crqUnyCF6VMAKtCaXqF3BsURQhP6pYXGMJl+XGZC/AkAQRYwo1lc4EAyOsSUEqQC/0uiggTpxpAWBJ8abMAsFbSAwZQTniGckfkWF0t+vrQgnIzKBQJaU4F2YBHxyymAdsrTJ/n0Jw7lDUSZyU9nHrWk41FqUmnX1JLukAEHwGVSvxnPIFpQpBCcpQPVGIEESCACJ4XpKRVQ2VU+4C+tBMBZzZlY2iVyAlCBY1vb2gE9yJVJdK2rk+7aUKD/PlSoCFlMEufDwO+Bb3oEAe71AOA9uowKhMV5kAIUgLTefg+yEmBkcRAwRunycIdevGL3ostc78zFjCmzIu0IiD6lqHa1baXja3MUW9n2SI+dw0led7NXm6hRsRQp50oacMSnMEAa6EUvGQi3Xgq11708cqEIaRLAkjpYsDiJLkMfstyWSNgpC2CGCQPcVjFArsAGRnAL71e7s9xuwxxu601BPFcR60wFTSgxWmIhhRRz+A9xZfF0XPxi1cl4LKrInY3R29ocs/jAPFYRaX4slgqgYMgpVq+OUZTki2GgvEzOygVwAGUbVyEOU4YOkqucoiVMOMtVYcA2UNxl9KLg/8NhxgyZX6bHBaP5KQsQhgz8IOQ2oxcMONXxmOd8IQ644c5YEQUPDGAALjzZzwHuBK0ETeiXbQC/iJZKBcrAaEbHYAqQJjL84rzjSp+tZ5mOCgOy0OlOk+AObA71CUcACVI3ytQkq8OZU20qWrS61TLAQp9lfcIvk3rQuBYQBwDBa6eIQga/bjUIuEAGYgv0zXFGdrLdowJMN/som452tNvAZWvLcXRh1va2Z4jqbxulAZgQt7jLkIhYE5t3U1b3uq2TBDubhAHLDbjABY7lb7MCBPIWNw+wUGNzu2/UR973zljArG5o4OIYz7gGBIHbjDAAAbt+CAMS0O6Ph5wm4v87OU4SQIKEyxsEe6iCw3UnBUtQWuIYa3dLEBAFAfj850AXQAY6bhCrqtSCE0juLEv5cW3u8+kIcWZYAaBB/ylgMCulqEsujMhX+rsmq3a5y7MghpkXYASEiDjOFdbvl/A86HAfukOMXs0EcDJt/BWgYjALydFy9HwgdcAFOFmuxcxFg24sCAMA1wCQK6TxVMOcQRof0zKpkeg4ObjYXR6DMZgd2wXW99ohRXGXvB3uQJd7DbkpkHEOMZT47WrfzSrTgkQAiQZB6gOnnksI+k+x5vOf6hL4AAQsYKWoVaP/LIB13+vymjC9PVAq0PLNu5wHjrA3pHFAupyKfvS6mYD/zlVyetT7XPWAvOQBKJCAdB59VA0uKdQnv/6DnJMgsyyv/wTvTqhaTpA983vgI0gToBhTpE1QhUv9IwEX4EQNQHjlE04+AW/Wt3kgwAjDJmsr9lrfB36c0XYsUX7mh34RxXpHx1KtZ4IPVFlz4XcFIUkEYT6YBlWjBFkpiAD9YwGcVUD65U5L1UmM5UDjNIQm2FE+IQoIV4GbBwePZm1vZWR604EeqBki4G0oIYKoR4J8pX6BxXy1lFgelBhOJ1q0hxAwiEiC5GNdp4JQx0k4uH7GRYa9RyWLBBjvd4dGZ4Q8gQBtoIQVGANs5YQpJFdSOIUBgAEqBxJYGHeY109w//hd43R3xKVB8+EAfDeGL2WHHhRIA/GAojQXX2M+qEVOFwRVDwAAUJV0AHABDqNfBIgAKddJqDFyeLhB/XMBhCJI8WUTvuaHFcgDsGZuUmZQhTiFHCAHIdhz5nd+jRhTjzVOeecwCLB0ndR0RfRSCFREArE901VS2XQAu2hBD/A1tuQ/9wRTx4dAyVd1nEiE9DFRfcVKPcFyvqiEIMBn5gZM3meI/eIFBTcSixh0WrgRJncRl2cR7mR8BIE5IgR5wXUaC+GQQfSPM7EA8VaPfuho5kZQxMiP/QKCV2gNGTCSJFmSGRAFzfgS7FQR+qUSiFWDO/EL0IaRftgGoGZtG/+oQsVoiCqQkh1RXL7lW/NCE4mRiGY4lCXxcV/3Eg0QAjRZjyRQb9aGY3a0k4a4BLvobi5RDEn4lH4YbBnYZUWmkx65MC2glQwGDpzmlb44bdUma8NYOlZpiBiQlWiZEoFAAC/ABNXHlkoYAuUWagMmP3NpjGd5l273AgSwmC/QCIvmlxVYBmOgfTbmYb5TmFOIiIjpEnm5mIt5Ah5ABTMJmWK3cA0HaTkZhWWpMBwQY5u5EgigmJ7pmaApmqQpdjAnc6FGlYWDmZlplK/JEZ05m7OpA04QAl15m+JGdqH2PlBYNqv5LhxwmMFpErFJnNhJAMaJnMopb50XarTWm9H/qTB1WZ0mMZzZSZwm8AUx0J0Kl32QZmxu45uGaZ4kwQAekJ76uZ7t6Z7ShoGQBnpYQ59TaAdLaZ8UMQonoJ8Mupd96Z8GwISQBmhkQ6AeKAI+iaAS0QBEwKAeqpd8CaGeFohdJmkDOp4XUwca+hEJoAMf+qEecAmj6Z7ASJmr5ZxOY6EeuAEUmRGYszlAapd28wov+qK1OaPKeY9hGWBSUGtDo6MeyGwigQCpkANWeqVYmgPRkKEz4wAmUKRFegKcwJ3+qZFdhnZPiqIXwwLAOREIkAMe6gEZ2gDcJQH08V0CsRiooacJoUaqY3ig+BJFKRDawz1MgZ5g+qHbmZy3/2mTbSagkqOm0kmdH/GmceqTqyRK/eNA+uWOUXdExZF12gibY4hYo/puhpCoqqoDkdCH7hmVNlpT6BYyUOqBS3CgEmGpDCqnDpF/1COHN3iHBwFVi2N0BHE9TIRFqLhctHM9NIJIFbBcSFNFV1QcUIRGAGA+lfUi5tOmOiEBC6qqqsqf7gmWXYZvkSqp4aICPWoRuqqfvMoQiIV7BJFAczFL9GGsMeWIOpgA19JgFjBLaSODgoRLlOROnORNF/RJoVSDskRLnFRJXxNAVkgURCquGGsCpfCgkOmWUIajhqOuCiOllQqnu5qSTkWGgCWsIqWNAadBo5hE2gRW8HSJp/8YQDWoRhHEAFr1P+skgfjUQU41hkZxAUeAsUgLohzrl4AJZTWXriJbLBMgpBXxrukZrwsxrzYYrPpKSqdKXC25USblYBulew6WWU83tF8rFKOQtG5rCI2ApGwpmbE6R3WkL7V6oYnHEVabnVi7EL5KXC0FU55qRDDZRSkDRMGlTQEUATXbiRuls4T6QeA4ucAqtESbSGsLFAvACW7rtkd6m6Y5ZPoInVE7LW+giCYLrz6JABqkg9rUqbYofwQhSFQChJT4gjfURAXkSAlAATfrdNqDu4rRSZaFWZerT2BVPQLxQ3s7FA4ABZ/7uaAJB4z6lLk5ZBz5Nqf7LmXkEX3/i51/G5F16l37w6eAiqcDcZACUQFWJH6R1EljtDjZNQHlMlyEGq3MNRjUxayDgad4egHLhWr9Q7U8gQvTm8CLSppZ0IQclppP073FwgEVixHhS5zjaxIgZMApexI/pIZEsQAdmsAKvAtOCZnfmWJPaDoSjCupC74P5mBcSpDM1RAAV8EksQBShKs4YbQk/MPk6pfYV7coxMItzCpTu6IT0bY/3MQm4Av96ZUg4AlL6ktxySh5O4Ui8LxKzBDG0MRgrLR+KaEcVrp3dMS3MgRdDBEMIJth3MQOypaflmKWecZovCpBwMMrmgDh+sZNHLpPWaMPHGgHdce4wqNr7BCm/+DHfgzIGKmkN/acFZLFhkipiRx1I8zIb7zAj2ymN6oHktxihnwrYXDJC+HDmszInFyP5BZgV9wllDyF32vKHNXHqezHUBAJUeyLsCpgBAbLo3wrKsDFtAwAi3zLtxzEvmiuqwWphRzMrFJ6xVwQmYzMqXwE2bC0FrgHb6lihGwisTyFpTzNwXW01mzNceyLIVB2q2WiwAzNq5LE5Ny+LnrO5xyjcit2dMtaEAdb8LwqiDzPAIDA9mzPjmx9o1tT4fnM//woOJzIyVDQEn0CRJAF15twF6ibAiWfSxLOU7gCGwGUQRmHdrMA+SnREr3Km9fAbeXM4NzQnhIEG4EAx/8QAjZ90zgdAlowwxyRckkEkTVRAf46FAjwpSiN0qzqqtaXwgJFoewF04/CphqBAFogdiHgk/0TAfz7V4TFuESruxEEVQgEwitRYZP01T5RAfV81CitzKUJnwKFrifi0Tvarg5B1VaN1f6DWoTEVF69uQWcRXbagGyYMozneAkhkYgUF5NXJi1pPkiZExTgAUew1mxd0E+8lrhJxW7Vz5MM1Y/C02ZY1S531XN3Qz7L1WedTWsLT2RNuRtjdb8nEMFXf2ToSsaHfF2EQF64qct3gk7n2kKxAwKgAUDQA0WwBoZgArZ82amczmJHxnL0tHMN2o6iBlNN2gln2qv3Qw//8EMK5I0bZRBqhD6l9Lz7N1FbVEAASIZ/0QCv6EWmiopguICEDXImRTUgJBQ9AHczoAEZkAa94AEvYNTOzciN+Zicd5NzlHYvbd1wMs4WrN3yxt2AVFSd9FeM9Lt/vU2jcniGWq/8hEk5uIODO4c/6E2cJISzi7aOGBQNAATL+HM/IAQZgAp4QNnSe+B/HJr53GqC/EtwJsoQ/iUYkN15fdprqNoa1cFB9EQQVk5uWHdQBKxkSIfTFKieGrZEhVcaMOPmZ9zIvQYewNw8Pr3Ve9GdBsnn1n3pQdceKNUTnuSr17wU5dfZxIK8NRDOOxCgBIuB23utAUSpOBisaOWv/xiLjgsAtLjlB7AAhNJf0zcDYF7p/x3gvUAEBX7mSKvSvzZtDqw7cq0ecA5+GxDZD4HXpa3Xfs7khWVBO6S5rY5AViiO5GhB5+hBuu0A7IhanmpLEUSxQZEAlV7sQVfjN57jR7DjnP6int5qrXxCIEvqRa5Qoh1JFC5uFp4SkN2JgkGKiUEnDJnYiD1JQJ0QH6cggQ0UiGDs7o56Yp7cZd7cza6e7Jlwvdw+HTCI1F7tX/LQqY4NJDDwBF/wJAAH144R/KXVDRG2KJGAw/3uEm9+l54GRaDpBl7vnunWwCZss3a3b+7vX4Ld9jJwJr9cdg0SjcfBqD6lLX8T/T3xMv+/jMieB8rO7M0O3dLGzSdkxlQm8ioC0sWcATNf9JWuAS4w5vPO6Trfaet8Qtv780CPITJNywzgAkaf9cX+AQBu8Rjv3KApo9G2z7oDwU0y9Txy5LSMAF+u9W5v7DV/8yh90AaQ0CssZmif9nqMlmz/9n4v8Uiv9GZuzWJKpoyW0e7jWnif9yly6rRcAZT+95Iv8Vwf4Be/6ams0ix9diB/9ox/IY5vysQ++aQ/83Gv47isy62WwoPpJZ8P+i8fnKNf+rRf9IEv74NPwsrMA9XAPnUsZ68/IByQ8N82+7V//EVf+V6P+Z+rsdU3xaEDwaXugcTfbEaA/Nj/9qe/7En/m84ayZulFvwCUv28RtzZf/5+f/tknvtFCrfQ9mljGf7i3x7kn2rmj/747/fKf/kZDxAEBA4ceMIDFRk87lR5MsAhhAARJU6kWNHiRYwZNW7k2NHjx4oJAIwkWdLkSZQpVa5k2dLlS5gxZc6kWdPkDgE5de7k2dPnT6BBhQ4lWlToDyEZ8szycAQKQagniGTh4UdMnIcgtW7l2tXr14gsbI4lW9bsWbRpaeI02tbtW7hx22pw0UPZGg8mdEDV4STLHm0+BkAEW9jwYcQaV6hl3NjxY8hn2cqlXNny5aAfNGRIU4SIIRMCdewadgAG4cSpVa/WupgsggOxZc+WLTLy/23cudVOxtzb9++4SJUyJZJKljjWyZUvn+h6LIIbBaRPp14Ah+2WDBBsR8BYgQKbDhQ4GImgQoIKDXS/ZKBAQm7ewOXPpw+Ubg9vzPXvR+zcJvTqArzuJQVme4CB5w4Ab6TvamrgAAvKMxDB9U5K4ADsJDiAvNviq+9DEOfLhD8SS9zKv5oADJC6AV0qsAIEKDhggpEWcAC9BcpLAD31arwxvQogREC97QDYLscFEEDQRhxPkrE7ABioIMcJMDSpgSERSABKAC7YsUcsG1iAQi8ToJCBHaFMkoEGEiBvARkpQADJByLAzcMQ89STMgxM9PPPjFCkScUVpWuxpQK7u/9gRgAWsOCBAi3IEcICD+iOgQdkqzQ2kWIDoEryHDhgykcjzbGkByIsSTsLLDXpwkxj605GBR44EIALS3V0NgBEtSCCDY08IFYMYZMNSg0phAzPPZt1dqg+AZV2WkFnIrTQQ1mKtMBbNSTPWwDUY6BKkVoVqU3YFgTAU1FprLIBcMEliYED3iupUgosPCDfCylYNN9/cZ1RSQ0nWGABCRY4wE6F7YRN0iDBuxC7Lq2MjNlnM9Y4p2in9djEFsq6dsVsV4o00woYpC0BOGfr9ICS0iXJUwAyfZDGTTmN2eJ5Y6z3VSvTvXA2iS1OlCRjeZVZ5ol3ptgxjDeWes+OP7b/Wr+nB42uUEOzTinRRR9Qj1zuGghygjattBlpBWeGGQANC7zg02K361FC7O5eVN2Rmm73bO4QbJpuDqNcmLvulm57cLw7nPrxjGeY4GrKmfNappEFvPyko2WMcFELLkBAAvQGLlAkDSNIQIIJ6I2gSJrpHXYk0EUn3aS2+46AdGCfvlCBBDJ1oAFbHTCPxsHD5h0AcxFwIELFwTv7gh4vnDuyTyDXfk8NNqj8e9Y2hynz6kpWSQIFlpxgvC5bhfCCBQp0j31cgX0A9dhSbnAkChRImXb3hc4k7wJgbFSnrwjYyjbjMqBIxFO4C7iPRnDK1ANo1J73YLBRlaJQAnGT/4DthRBE3QNfCRMjvpeQj0UorNCgGOUSxrUwSCw0CwhFeEP5kNCEO/wKB2jIEgR84wZDJGIRb0CNH7YwJjIq3EpiuB5MSeqDOKSib3TIQyxqZQNcskmSEPfFsilRjGMUYwVmUEU0VgYIIshiGz+yRTLGUY5zNAsCNJBGPMIlA27kI0fgSEdABlKQKbFjHg1plD32UZEXwcCpBvlISMqxAUA4ZCWFkshFZlIiGIhkJz2pxAxYUpQ+waQmM7mET6ZSlZDpwShdqZNWmNKU1VplLW05k6i9Mo0pkKUm1XBLYAYzJojQpSt52ctFJlGYy1ylDYtpyWMik48+ZGY1rQkAM/8+05IjkiYf/3hNcN6ykNo8ZNW6iUUWKCuc60zlJMlZznO6kZPspGcqW/nOPJozniYkRj392clc4lN7+twn+OTwT4QO0ggCTaPkCopFZdZSO45M6BwT8AGGVvGKDwXfBq4nyO98p4kxORpjbnS3iqbwjhnF4UY5WrnWPbJWEBopTEqqlpum1CULCCVLb+jSl14tCJEsKfoSACx7VeoBFMhRexaWqUu5z15OjcD6ELS/BjHAfQd0QKYsAJ4FVElBFNVpSebg0596L6jf+yUkSyo/DR0AQf5CQKtS1irgAWtIdfLZXRV0VFfRzFMMkAACLpAp7QCLAuU6wAXOVlaUZA//rSFc41q/F9H1vNVVR2vTBHrnOpWZ56+0Ai0AjibYt2lppt05mut2RDPIliSbk9VeKS37MY+iJWm0WZlNXWXazVoKNks9ncyAq6WFhbSwuTvt2zx1od3p9bjCglRIY2sSBAiBtrW9LeXQplsbOES843UIDX5Y11Gp52iJatrEHiS2XRk2d116r5ha1Z3YsMlT6w1udxT2gFN99Lojued2p2bb7korDGlBQHjJS17zvsRl003UcGcqEhnFBqoAkFEEagWeDA8ruCKGGXQf5Sro2klUkALWgEtCTAMfOMFWCxl4Hwzh84ZxolGak5G2FKaRnHTHUdrR8IJspqMtoAJT/ypSrxLQgCH/aCRmQ486B3zRGEstljOelgpq+hwH37i8mL1NTl18luxmeWPR5PKfvmtjMY95kCc9M2MEoWaNsbnNJlowg8Ms5gjXuaKSxbOz9LxnEtUYznEOtKAROttC74mbiC5Rbv0cZzlXyMxocdStRoImLnbpyXNsMoeDlRZ3RppqlDZREMgqsj/fuNG6oXNjLvS/NvUOaRLYsBxhu4AEvposZ1W1ngjKauUcVC0NxvQAZr0SeH0nYW1ygHiYOpIKfCdv6POfk9WTpgm0DgHhJtP6rk1ta7+6TvNSgK6DvNqToFsB1+6SuXNE7TYF2dwIYkD/YoqrLZG7V5zikP+o/ocWCWC02CE6NrJXI4KD61YWNqB4xS1uA2TQcAG2koAEXmesX+3L1Kz7GaYg1KrpGtB+EWiVimekIejF5sT5chrQnrZpkCt24BOAOXU9JSNI3S+KwRPbuhYGLDvF1T0zUxVaGOCChTPc4ft5c1q8CMYvolQlsImAA5Yks/oebrimts3cmtsoTykMZsASXau007a9AS3UT8R5294LALaj9+2qei+SfLYlGaUs7ag1SYEYc4aof8ihU2fOED65qQhgKXey4u10SXJ2o4/EU7zdTtuMS5ILzZ1noT2JcTdPm84v6PPAnTDhM3+vt6WFAgpPfA7VyvjkQNyTB2PA84r/5fmFPchOUyY78TFPeGD16GDRM0mQBCywm/92Z+DhOt4PoPwk5a7vU2YiSdTjetiOBOVquQDUa2973Cun6pBEwO4ScF8LZwrDo31AlLxq+OM7F2aiUp3HUy8svjEcexGW2eiOoZEN7BqWCxu4/vu4+QK6djMTjnu/l9G8t0Eq21AYGmEMYju/3wCq9EMMx9u9BPgOORGWCOifwnGA9ZkAXOO2lKGzHekb25hBI+kf4FkAagsXNzmJYJuyHQlCIglCG2SbFKSfG9Q2HexBkmDBeUOQaHMPwanBBVqfGjw1tUg4D/zA2wvBxNA9cZovQBKVAbQWMawQ4hk+xni6LfSN/8rywtTAAK1TJQ0aJPSxMpioQyW6w8fIhTbsDQSDw8LwAkcrxNyAtD+kjEAURK/YgC8zREjktAJLRLlYREbkClSKRE1sDEqgxMqwxEsECQ4ow00sRZExP0+EC0kIxcJYP1N8RZvQhVSMi0NjRa1QNljMxZqogB+YxbeoRVv0CC94RF0sxpVYADPwRbcAxmDkiD4wRmhcItpTxqFgxmbMCBEgs2iExQboKWociiC4Rq1YAmHbRnMsCSOYxm/8iYYTR4sQAZo7R3ksPUpax6BoR3ekCDmcR340iUqwx3vMR47gAEXrx35EAFQEyJ34AHwUyADYR4OMyH9USJ4AQYeUCP+CjEiNREiK3AmLvMiHnEONlMdKUEeA/EiHzMiRjEgE8EaKREmBDAKRXMlzTMeOFAAXUAGQrAgRIEWanMduvElQFEhy/EmNlIAzosihdMcN0Eaj3MQFQDyl3EmKeMan1MgKWCmAXMprZIHnu0p+VASKXEWqDAAOaAKwHMmWVEhrFEeZTMuRNIKkXMe2bEYVcEq4hEqppMuyfINyzMtzdADt4sudnIBQA8x+LASTTMVwBEkRKEjENMgG2EtlbEhWTIK/jMxzrIDBrEyQnICv1MzEXMxEtExGFAFoEE2ajEplZMiL9EvVpMkLqMdUhMlLxIDDjE2DNIJerM0uvMam1M3/n1wAOiDN87NNODxL4TRKBkhGT0ROL8TM5TRKB0jINsxJd8TN6XxK3qRErgzB4NzOp1QE41y478Q9ERAL8XzKBRiERDzPqeOAIcjM9exHBrizNoRPh6sDPKzPlazONiRLWwyC3PTPlZSAzqy9umQ8FiBGA43L3lRQW9wAn3xQo4SFuYy6BUU2FYBMC2XP4pTQS1QBN/hQwFyAXCjPGGtMQZRP+jTRkWSAVVDR7TLNPXNRGEVMBqDMSLNRLsPRHNVR51Q1H00wDlCC/gxSsGxOVXPNEDzSJFXSJR1SNYNOI0VSKVXNHaVRhrLS25LPKM3StJRRLsUnL10rIBVTLQ3R/xg705dSgflUU+EkzgydLOx0OBJ9UTlNywWAhQidLP3kqA3w0D2NTSNIUJ8K1IJigQot1NhMAOvMKEWNpyBwUEcVTQfAz0SlNA6ogwK9VN1kgEEo01ESUC4TgSEIU1CNzQVQhD/Fpw3dpw1gAT1dVdWkgEjVplg9JwzAS1uFSwcwA1I1pF1FJg5Igk/9VfFkADp41WIqVlnagCaoVWWdUwmgzWfihe7q1WqV0gsYVW0q0kwSgTdI1m410AWgBEQdJXFVpAloAWo91/WsgDMY1htqVzcSgSQITXkN0gYohHWFp4d613jtVwP91jrNIw3wgoJSgXI1WFBdgGZwSYX9zf9e4oAgYBmItVUEUAStxCM33SEWaIKZ3NhCdYBBSNiWsthM2oA+4FeTvdQFSABBsNdnEQKW7SMRWAJfjVkYbQAjyACb3ZNJvRqMTRif3dh/FVocKlqP4QAMaIGSTdpuRYBCYNoQclpAgVqppVqvRQBKwFrI0VoTEYGonVqvhVig7QGVfZZnyNcloAC0TVuTbRMz+NiMgVY/cVmNpVu/NQkboQMXGFrM0Fv+4IAJkANL/Vu6ZQAjMANnDRHDZY4NiNu5Zdy/tRFFAIK2nY/JZQ2zHUbMHd2XaBNdGNwQ0daPEYEJGIL0IF3YzUMJmAPOrQ98RQzWdd3LjV3eXZUKoIPUDIhcy7hdsNiAIJCD1+1d5Z0JGzEC2hVeuCDerVCBCQiDFoCf5c3esZASSqBdvH0L6e2IDajeFjAy7T1fs2gAB5CAHegBF/heoVjY1ZjVIFADCaAe9M3fxui9BECEOciA9y3PkK0IDphVDAgDNUiAC1BV/W1gp9OS/m3fDMgADahgzchZiyjgDdgADMCAIFiBBN4SBnZgEr6NqyNCCVgBFV5hFfYCItySIylhGZ5hGq5hG75hHM5hHd5hHu5hH/5hIA5iIR5iIi5iIz5iJE5iJR6jgAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After careful review of 426 cases originally classified as NLPHL, morphologic and immunophenotypic studies confirmed the diagnosis in 51 percent while the rest were reclassified.",
"    <div class=\"footnotes\">",
"     NLPHL: nodular lymphocyte-predominant Hodgkin lymphoma; LRCHL: lymphocyte-rich classical Hodgkin lymphoma; CHL: classical Hodgkin lymphoma; NHL: non-Hodgkin lymphoma.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Diehl V, Sextro M, Franklin J. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999; 17:776.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39822=[""].join("\n");
var outline_f38_56_39822=null;
var title_f38_56_39823="Sialolith";
var content_f38_56_39823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Salivary gland stones: Sialolith",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martha Ann Keels, DDS, PhD, Duke Pediatric Dentistry.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_56_39823=[""].join("\n");
var outline_f38_56_39823=null;
